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ABSTRACT 
 
Human papillomaviruses (HPV) are very common in the sexually active population and contribute to 
610,000 cancers per year occurring at different locations. The initial step of HPV-related 
carcinogenesis is the induction of transforming processes in the host cells mediated by the viral 
oncoproteins E6 and E7 that interfere with critical host cell pathways. The transforming infection is 
highlighted by overexpression of the tumor suppressor protein p16
INK4a
. Only a small number of 
precancerous lesions progress while the majority can be controlled by the host’s immune system and 
undergo regression. Progressing lesions under the immunoselective pressure seem to acquire 
characteristics that enable them to circumvent the host’s immune attack and promote disease 
progression. Immune evasion might be mediated by the immune microenvironment of the tumor as 
well as by tumor cell intrinsic features.  
The here presented thesis addressed different questions and strategies with regard to the role of the 
immune system in HPV-associated diseases and can be subdivided in two main parts: In the first part 
immunologic characteristics of precancerous lesions and cancers are investigated to gain insight into 
possible immune evasion mechanisms developed during disease progression. In the second part 
treatment options to positively influence the balance between immune evasion and anti-tumoral 
immune responses are evaluated. 
In the first part a) the immunohistochemical characterization of cervical precancers and cancers for 
infiltration with different T cell phenotypes revealed that generally increasing T cell densities occur 
late in carcinogenesis – and not yet with the onset of early transforming infection - and are 
accompanied by immunosuppressive regulatory T cells (Tregs). Mean cell densities for Tregs in the 
stroma significantly increased from 121.6 cells/mm
2
 (range: 24-286.8 cells/mm
2
) in low-grade lesions 
to 308.8 cells/mm
2
 (24-724.8 cells/mm
2
) in high-grade lesions and 673.6 cells/mm
2
 (52.8-1564.8 
cells/mm
2
) in cancer which points to their immunosuppressive role during carcinogenesis. The 
demonstrated large variances in T cell densities within one diagnostic category, however, point to a 
remarkable heterogeneity of the immune control with potential interesting prognostic implications. On 
keratinocytes themselves b) a selective loss for human leukocyte antigen (HLA) class I heavy chain A 
expression was observed in about 55% high-grade cervical intra-epithelial neoplasia (CIN) and 65% of 
cervical cancers. HLA class II de novo expression was found in 50% of low-grade CIN and in about 
85% of high-grade CIN and cervical cancers. These alterations could represent another fundamental 
mechanism contributing to immune evasion. A c) longitudinal analysis of immune infiltrates in 
patients treated with imiquimod, an immuno-modulatory Toll-like receptor (TLR) agonist, revealed 
that the patient’s local immune constitution might be decisive for a possible response to immune-
enhancing treatment strategies. Importantly, in patients responding to imiquimod immune cell 
densities increased during the treatment as epithelial CD3+ T cell counts (from 160.8 to 371.1 
cells/mm
2
) and CD8+ T cell counts (from 113.8 to 174.1 cells/mm
2
) demonstrated. The d) 
development and establishment of an automated cell quantification tool for high-throughput analysis 
allows the search for immune evasion markers and strategies to be continued in an objective, 
standardized and faster way.  
In consideration of the clinical efficacy of imiquimod and the observed stimulatory effects on the 
immune infiltrate density in part one of this thesis e) a new second generation TLR-agonist (TMX-
202) potentially having less side-effects than imiquimod was tested for the first time in an in vitro T 
      
cell stimulation model in part two of this thesis. Its potential to stimulate innate and adaptive immunity 
was demonstrated by an enhanced killing capacity of T cells that were stimulated with HPV-related 
antigens loaded on dendritic cells and then co-incubated with HPV16-positive CaSki cells. Based on 
the dense infiltration with Tregs observed in part one of the presented thesis the f) immune stimulating 
effects of Treg depletion was tested in an autologous in vitro model. In this regard, one major aim of 
the thesis was the generation of a new HPV-positive tumor cell line derived from an oropharyngeal 
squamous cell carcinoma that serves as model system for HPV-associated tumors. In combination with 
peripheral blood lymphocytes obtained from the same patient this autologous system allowed to 
address Treg depletion as an immunotherapeutic approach. The results demonstrated that this strategy 
might enhance the cell-mediated immune response against tumor cells and emphasize the role that this 
particular T cell phenotype is obviously playing in the carcinogenesis of HPV-associated tumors. 
Based on the results obtained in the first part of the thesis it is well conceivable that the combination 
of different immunologic markers contributes to the definition of a prognostic biomarker tool for 
progression and regression of precancerous lesions. Such a prognostic “immune score” has a high 
clinical relevance and allows risk-adapted treatment decisions minimizing the costs and long-term 
sequelae of surgical interventions. In particular the newly developed microscopy based method in this 
work allowing for the automated histological high-throughput quantification of infiltrating immune 
cells in cervical intraepithelial neoplasia provides an important methodical tool to realize this long 
term goal. The immuno-stimulating effects of the novel TLR7-agonist TMX-202 and Treg depletion 
demonstrated in the second part of this thesis by in vitro models indicate that immunomodulatory 
approaches could play an important role for the treatment of HPV-associated cancers in the future. In 
this regard, the established novel tumor cell line in combination with autologous immune cells 
provides a valuable in vitro model system for HPV-associated cancers that can be used to investigate 
further immunotherapeutic intervention and treatment strategies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KURZFASSUNG 
 
Infektionen mit humanen Papillomviren (HPV) sind in der sexuell aktiven Bevölkerung weit verbreitet 
und führen zu bis zu 610,000 teilweise unterschiedlich lokalisierter Krebserkrankung pro Jahr. Der 
Beginn der HPV-assoziierten Karzinogenese stellt dabei die Induktion des Transformationsprozesses 
durch die viralen Onkoproteine E6 und E7 dar, die mit essentiellen Signaltransduktionswegen der 
Wirtszelle interagieren. Das transformierende Infektionsstadium korreliert hierbei mit der 
Überexpression des Tumorsuppressorproteins p16
INK4a
. Nur eine geringe Anzahl der daraus 
resultierenden präkanzerogenen Läsionen progrediert allerdings weiter zu einem Tumor während die 
Mehrheit solcher Läsionen unter Kontrolle des Immunsystems wieder regrediert. Progredierende 
Läsionen, die unter dem Selektionsdruck des Immunsystems stehen, scheinen dabei Charakteristika 
erworben zu haben um einen Angriff des Immunsystems zu umgehen und ermöglichen dadurch die 
Progression der Erkrankung. Entsprechende Immunevasionsstrategien könnten sowohl vom 
Immunmikromilieu um den entstehenden Tumor herum ausgehen als auch auf zellinherenten 
Tumoreigenschaften beruhen.  
Die vorliegende Dissertation beschäftigte sich mit verschiedenen Fragestellungen und verfolgt 
verschiedene Ansätze, die die Rolle des Immunsystems im Zusammenhang mit HPV-assoziierten 
Erkrankungen näher beleuchten sollen und ist dabei in zwei Hauptteile untergliedert: Teil eins 
beschäftigt sich mit der immunologischen Charakterisierung präkanzerogener Läsionen und invasiver 
Tumore um einen tieferen Einblick in mögliche Immunevasionsmechanismen bei voranschreitender 
Progredienz der Erkrankung zu gewinnen. In Teil zwei werden dagegen verschiedene 
Therapiemöglichkeiten evaluiert mit dem Ziel das Gleichgewicht zwischen Immunevasion und anti-
tumoraler Immunantwort positiv zu beeinflussen.  
Im ersten Teil dieser Arbeit konnte durch a) die immunhistochemische Charakterisierung von 
Infiltrationsraten verschiedener T-Zellphänotypen in Zervixkarzinomvorstufen und -tumoren gezeigt 
werden, dass ein Anstieg der T-Zelldichte relativ spät in der Tumorentstehung erfolgt - und nicht mit 
der Induktion des frühen Transformationsstadium korreliert - und dabei stets von einem Anstieg an 
immunsupprimierenden regulatorischen T-Zellen (Tregs) begleitet wird. Die Mittelwerte der 
gemessenen Zelldichten für Tregs im Stroma steigen dabei von 121.6 Zellen/mm
2
 (Varianz: 24-286.8 
Zellen/mm
2
) in niedriggradigen Läsionen über 308.8 Zellen/mm
2
 (24-724.8 Zellen/mm
2
) in 
hochgradigen Läsionen auf 673.6 Zellen/mm
2
 (52.8-1564.8 Zellen/mm
2
) in Tumoren an was auf ihre 
immunsupprimierende Rolle während der Karzinogenese hinweist. Die beobachteten großen 
Varianzen in den T-Zelldichten innerhalb einer diagnostischen Kategorie weisen dabei jedoch auf eine 
bemerkenswerte Heterogenität der Immunsystemkontrolle mit möglicherweise vielversprechenden 
prognostischen Implikationen hin. Auf Seite der sich verändernden Keratinozyten konnte weiterhin b) 
ein selektiver Ausfall der Expression der schweren Kette A des humanen Leukozytenantigens (HLA) 
Klasse I in 55% aller hochgradigen zervikalen intraepithelialen Neoplasien (CIN) und in 65% aller 
Zervixkarzinome festgestellt werden. HLA Klasse II de novo Expression konnte dagegen in 50% aller 
niedriggradigen CIN und in 85% aller hochgradigen CIN und Zervixkarzinomen beobachtet werden. 
Die gefundenen Veränderungen könnten dabei einen anderen grundlegenden Mechanismus darstellen, 
der zur Immunevasion der Tumorzelle beiträgt. Eine c) longitudinal ausgerichtete Analyse von 
Immuninfiltraten von Patienten die mit Imiquimod behandelt wurden - einem immunmodulatorischen 
Toll-Like-Rezeptor-(TLR)-Agonisten - ergab, dass die lokale Immunkonstitution des jeweiligen 
      
Patienten entscheidend für das mögliche Ansprechen auf immunstimulatorische 
Behandlungsstrategien ist. In Biopsien von Patientinnen, die auf eine Imiquimodbehandlung 
ansprachen konnten bemerkenswerterweise hohe Immunzelldichten im Behandlungszeitraum 
beobachtet werden, wie die gemittelten epithelialen CD3+ T-Zellzahlen (Anstieg von 160.8 auf 371.1 
Zellen/mm
2
) und CD8+ T-Zellzahlen (Anstieg von 160.8 auf 371.1 Zellen/mm
2
) belegen. Die d) 
Entwicklung und Etablierung eines automatisierten Zellquantifizierungssystems, das speziell zur 
Durchführung von Hochdurchsatzanalysen geeignet ist, ermöglicht die Suche nach 
Immunevasionsmarkern und -strategien in objektiverer, standardisierter und auf schnellere Art und 
Weise fortzusetzen.  
Unter Berücksichtigung der klinischen Wirksamkeit von Imiquimod und den ermittelten 
immunstimulatorischen Einfluss auf die Immuninfiltrationsraten in Teil eins wurde in Teil zwei dieser 
Arbeit e) ein TLR-Agonist der zweiten Generation (TMX-202), der potentiell weniger Nebenwirkung 
als Imiquimod aufweist, zum ersten Mal an einem in vitro T-Zellstimulationsmodell getestet. Das 
Potential von TMX-202 das angeborene und adaptive Immunsystem zu stimulieren wurde in diesem 
Zusammenhang an Hand gesteigerter zytotoxischer Aktivität von T-Zellen nachgewiesen. Diese 
wurden mit dendritischen Zellen stimuliert, die mit HPV-assoziierten Antigenen beladen waren und 
schließlich mit HPV16-positiven CaSki-Zellen koinkubiert. Aufbauend auf die in Teil eins der 
vorliegenden Arbeit nachgewiesenen hohen Infiltrationsdichten an Tregs wurde zusätzlich f) der 
immunstimulatorische Effekt einer Verminderung der Treg-Zellzahlen an einem autologen in vitro 
Modell getestet. In diesem Zusammenhang war ein Hauptziel dieser Dissertation die Generierung 
einer neuen HPV-positiven Tumorzelllinie aus einem Oropharynxkarzinom, die als Modell für HPV-
assoziierte Tumore dienen soll. In Kombination mit peripheren Lymphozyten, die aus dem Blut des 
gleichen Patienten gewonnen werden, sollte das so gewonnene autologe System die Untersuchung 
einer Treg-Depletion als einen Ansatz zur Immuntherapie ermöglichen. Die Ergebnisse zeigen, dass 
diese Strategie die zellvermittelte Immunantwort gegenüber Tumorzellen verbessern kann und hebt 
erneut die Rolle hervor, die dieser spezielle T-Zellphänotyp offensichtlich bei der Entstehung HPV-
assoziierter Tumor zukommt. Aufbauend auf den Ergebnissen der vorliegenden Dissertation ist es 
denkbar, dass eine Kombination verschiedener immunologischer Marker zur Definition eines 
prognostischen Biomarkersystems führt, das die Vorhersage der Progression und Regression 
präkanzerogener Läsionen ermöglicht. Ein solcher „Immunindex“ ist von hoher klinischer Relevanz 
und soll risikoangepasste Behandlungsentscheidungen ermöglichen, um somit die Kosten und 
Spätkomplikationen von chirurgischen Eingriffen zu minimieren. Insbesondere das in dieser Arbeit 
neu entwickelte Mikroskopie-basierte Verfahren zur automatischen histologischen 
Hochdurchsatzquantifizierung von Immuninfiltraten in zervikalen intraepithelialen Neoplasien sollte 
ein entscheidendes methodisches Werkzeug darstellen, um dieses Langzeitziel zu erreichen. Die in 
dieser Arbeit an in vitro Modellen für HPV-assoziierte Krebsarten gezeigten immunstimulierenden 
Effekte des neuartigen TLR7-Agonisten TMX-202 und der Treg-Depletion zeigen, dass 
immunmodulatorische Ansätze bei der Behandlung solcher Erkrankungen in Zukunft eine wichtige 
Rolle einnehmen könnten. Eine Kombination der neu generierten Tumorzelllinie mit autologen 
Immunzellen sollte in diesem Zusammenhang ein verlässliches in vitro Modellsystem für HPV-
assoziierte Krebsarten darstellen, das weiterführende Studien zu immuntherapeutischen Interventions- 
und Behandlungsstrategien ermöglicht.  
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MT methyl transferase 
MyD88   myeloid differentiation primary-response protein 88 
n    sample size 
n   nano 
NFkB    nuclear factor-kappa B 
NK   natural killer cell 
NKT   natural killer T cell 
NMSC  non-melanoma skin cancer 
NO   nitric oxide 
OIS   oncogene induced stress 
OPC   oropharynx cancer  
ORF  open reading frame 
OSCC   oropharyngeal squamous cell carcinoma 
p   probability 
p   protein, peptide 
p.a.    per analysis  
p16
INK4a
  tumor suppressor kinase inhibitor of CDK4 
p53 tumor suppressor protein 53 
PAGE  polyacrylamide gel electrophoresis 
PAMP   pathogen-associated molecular pattern 
Pap test  Papanicolau test 
PBL    peripheral blood lymphocytes  
PBMC    peripheral blood mononuclear cell  
PBS  phosphate-buffered saline 
PBS-T    PBS containing 0.05% Tween 20 
PCR    polymerase chain reaction  
PDZ post synaptic density protein (PSD95), Drosophila disc large tumor suppressor 
(Dlg1), zonula occludens-1 protein (zo-1) 
PE    phycoerythrin  
PFA    paraformaldehyde  
pRB   phosphorylated retinoblastoma protein 
PRR   pattern recognition receptor 
PVDF  polyvinylidene difluoride 
qPCR   quantitative polymerase chain reaction 
Rb  retinoblastoma 
RB   retinoblastoma protein 
RGB   red green blue 
RNA    ribonucleic acid 
ROI   region of interest 
rpm  rounds per minute 
RT    room temperature 
RT   reverse transcription 
Abbreviations 
  
S   synthesis 
sec   second/s 
SCC  squamous cell carcinoma 
SDS   sodiumdodecylsulfate 
SSC   squamous cell carcinoma 
STAT   signal transducers and activators of transcription 
STR   short-tandem-repeat 
T   thymus 
t   time 
TAP    transporter associated with antigen presentation  
TAP-1   antigen-processing-protein-1 
Taq  thermus aquaticus 
TBE    tris-borate EDTA  
TBS  tris-buffered saline 
TCR   T cell receptor 
TEMED   tetramethylethylenediamine  
TGF   transforming growth factor 
Th    T-helper cell 
TIL    tumor infiltrating lymphocyte  
TLRs   Toll-like receptor 
TMB    Tetramethyl benzidine 
TMX   Telormedix 
TNF   tumor necrosis factor 
TNM   tumor nodes metastasis 
Treg cell  regulatory T cell 
Tris-HCl   Tris-(hydroxymethyl)aminomethane hydrochloride  
V   vacuolar 
v/v    volume per volume  
VAIN    vaginal intraepithelial lesion 
VIN    vulvar intraepithelial neoplasia  
VLP    virus like particle 
w/v    weight per volume 
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INTRODUCTION 
 
“Do not follow where the path may lead. Go instead where there is no 
path and leave a trail.” (George Bernard Shaw) 
 
 
1.1  The discovery of human papillomaviruses in the  
 causation of cancer 
 
The knowledge of the relationship between the carcinogenesis of cervical tumors and sexually 
transmittable agents has already dated back to the 19
th
 century when a link between the sexual 
behavior and the risk for development of cervical cancers could be established. The Italian physician 
Domenico Antonio Rigoni-Stern analyzed the causes of death of Veronese women who had died 
between 1760 and 1839 and observed a significantly higher frequency of cervical cancers occurring in 
sexually active women, compared to virgins and nuns who were affected by cervical tumors only very 
rarely (GASPARINI and PANATTO, 2009).  
The awareness that cancers can be attributed to infectious agents raised in the beginning 20
th
 century. 
Peyton Rous, in 1911, demonstrated that cell-free extracts of chicken sarcoma can be transferred from 
one individual to another (ZUR HAUSEN, 2011).  
The history of the discovery of the human papillomavirus (HPV) as causing agent in the development 
of cervical cancer however started considerably later in the 1970s. At that time, Harald zur Hausen 
subverted the widespread opinion among scientists and clinicians that the sexually transmittable 
herpes simples virus type 2 (HSV-2) may be causally linked to carcinomas of the anogenital tract and 
proposed papillomaviruses to contribute to cervical carcinogenesis (ZUR HAUSEN et al., 1974). He 
proved that not HSV-2 but HPV DNA is detectable in the tumor tissue and hypothesized that the viral 
genome is persistently present and transcriptionally active in HPV-infected cancer cells (ZUR 
HAUSEN et al., 1975). 
His findings considerably contributed to a detailed description of the phylogenetic heterogeneity of the 
human papillomaviruses, to the identification of the major HPV types associated with cancer and the 
characterization of the oncogenic potential of the HPV proteins E6 and E7. His work awoke the 
general interest of the scientific community on viruses as cancer causing agents in general and on HPV 
in particular leading to the opening of a completely new research area which aims at understanding of 
the molecular mechanisms and, in a second step, combating HPV-related diseases. Having the courage 
to leave the path chosen by the research community of his time and thus paving the way for the 
following generations of researchers to participate in the battle against cancer caused by one of the 
most common sexually transmittable agents he was rewarded the Nobel Prize in 2008.  
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1.2  Characteristics and life cycle of human papillomaviruses 
Human papillomaviruses are non-enveloped DNA viruses containing one single-stranded circular 
DNA molecule with a size of about 8000 base pairs. They belong to the family of papillomaviridae 
which can further be subdivided into five genera (Alpha-, Beta-, Gamma-, Mu- and 
Nupapillomaviruses) (DOORBAR, 2006). The viral genome (Figure 1.1) comprises eight open 
reading frames (ORF) covering three distinct functional parts, namely the early genes’ region (E1-E7), 
the late genes (L1 and L2) and a non-coding part called long control region (LCR) containing cis-
regulatory elements (ZHENG and BAKER, 2006). HPV is characterized by an icosahedral capsid of a 
diameter of about 55 nm and consisting of 72 pentameric subunits, the capsomers. The capsomers are 
made of two structural proteins, the late proteins L1 and L2. 
 
 
FIGURE 1.1  THE HPV16 GENOME. The genome comprising 7904 bp is represented by a black circle with the early 
(p97) and the late (p670) promoters marked by arrows. The six early ORFs (E1-E7) are expressed from 
either p97 or p670. The late ORFs (L1 and L2) are represented as yellow structures and the long control 
region (enlarged and visualized as black line) contains the E2-binding sites, the binding sites for E1 and 
the TATA element of the p97 promoter. Adapted from (DOORBAR, 2006). 
Human papillomaviruses are characterized by a strong tropism for epithelial cells and the mucosa. The 
virus’ life cycle is initiated with infection of keratinocytes of the basal squamous epithelium which 
requires either microlesions as they can be found for example in the cervical epithelium or other 
anatomical structures like the characteristic tonsillar crypt epithelium. HPV infection therefore 
exclusively affects undifferentiated epithelial stem cells as cell division and keratinocyte 
differentiation are the prerequisite for the completion of the virus’ life cycle and replication (CHOW et 
al., 2010). The infectivity is predominantly mediated by the viral proteins L1, but also L2 capsid 
proteins (BUCK et al., 2013) enabling the virus to bind to the host cells which is followed by uptake 
of the virus via clathrin-based endocytosis. The late proteins also seem to be involved in transferring 
the viral DNA to the nucleus following disassembling in the late endosomes and lysosomes 
(DOORBAR, 2006). Initially, following infection the keratinocytes undergo lateral cell divisions and 
thus build a reservoir of stem cells harboring the virus (NGUYEN et al., 2014). Viral DNA replication 
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in this phase is tightly synchronized with the amplification of the host cell DNA during S-phase. 
During this latent phase of the infection the early proteins E1 and E2 are expressed which fulfill 
different functions during early infection (see also Table 1.1 for HPV protein functions). In addition to 
the role they play in the replication of the viral genome, they assure that the viral DNA is maintained 
as an episome at low copy numbers of about 10-200 copies. The viral early proteins E1 and E2 seem 
to prevent the integration of the viral DNA into the host’s genome as well as they assure the correct 
viral genome segregation during stem cell divisions (MCBRIDE, 2013). E2 initiates the amplification 
of the viral DNA by binding to the HPV upstream regulatory region and by forming together with E1 
that is recruited to this non-coding region the E1/E2 initiation complex. The E1 protein functions as a 
DNA helicase, and recruits several other, cellular, proteins to the viral origin of replication such as 
RPA (replication protein A) and DNA polymerase α primase (CONGER et al., 1999; DOORBAR, 
2006). Furthermore E2 controls the early promoter of high-risk HPV types, called p97 in HPV16, and 
thus strictly regulates the early proteins, which is of special importance regarding the expression rates 
of the viral oncogenes E6 and E7 expressed at low levels only (DOORBAR, 2005).  
With the migration of virally infected basal stem cells into the suprabasal cell layer of the epithelium 
the cells quit the cell cycle in order to undergo terminal differentiation. This initiates the productive 
phase of the viral infection characterized by activation of the viral genes in parallel to the 
differentiation program of the keratinocytes.  
 
 
FIGURE 1.2 THE HPV LIFE CYCLE. The cell layers of the mucosal epithelium are indicated on the left. Cells 
expressing cell cycle markers (red) that occur in the suprabasal cell layer are characterized by viral 
oncogene expression (E6 and E7) (green cells). The activation of p670 in E6 and E7 expressing cells of 
the upper epithelium leads to expression of viral proteins required for viral genome replication. The 
successive viral protein expression stages indicated by arrows represent distinct steps of the viral life 
cycle directly influencing also the host cell: low-levels of E1, E2, E4 and E5 (light green) accompanied 
by viral oncogene expression (E6 and E7) leads to induction of cell proliferation. Elevation of the proteins 
involved in replication (dark green) allows increased viral genome amplification. L1 and L2 (yellow) are 
expressed in the upper epithelium, where viral genome is packaged into infectious particles. Here, E4 also 
is expressed and probably contributes to the viral release. Adapted from (DOORBAR, 2006). 
 
As suprabasal keratinocytes that are terminally differentiated undergo cell cycle arrest, the virus has to 
reactivate S-phase of the host cells to complete its life cycle. The viral oncogenes E6 and E7 are 
required for the reactivation of the host replication cycle. However, their expression is still under 
control and locally restricted to a few cells in the lower part of the epithelium. These cells assure the 
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viral replication to be maintained and infectious virions to be produced once the keratinocytes quit the 
basal cell layer and migrate towards suprabasal layers (DOORBAR, 2006). The mode of action of the 
viral oncoproteins acting in the host cells are explained in more detail in section 1.3.2. In the mid and 
upper layers of the epithelium, the viral DNA is replicated, the amplified genome is packed into viral 
capsids and infectious virions are finally released. These processes are controlled by the late promoter 
which is dependent on the differentiation program and activated with the migration of keratinocytes 
through the epithelium. Its activation leads to increased expression rates of viral early proteins E1, E2, 
E4 and E5 which are involved in HPV DNA replication (Figure 1.2). However, E6 and E7 expression 
levels still are tightly controlled by the repressive functions of E2 on the early viral promoter (HAMID 
et al., 2009).  
 
viral 
protein 
function in the viral life cycle activities in the host cell 
Early proteins:  
E1  viral genome replication DNA-binding activity, helicase activity, ATPase 
E2  
viral gene transcription, viral genome 
replication, viral genome maintenance 
transactivation/transrepression, DNA-binding 
activity, DNA segregation in mitotic cell 
E4 
viral genome replication (enhanced 
amplification)  
destruction of keratin network, induction of G2M 
arrest of cell cycle 
E5 
possibly involved in proliferation and/or 
inhibition of apoptosis 
interference with cellular signaling pathway 
E6  
reactivation of cellular replication 
mechanisms, proliferation, immortalization, 
inhibition of apoptosis, viral genome 
maintenance  
interaction with various cellular proteins, e.g. p53, 
c-Myc, Bak, Bax, PDZ domain  
E7 
reactivation of cellular replication 
mechanisms, proliferation, genomic 
instability, inhibition of apoptosis, viral 
genome maintenance  
interaction with various cellular proteins, e.g. pRB, 
HDAC, E2F6, p21, p27, CDK/cyclin 
Late proteins:  
L1  major capsid protein  
L2  minor capsid protein   
TABLE 1.1 THE HPV16 PROTEIN FUNCTIONS. Depicted are the early and late proteins, their main functions in 
the viral life cycle and their activities in the host cell. Adapted from (KAJITANI et al., 2012).  
The viral proteins E4 and E5 also seem to be involved in viral DNA replication. E5 is involved in 
EGF-mediated signaling in order to maintain an environment that is favorable for replicative 
processes. The viral E4 protein expression levels increase during genome amplification and induce G2 
cell cycle arrest of host keratinocytes and thus prevents cell proliferation by counteracting E7 effects; 
it enhances viral genome amplification and thus is likely to contribute to an increased viral synthesis 
rate. Its interaction with and destabilizing effects on the keratin network of host cells implies that E4 
could also be involved in viral release (reviewed in DOORBAR, 2013).  
Finally, the structural L1 and L2 proteins necessary for capsid formation and packaging of the viral 
DNA are expressed and accumulate during viral replication. Following assembly – in which E2 is also 
involved by binding viral DNA for loading - of capsids containing one copy of the HPV DNA the 
   1. Introduction 5 
infectious particles are released from the fully differentiated cells that reach the outer surface of the 
squamous cell epithelium (DOORBAR, 2006).  
The viral gene expression pattern is tightly associated with the biological infection stage. The above 
described life cycle represents the productive or permissive infection stage characterized by viral DNA 
replication and release of newly assembled virions. In case of persistence of the HPV infection, the 
productive live cycle may be quit and the proliferation of terminally differentiated epithelial cells in 
the lower third of the epithelium can be induced (DOORBAR, 2005).  
This shift occurs under the influence of deregulated expression of E6 and E7 oncoproteins leading to 
abolishment of cell cycle arrest while DNA damage responses are inhibited. These processes induce 
the transforming infection stage which will be described in more detail in chapter 1.3.2.  
 
1.3  HPV-associated cancers  
More than 100 different HPV genotypes have been described so far (BERNARD, 2005). Those that 
are the clinically most relevant ones belong to the genera of alpha-papillomaviruses and cause not only 
cancerous precursor lesions and cancer but also genital warts (DE VILLIERS et al., 2004). 
Furthermore, papillomaviruses are classified into two groups depending on their potential to cause 
cancer: low-risk types leading to ano-genital warts or common skin warts whereas the so called high-
risk types - representing only a handful of all genotypes described so far - are involved in cancer 
development. Among those the high-risk types HPV16 and HPV18 are the most prevalent ones with 
their DNA being detectable in around 80% of cervical cancers (SCHIFFMAN et al., 2007). The most 
prevalent low-risk HPV types are HPV11 and HPV6 that cause the vast majority of genital warts 
(STEBEN and GARLAND, 2014).  
This chapter deals with the contribution of HPV to tumor development and the mechanisms involved 
in the establishment of precancerous lesions and their progression towards invasive disease.  
 
1.3.1 Prevalence, incidence and mortality of HPV-associated diseases 
 
HPV infections are common within the sexual active population and thus considerably contribute to 
the global health burden: the prevalence in the younger population aged 15 to 25 years is very high 
and an individual’s life time risk to enter in contact with these viruses and get infected is about 80% 
(DUNNE et al., 2007). Although the majority of HPV infections are cleared within two years – the 
mean clearance time even is 5 months - remaining without any consequences, more than 5% of 
cancers appearing worldwide are related to HPV infections that persisted (DE MARTEL et al., 2012). 
Incidences for different HPV-associated diseases vary between women and men (Figure 1.3).  
Cervical cancer is the fourth most common cancer in women following breast cancer, colorectal 
cancer and lung cancer in the latest GLOBOCAN statistics. Nearly 530,000 new cases of cervical 
cancer are diagnosed each year (2012), the main burden however occurs in developing countries that 
show a 10-fold higher incidence compared with industrial nations. Here, cervical cancer represents 
almost 12% of all female cancers and it still remains the most common cancer in women in Eastern 
and Middle Africa (FERLAY et al., 2010). This difference is explained by lacking screening programs 
and early detection of precancerous stages and cervical cancer. The pap-test, developed in the 1930s 
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by George Papanicolaou, allows the early detection and treatment of precancerous stages and since its 
introduction has led to a significant decline of the cervical cancer incidence in industry nations (GIBB 
and MARTENS, 2011). In 2012, an estimated number of around 270 000 women died from cervical 
cancer worldwide. This makes a percentage of 7.5% of all female cancer deaths. Here again, the 
majority, more than 85% of all deaths related to cervical cancer, occur in low- or middle-income 
countries (FERLAY et al., 2010).  
Even though cervical cancer is the best characterized among the HPV-associated diseases HPV 
infection can also occur on other epithelial or mucosal sites and can cause several other cancer types. 
While virtually all cancers of the cervix uteri are attributable to precedent infection with human 
papillomaviruses, persistent HPV infection also causes precancerous lesions and cancers at other ano-
genital sites and contributes to a proportion of vulvar, vaginal, penile and anal cancers (PARKIN and 
BRAY, 2006).  
 
 
FIGURE 1.3  CONTRIBUTION OF HPV TO THE HEALTH BURDEN. Estimated incidence rates of HPV-associated 
diseases (related to HPV6, 11, 16, 18) in women and men in Europe. Adapted from (STANLEY, 2012b). 
The contribution of HPV in the carcinogenesis of a proportion of head and neck squamous cell 
carcinoma (HNSCC) today is widely accepted (GILLISON et al., 2000). Especially, the oropharyngeal 
tract can be concerned by HPV infection and recent studies revealed an increasing incidence of HPV-
associated cancers of the oropharynx (OPC), the pharyngeal region located at the back of the throat, 
and here primarily the tonsils, the base of the tongue and the soft palate are affected (CHATURVEDI 
et al., 2011). Also here HPV16 is the most prevalent type with about 90% of HPV-positive carcinomas 
located in the oropharynx being positive for HPV16 DNA. Also in the other ano-genital sites, except 
the cervix uteri where HPV18 plays a non-negligible role, the vast majority of cancers are associated 
with HPV16 infections (BOSCOLO-RIZZO et al., 2013). The incidence rate of head and neck 
squamous cell carcinomas equals that of cervical cancer with about 550 000 new HNSCC cases per 
year worldwide making it the 7
th
 most common cancer in men. Thereof around 85,000 cases represent 
oropharyngeal cancers. The mortality rate is higher than in cervical cancer with around 305,000 deaths 
per year related to HNSCC. However, the etiological heterogeneity – with tobacco and alcohol being 
the major risk factors for HNSCC – makes it difficult to estimate to which extent HPV contributes to 
oropharyngeal cancers (GILLISON et al., 2014). Estimates for HPV-association among oropharyngeal 
cancers are higher for industrial nations (60-70% for the United States) which have experienced an 
increase in incidence for oropharyngeal cancer in the last two decades, whereas less than 10% of OPCs 
are believed to be caused by HPV in developing regions (CHATURVEDI et al., 2013). Worldwide, 
   1. Introduction 7 
these data lead to an estimated proportion of about 25% of OPCs attributable to HPV infection 
following an IARC review published in 2012 (CHATURVEDI et al., 2013).  
 
Distinct HPV types were found to play a role in the autosomal recessive hereditary skin disorder 
epidermodysplasia verruciformis which is characterized by a higher susceptibility for persistent 
infections and development of benign lesions and also malignancies of the skin (HARWOOD et al., 
2004). HPV also contributes to non-melanoma skin cancer (NMSCC) (reviewed in MOLHO-
PESSACH and LOTEM, 2007 and SMOLA, 2014) and might be of higher relevance in 
immunosuppressed individuals (REUSCHENBACH et al., 2011).  
The mechanisms of HPV-induced carcinogenesis in the following chapters will be explained by means 
of the well-studied cervical cancer and its precursor lesions, the so called cervical intraepithelial 
neoplasia (CIN). The underlying tumorigenic mechanisms, however, are the same in other HPV-
associated cancers.  
 
1.3.2  Viral oncogene overexpression and the transforming infection stage 
A small percentage of HPV infections – those that are not cleared and persist over months – finally 
shift from permissive/productive to transforming infection which is accompanied by a massively 
deregulated expression of the E6 and E7 oncoproteins. The affected cells that had undergone cell cycle 
arrest are driven continuously into S-phase and finally shift from the production of viral infectious 
agents to an intensively supported proliferation (DOORBAR, 2005). The deregulated expression of the 
E6 and E7 oncoproteins therefore can be considered as the prerequisite for the establishment of 
precancerous lesions and the development of invasive cancer. The transformation zone of the cervix is 
preferentially affected by HPV-induced neoplasia. Here, the cells of the stratified squamous 
epithelium and the columnar endocervical cells converge, for which reason this area is also called the 
squamocolumnar junction. Under hormonal influence the transition zone during the female life cycle 
is subject to substantial anatomical changes and rebuilding processes with changing proportions of 
columnar and stratified epithelium (BURD, 2003).  
 
 
FIGURE 1.4  TRANSFORMING INFECTION IS INDUCED BY FUNDAMENTAL CHANGES IN THE VIRAL 
GENE EXPRESSION PATTERN. While the majority of low-grade lesions (CIN1) represent permissive 
infections with the underlying viral gene expression patterns described above, high-grade lesions (CIN 2 
and CIN3) are characterized by an increasing proportion of cells with deregulated E7 expression which is 
accompanied by decreased expression of the early proteins involved in viral replication. This may be 
accompanied by the integration of the viral DNA into the host cell genome. In CIN3 and cervical cancers 
are characterized by more and more decreased or absent viral replication and increased E7 expression. 
Adapted from (DOORBAR, 2006). 
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Recently, a cell population retaining embryonic characteristics within the junction has been identified 
that is speculated to be particularly susceptible to HPV-induced carcinogenesis (HERFS et al., 2012). 
The occurrence of HPV-associated HNSCC at oropharyngeal sites, specifically the tonsils, could also 
be explained by the histologic characteristics of the lymphoepithelium of the tonsillar crypts. Here, the 
so called reticulated epithelium seems to be the preferred site for HPV infections (WESTRA, 2012).  
The loss of the repressive effects of viral E2 on the early promoter p97 is considered to be the reason 
for the deregulated oncogene expression and leads to a massive up-regulation of E6 and E7 expression 
rates in higher lesion grade (Figure 1.4). Different events are discussed as underlying mechanisms for 
the loss of E2 function. One is the integration of the viral episome into the host’s genome which 
disrupts the gene locus for E2 (VERNON et al., 1997). However, also cells with unintegrated, 
episomal viral DNA show E6 and E7 overexpression, a finding for which other, epigenetic 
mechanisms such as methylation of the E2-binding sites changing the binding affinities and thus the 
transcription rates might be responsible (CHAIWONGKOT et al., 2013).  
The oncoproteins E6 and E7, once they are expressed, perfectly act together, complementing the 
functions of each other, to re-induce proliferation in terminally differentiated cells and to circumvent 
apoptosis at the same time.  
 
 
FIGURE 1.5  HPV16 E7 CIRCUMVENTS ONCOGENIC STRESS INDUCED CELL CYLCE ARREST BY 
TARGETING pRB FOR DEGRADATION. A) In normal cells CDK4/6 is negatively regulated by 
p16INK4a. If absent CDK4/6 is activated by binding of cyclin D and phosphorylates pRB which is 
degraded. Loss of the suppressive subunit pRB activates the E2F transcription factor which mediates S-
phase entry. B) Oncogenic stress induces KDM6B expression and increased p16INK4a levels which 
inhibits CDK4/6 activity and phosphorylation of pRB, resulting in G1 cell cycle arrest and senescence. C) 
HPV E7 targets pRB for degradation and circumvents growth arrest. Adapted from (MCLAUGHLIN-
DRUBIN and MUNGER, 2013).  
Cell cycle progression, the transition from G1-phase to S-phase in dividing cells, is tightly regulated 
by the complex built of the cyclin-dependent kinase 4 (CDK4) and cyclin D. Under normal 
circumstances binding of the regulatory subunit cyclin D to CDK4 activates the complex and allows 
CDK4 to phosphorylate pRB which then dissociates from the E2F transcription factor. E2F migrates 
to the nucleus where it induces the transcription of genes necessary for cell cycle progression, such as 
cyclins A and E. In normal, non-dysplastic cells, the cyclin-dependent kinase inhibitor p16
INK4a
 
negatively regulates the kinase activity of CDK4 and CDK6 by binding to them and inhibiting the 
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formation of active complexes with cyclin D. This prevents hyperphosphorylation and inactivation of 
pRB and the release of E2F transcription factors. Consequently, cells expressing p16
INK4a
 under 
normal conditions are retained in the G1 phase and do not enter S-phase (Figure 1.5) 
(MCLAUGHLIN-DRUBIN and MUNGER, 2013). 
Due to the potency to drive host cells into S-phase which is crucial for the induction of the 
transforming infection stage, E7 directly contributes to carcinogenesis (reviewed in MCLAUGHLIN-
DRUBIN and MUNGER, 2009). E7 is assumed to bind to the retinoblastoma (pRB) tumor suppressor 
thus interfering with the pRB pathway and abrogating the host’s capacities to control cell cycle 
progression in the way similar to how other viruses achieve the same goal (JONES and WELLS, 
2006). Binding of the E7 oncoprotein to pRB leads to the disruption of complexes built of pRB and 
transcription factors belonging to the E2F family (Figure 1.5). Although no external growth stimuli are 
present, E2F is released from pRB and activates other host cell proteins involved in DNA replication 
such as the cyclins A and E (DOORBAR, 2006). Furthermore E7 was demonstrated to interact with 
other proteins of the host’s cell cycle regulation machinery, among others the activator protein 1(AP1) 
transcription complex (ANTINORE et al., 1996), histone deacetylases (LONGWORTH et al., 2005) 
and also the cyclin-dependent kinase inhibitors p21 and p27 (NOYA et al., 2001) are concerned.  
Interestingly, during natural infection E7 does not always induce cell cycle progression in 
differentiated keratinocytes. In some cells which express high levels of p21 and p27 the CDKs seem to 
be resistant to oncoprotein effects as here E7 builds inactive complexes with cyclin E. Consequently, 
mitosis is induced only in cells that are characterized by low p21 and p27 levels or by E7 levels that 
are high enough to overcome the cycle arrest (DOORBAR, 2006).  
 
 
FIGURE 1.6 HPV16 E6 INTERFERES WITH THE P53 PATHWAY. Binding of E6 to p53 promotes its degradation 
and thus prevents cell cycle arrest and apoptosis. Adapted from (YIM and PARK, 2005). 
The interference of E7 with the pRB pathway is complemented by E6 which abolishes the p53-
mediated apoptotic signaling. Modulation of apoptotic pathways is a common and effective 
mechanism known from a number of oncogenic viruses and contributes to malignant progression 
(reviewed in FUENTES-GONZALEZ et al., 2013)). During transforming HPV infections, the cell-
cycle entry of upper epithelial cells normally should lead to apoptosis mediated by ARF (ADP 
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ribosylation factor). However, under the influence of the viral oncoprotein E6 binding to E6AP (E6-
associated protein) p53 is ubiquitinylated and degraded (DOORBAR, 2006). The interplay of E7 
together with E6 impairing different host cell pathways leads to deregulated cell proliferation while 
the central apoptotic pathway is impaired. Apart from the interaction with p53 the viral E6 protein is 
also reported to target telomerase and different PDZ proteins involved in cell signaling and other 
cellular processes and thereby further supports transforming processes within the host cells 
(GANGULY and PARIHAR, 2009; WISE-DRAPER and WELLS, 2008). 
The inhibition of central DNA repair mechanisms at the same time when host cells undergo 
deregulated DNA synthesis has massive further consequences on genome integrity and provokes 
additional genomic alterations (DUENSING and MUNGER, 2002).  
 
In addition to the well-established mode of action of the viral oncoproteins E6 and E7 also E5 is 
discussed as another protein being involved in the development of cancers (reviewed in MIGHTY and 
LAIMINS, 2014)). One possible mechanism might be its ability to also inhibit ubiquitination and 
subsequent degradation of Bax and thereby preventing hydrogen-peroxide induced apoptosis (OH et 
al., 2010).  
 
1.3.3  A biomarker for transforming infections: p16
INK4a
 overexpression  
 
The expression of cyclin-dependent kinase inhibitor p16
INK4a
 is induced in aging cells and therefore a 
sign of senescence accompanied by cell cycle arrest and chromatin condensation. Its ability to prevent 
cells from further proliferation is of special interest in premalignant and malignant cells that have 
acquired genomic damages. In these cells p16
INK4a
 acts as a tumor suppressor preventing cell cycle 
progression and further accumulation of DNA damages. Due to the biological importance of the CDK 
inhibitor there seems to be an evolutionary pressure for loss of p16
INK4a
 gene function in neoplastic 
context. Indeed, many cancers of different sites show evidence of a functional loss of p16
INK4a
 by 
epigenetic modifications, deletions or point mutations. (LIGGETT and SIDRANSKY, 1998; ROCCO 
and SIDRANSKY, 2001).  
In cervical intraepithelial neoplasia and carcinomas however, p16
INK4a
 is overexpressed. This can be 
directly linked to the deregulated oncogene expression and therefore p16
INK4a
 represents a well-
established and recognized marker for transforming HPV infections (VON KNEBEL DOEBERITZ, 
2002). In this context its biological function as growth arrest inducing protein is abolished by the viral 
oncoprotein E7 that inactivates the down-stream inhibitory signals of p16
INK4a
. The overexpression of 
the viral protein E7 in dysplastic cells with underlying transforming HPV infection causes oncogenic 
stress to the host cell. This leads to an epigenetic remodeling particularly of the CDKN2a 
(p16
INK4a
/ARF) gene locus and a substantially increased p16
INK4a
 expression.  
Histone lysine methylation is one epigenetic mechanism involved in transcriptional activation and 
repression and for this reason plays a non-negligible role in cell cycle regulations. The enzymes 
involved in this epigenetic chromatin remodeling are histone lysine methyltransferases (KMTs) and 
demethylases (KDMs) that influence lysine methylation pattern of histones. The trimethylation mark 
at lysine 27 of histone H3 (H3K27me3) results in epigenetic silencing of the gene. The histone 
demethylases KDM6A (UTX) and KDM6B (JMJD3) however are able to remove the repressive 
methylation pattern and therefore are involved in transcriptional activation. The expression of the viral 
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E7 leads to oncogene induced stress (OIS) and transcriptional induction of histone demethylases 
KDM6A and KDM6B which remove the H3K27me3 mark. This results in epigenetic reprogramming 
by changing the levels of histone methylation of the p16IN4a/ARF gene locus and enhanced p16
INK4a
 
expression (MCLAUGHLIN-DRUBIN et al., 2011).  
 
Cells in the transforming infection stage however are not subject to p16
INK4a
 mediated cell cycle arrest 
and the cells continue to proliferate in presence of the overexpressed cyclin-dependent kinase 
inhibitor. This is explained by the interference of E7 with p16
INK4a
 downstream targets, namely pRB 
which is degraded under the influence of E7 activating the CUL2 pathway (HUH et al., 2007).  
In this context, p16
INK4a
 therefore cannot be considered as a senescence marker anymore and remains 
without mechanistic relevance. It is rather a marker for the transforming processes ongoing within the 
virally infected host cells. The immunohistochemical staining pattern in these cases shifts from patchy 
in case of real senescence to strong and diffuse in dysplastic lesions (KLAES et al., 2001). 
 
 
FIGURE 1.7 EXAMPLES OF p16INK4a IMMUNOHISTOCHEMISTRY ON CERVICAL TISSUE SAMPLES: 
 shown are representative examples of A) normal epithelium negative for p16INK4a, B) cervical 
intraepithelial neoplasia (CIN3) with p16INK4a-positive epithelium and C) cervical carcinoma with strong 
p16INK4a staining. Details of the epithelium are shown on right side.  
 
Recently published data (MCLAUGHLIN-DRUBIN et al., 2013) on p16
INK4a
 functions demonstrated 
that p16
INK4a
 overexpression is not only a bystander effect of oncogenic stress induced by HPV E7 
protein and not a consequence of pRB inactivation by the viral oncogene, but is elementary to 
maintain the neoplastic phenotype and the continuous growth of cells with underlying transforming 
HPV infections. Dysplastic cells under the influence of viral E7 become dependent on KDM6B and 
p16
INK4a
 expression for survival.  
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1.3.4 Histomorphological classification of cervical precancers 
In histomorphology, HPV-induced lesions are subdivided in three distinct progression steps and 
described by successive grade of cervical intraepithelial neoplasia (CIN) depending on the extent of 
morphological aberrations (MARTIN and O'LEARY, 2011). With increasing dysplastic cellular 
alterations beginning in the basal and suprabasal layers and eventually reaching throughout the 
complete epithelium the lesions are termed with increasing lesion grades from 1 to 3. CIN1 usually is 
described by the occurrence of so called koilocytes, indicating that viral replication is ongoing in the 
suprabasal layers of the epithelium. The altered cellular morphology concerns less than one third of 
the thickness of the epithelium. Lesions characterized as CIN1 are not yet considered as 
premalignancy in the narrower sense and therefore usually are not treated. With persistence and 
progressing disease cells with more severe dysplastic cellular alteration expand and may grow beyond 
the lower third of the thickness of the affected squamous epithelium and these lesions are named 
CIN2. The lesions that grow further and even beyond two thirds of the epithelium are referred to as 
CIN3 lesions (DARRAGH et al., 2013; RICHART, 1973). 
The Histomorphological defined CIN grades cannot be translated unequivocally into the biological 
infection stages. CIN1 and a part of CIN2 lesions retain the capacity to undergo the normal squamous 
epithelial differentiation and thus for viral replication and represent the permissive (productive) 
infections. However, the control of the viral oncogene expression in basal and suprabasal cells may 
have already been lost in a part of CIN1. The vast majority of CIN2 lesions and virtually all CIN3 
lesions are in the advanced transforming infection stage. Due to this discrepancy markers are needed 
to highlight the biological infection stage in biopsies. As it is directly link to oncogene activity 
p16
INK4a
 overexpression represents a reliable biomarker to identify lesions that have quit productive 
infection and entered the transforming infection stage independently of their histomorphological 
appearance (BERGERON et al., 2014; VON KNEBEL DOEBERITZ et al., 2012).  
 
 
1.3.5 HPV infection stages interpreted as a progression model  
 of cervical cancer 
 
The cervical carcinogenesis can be subdivided in clearly defined successive steps (Figure 1.8). Latent 
infections (step 1), during which the viral DNA has been replicated yet, usually remain clinically 
innocuous and are characterized by basal infected keratinocytes that divide continuously to establish a 
reservoir of cells harboring the episomal viral DNA. Permissive or productive infections (step 2) are 
characterized by viral replication cycles which become induced in suprabasal differentiating epithelial 
cells. This stage is accompanied by the occurrence of visible low-grade lesions. Here, the viral 
proteins are expressed - with E6 and E7 under transcriptional control -, viral DNA is synthesized and 
finally viral particles are released. In case of persistent HPV infection the lesions may progress 
towards the transforming infection stage (step 3) which is accompanied by a fundamental shift in the 
viral gene expression pattern with E6 and E7 oncogene overexpression as described in chapter 1.3.2. 
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This shift is the key event for the development of high-grade precancerous lesions and cancers with 
critical host cell pathways being reprogrammed to overcome the cell cycle arrest of fully differentiated 
cells and promote the proliferation of these keratinocytes.  
With regard to the histomorphological classification precancerous stages are graded from CIN1 lesions 
to CIN2 and CIN3 depending on the severity and the extent of the affected epithelium as described in 
chapter 1.3.5. Thereby CIN1 overlaps with both biological categories with the majority of them 
representing permissive infections and a smaller proportion of them being in the transforming 
infection stage.  
As the shift to E6 and E7 oncogene overexpression is accompanied by the induction of p16
INK4a
 
overexpression (chapter 1.3.4) in the affected cells p16
INK4a
 is a surrogate marker for transforming 
processes ongoing under the influence of the viral oncoproteins that interfere with the host cell 
replication machinery and tumor suppressors. A strong p16
INK4a
 expression can be detected in around 
40 % of low-grade lesions, the vast majority of high-grade lesions and virtually all cervical cancers 
(DARRAGH et al., 2013; TSOUMPOU et al., 2009). As it is consistently expressed along with viral 
proteins E6 and E7 it represents an interesting target for immune therapies.  
 
Although virtually all cervical cancers can causally be linked to human papillomaviruses, a woman 
who is infected does not inevitably develop a precancerous lesion and cancer. Most of the HPV 
infections are cleared spontaneously within several months. Only a long-lasting persistent HPV 
infection may lead to the development of precancers which is a rare event. The natural history of HPV 
infections and the development of premalignancy and eventually cancer can be considered a dynamic 
process in opposite directions, progression and regression. With more than 90% of HPV infections 
being cleared within 2 years only a small percentage of women originally infected will develop a 
precancerous lesion (SCHIFFMAN and WENTZENSEN, 2010). And also established CIN lesions 
show a clinically heterogeneous behavior: Here again, only a part of them will further progress 
towards higher lesion grades and the majority of them (60% of CIN 1 and 40% of CIN2) will regress 
in dependence of the host’s immune surveillance capacities (MCCREDIE et al., 2008; OSTOR, 1993). 
Even CIN3 lesions with extensive morphological abnormalities are reported to regress to a certain 
extent (MUNK et al., 2007).  
There are sporadic reports on a higher progression risk of p16
INK4a
-positive CIN1 compared to the 
p16
INK4a
-negative ones (WANG et al., 2004). Nevertheless high-grade lesions, although they are all in 
the transforming infection stage and thus all show p16
INK4a
 overexpression, do not all progress. This 
demonstrates that p16
INK4a
 which is a reliable surrogate for oncoprotein activity and the biological 
infection stage cannot predict progression of a lesion and other markers are necessary for the 
development of a prognostically relevant tool.  
 
The prevalence of HPV-infection is highest in young women aged 15-25, and the mean age of women 
diagnosed with high-grade cervical lesions is approximately 28 years, while invasive cervical cancer is 
established much later in women aged approximately 50 years at time of diagnosis (DOORBAR, 
2006). Only a part of the precancerous lesions persist, progress and grow further out over time to 
bigger lesions and to higher precancerous stages and finally only the minority of individuals that have 
acquired a HPV-infection during their life time develop cancer. This demonstrates that cervical 
carcinogenesis as very slow process. Considering these clinical characteristics one might speculate that 
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accumulation of genetic changes of the host in combination with predisposing factors might be 
decisive for whether a tumor develops or not.  
The progression towards cancer could biologically be explained by accumulation of specific cellular 
and chromosomal changes and subsequent outgrowth of distinct cell clones. It has been demonstrated 
that the viral oncoprotein overexpression affects the integrity of the host genome in different ways:  
Both oncoproteins E6 and E7 are able to cause major numeral and structural chromosomal aberrations 
and also DNA damages (DUENSING and MUNGER, 2002). These changes are caused by disruption 
of the centrosome duplication control mechanisms and the simultaneous induction of multiple spindle 
poles (KORZENIEWSKI et al., 2011). The resulting mis-segration of chromosomes and aneuploidy of 
the host cells contribute to further genomic aberrations. Although deadly for most of the cells raising 
during such process this might generate some cells with growth advantage and lead to the outgrowth 
of these cell clones (DUENSING and MUNGER, 2002; KORZENIEWSKI et al., 2011).  
 
 
 
 
FIGURE 1.8  CERVICAL CANCER PROGRESSION MODEL. Cervical carcinogenesis is a characterized by 
successive biological infection. It is, however, a dynamic processes as lesions also can undergo 
regression. Persistent transforming infection is accompanied by accumulation of secondary genomic 
alterations that might provide distinct cells with growth advantage. Selection for these cell clones and 
expansion leads to tumor growth and invasive disease. The transforming infection stage is highlighted by 
p16INK4a overexpression. Histomorphological classification represents a two-tiered system that does not 
match the biological infection stages totally as transforming infections can be observed in a proportion of 
low-grade lesions already. Adapted from (DOEBERITZ and VINOKUROVA, 2009a).  
Studies that are based on comparative genomic hybridization report on different genomic changes in 
cervical squamous cell carcinoma such as gains at chromosome 3q, losses at 3p and losses at 11q with 
the aberrations mainly located at the terminal chromosomal regions. In cervical precancerous stages 
there are also chromosomal aberrations, with increasing frequency from low-grade CIN to high-grade 
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lesions and finally cancer. The same gains and losses affecting 3p, 3q and 11q of cervical squamous 
cell carcinoma are already present in high-grade lesions, however at a lower frequency. Genomic copy 
number alterations have substantial effects on gene dosage that may involve overexpression of 
oncogenes on the one side and decreased expression of tumor suppressor genes on the other side. As 
the above described changes of different chromosomal regions are all present in SCC one might 
speculate that these aberrations provide growth advantage for tumor cells and are selected during 
cervical carcinogenesis (reviewed in THOMAS et al., 2013).  
The chromosomal instability of keratinocytes is likely to induce secondary genomic alterations that 
may give rise to cells having distinct features providing them with growth advantage (BECKMAN and 
LOEB, 2005). During continued persistence these cells are further selected by evolutionary 
mechanisms leading to clonal expansion of cells that are adapted best to the host’s immunologic 
environment. 
 
Still, the causal relationship between integration of the viral genome and induction of chromosomal 
instability leading to further genomic alterations is discussed controversially. Different 
hypotheses/concepts regarding the chronology of the events may be discussed: On the one hand 
integration of the viral DNA is hypothesized to be the first event leading to genomic rearrangement 
and for this reason is responsible for chromosomal instability and aneuploidisation (HOPMAN et al., 
2006; PETER et al., 2010; PETT et al., 2004). On the other hand genomic instability is considered to 
be an early event and rather prepares the integration of the viral DNA by creating fragile chromosomal 
sites (DUENSING and MUNGER, 2004; MELSHEIMER et al., 2004, reviewed in WENTZENSEN et 
al., 2004). Nonetheless, cervical carcinogenesis can be seen as a multi-step process including 
deregulation of viral protein expression and breakthrough of the host’s cell cycle machinery finally 
leading to chromosomal instability, accumulation of DNA damages and secondary (epi)genetic 
alterations that altogether favor the outgrowth of cancer cells (SNIJDERS et al., 2006).  
Whatever the chronological succession is, chromosomal instability seems to be the decisive event for 
the onset of malignant processes and the transition from precancerous lesions to invasive disease 
(BIGNOLD, 2002, 2003). The resulting destabilizing effects of aneuploidy in terms of chromosome 
synthesis, segregation and repair during mitosis lead to further secondary genomic changes giving rise 
to a huge number of cells provided with different characteristics (reviewed in DUESBERG et al., 
2011). Those that are best adapted to the environment of their host, especially the immunologic 
environment, will survive and undergo clonal expansion and thus promote carcinogenesis.  
An effective immune response is considered to be crucial for the clearance of infections and for 
regression of established lesions. Considering the complexity of the immunobiology of HPV 
infections (described in section 1.4.1) and the multitude of mechanisms developed by the virus to 
circumvent the host’s immune attack (see “immune evasion”, section 1.4.2) it appears that secondary 
genomic alterations are likely to affect mechanisms that contribute to immune tolerance or 
immunosuppression and that enables the virus to remain undetected. Another frequently observed 
genomic loss (LOH) is that at 6p21.3 locus which harbors the genes for HLA class I antigens 
(CHATTERJEE et al., 2001; KERSEMAEKERS et al., 1999). This results in MHC-class I down-
regulation which substantially contributes to impaired antigen presentation and recognition by immune 
cells that could eliminate HPV infected or precancerous cells, such as cytotoxic T cells (CTLs). Other 
secondary genomic changes that alter the immunological features also might contribute to survival and 
growth advantages of cells which undergo clonal selection to finally grow out to precancerous lesions 
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and invasive cancers. The HPV-transformed cells within these lesions and tumors are able to 
circumvent the host’s immune attack by different mechanisms and therefore constitute the “immune 
evasion phenotype”.  
 
Considering the fact that all projects of this thesis are centered on questions of immunology, the 
following chapter will address different immunologic aspects in general and in particular related to 
HPV-infections.  
 
1.4  The immunobiology of HPV infections  
1.4.1 The role of the host’s immune system in the defense against HPV 
The host’s immune system plays a crucial role in whether a HPV infection persists or is cleared and 
whether a developing lesion regresses spontaneously or persists and finally leads to invasive cancer. It 
has been demonstrated that immune deficiency and immunosuppression of allograft transplanted 
patients increase the risk for persistence of the precancerous disease and development of cancer 
(DENNY et al., 2012; PALEFSKY, 2009). In contrast, cytotoxic T lymphocytes (CTLs) are associated 
tumor control and a decreased risk for cancer (MATSUI et al., 1999). The presence or absence of 
distinct immune cell phenotypes in the lesion and the surrounding tissue is considered to be highly 
important for the prediction of the clinical outcome of the patients and should be considered in the 
treatment plans as a prognostic parameter.  
The following sections will address the different arms – innate and adaptive - of the immune system 
and their role in HPV-related diseases.  
 
 
INNATE IMMUNITY AND HPV  
 
The innate responses represent the first line defense against invading pathogens and comprise 
mechanisms that, in contrast to adaptive immune responses, act independently from antigen 
specificity. Activation of the innate immune system leads to an immediate reaction without 
establishing however an immunologic memory of the encountered pathogens (MOGENSEN, 2009). 
Cells of the innate immune system recognize highly conserved molecular patterns that are shared by 
many different pathogens leading to a general activation of the immune system. Here, Toll-like 
receptors (TLRs) play an important role (HEINE and LIEN, 2003) which will be explained in more 
detail in section 1.4.x. Cells of the innate immune system comprise dendritic cells (DCs) and 
Langerhans cells (LCs) which are professional antigen-presenting cells (APCs), and also 
macrophages, natural killer (NK) cells and natural killer T (NKT) cells. They release pro-
inflammatory cytokines and thereby substantially change the immune milieu of the infection site by 
attracting further innate immune cells and, in a second step, by induction of the adaptive immune 
response (JANEWAY and MEDZHITOV, 2002). Antigen-processing and cross-presentation by DCs 
and LCs enable T lymphocytes to get activated and to perform their tasks as cells of the adaptive 
immune system (reviewed in AMADOR-MOLINA et al., 2013).  
NK cells are an important cell type mediating innate immunity as they are able to recognize abnormal 
cells, for example by aberrant Human Leukocyte Antigen (HLA) class I molecule expression. NK cell-
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mediated cytotoxicity which is induced upon stimulation of activating NK cell receptors such as 
NKp30, NKp46 and NKG2D then eliminate these virally infected or precancerous cells (reviewed in 
AMADOR-MOLINA et al., 2013).  
In the setting of established HPV-associated precancers and cancers however, many innate immunity 
mechanisms are impaired, such as cytokine release, antigen-presentation by LCs and type I interferon 
(IFN)-responses favoring the persistence and progression of the lesions and carcinogenesis, that will 
be explained in more detail in section 1.4.2 (reviewed in STANLEY, 2008).  
 
 
HUMORAL IMMUNE RESPONSE TO HPV 
 
The viral protein that most potently induces antibody responses in patients with underlying HPV-
infections is the late protein L1. However, titers of neutralizing antibodies remain relatively low in 
naturally occurring HPV infections. This might be due to mechanisms developed by the virus to evade 
recognition and elimination by the host’s immune system that will be discussed in chapter 1.4.2. These 
immune evasion strategies prevent the induction of a strong immune response (STANLEY, 2008). 
HPV infections studied in animal models revealed that even low antibody titers provided protection 
against subsequent HPV infections. The observation that the protective characteristics of these sera 
could be transferred to other individuals gave rise to the development of the currently used 
prophylactic vaccines that use L1 of different HPV-types as an immunogen in a bivalent (Cervarix®, 
HPV16 and 18) and a quadrivalent formulation (Gardasil®, HPV 6, 11, 16 and 18) (reviewed in 
STANLEY, 2006).  
 
 
T CELL MEDIATED IMMUNE RESPONSE TO HPV  
 
T lymphocytes can - independently of antigen-specificity - be quantified as different T cell subtypes in 
the epithelium where the lesion or the tumor is located and the adjacent stromal compartment which is 
generally characterized by higher densities of immune cells (GUL et al., 2004; SHAH et al., 2011). T 
cell phenotypes that could be relevant in the course of HPV infection and development of 
precancerous lesions belong to different arms of the immune system and might contribute to either an 
effectively mounted response against the infected keratinocytes or to immune suppression and T cell 
anergy and thus to disease progression (GARCIA-CHACON et al., 2009; PATEL and 
CHIPLUNKAR, 2009). Immune markers that provide information about the quality of the immune 
cell composition in the locally confined regions around the lesions include different T cell markers: 
CD3+ T cells generally are quantified in order to obtain information about the total T cell numbers 
present in the affected tissue. To define the proportions of different specialized T cell subpopulations 
the total infiltrate consists of, other markers might be interesting: CD4 is generally used to characterize 
T helper cells whereas CD8 identifies the presence of cytotoxic T lymphocytes (CTLs) that can further 
be characterized by Granzyme B (GranB) which is typically expressed in activated, granzyme-
producing CTLs (BONTKES et al., 1997; NEDERGAARD et al., 2007). Forkhead box transcription 
factor 3 (Foxp3) however is a marker for regulator T cells (Treg cells) and rather indicates the 
activation of the opposite, immunosuppressive arm of the immune response (WU et al., 2011). CD3 ζ-
chain is a dimeric signal transducing molecule of the T cell receptor (TCR) that is responsible for the 
activation of T cells following binding to and recognition of HLA-bound antigens. It therefore is 
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considered to be a parameter for the successful T lymphocyte activation and effectiveness of the T 
cell-mediated immune response (WHITESIDE, 2004). 
 
With regard to the first approach, previous cross-sectional studies evaluating the densities and 
phenotypes of tissue infiltrating T cells in general report on elevated numbers of different T 
lymphocyte subtypes, such as CD3+ T cells, cytotoxic CD8+ CTLs and also Treg infiltration, with 
increasing histomorphologically defined CIN stages (EDWARDS et al., 1995; NEDERGAARD et al., 
2007) (ADURTHI et al., 2008; WU et al., 2011). However, only the minority of CTLs in CIN is 
reported to be in the activated, GranB-expressing state (BONTKES et al., 1997). Single studies also 
report the inverse correlation between global T cell infiltration and histomorphologically defined 
stages (SILVA et al., 2010). Regulatory T cells are considered to exert immunosuppressive functions 
in the microenvironment and are reported to be increased in high-grade lesions and invasive cancer 
and might contribute to the progression of the lesions towards cancer (ADURTHI et al., 2008; 
JAAFAR et al., 2009; NAKAMURA et al., 2007; WU et al., 2011) and (reviewed in PATEL and 
CHIPLUNKAR, 2009). Down-regulation of CD3 ζ-chain expression has been demonstrated in 
different tumor entities such as melanoma (DWORACKI et al., 2001), head and neck cancers (KUSS 
et al., 1999) and also colorectal carcinomas (NAKAGOMI et al., 1993) which emphasizes 
(NAKAGOMI et al., 1993)its relevance for disease progression. However, the data published for 
cervical cancer and its precancerous lesions are way scarcer (ZEHBE et al., 2002). Interestingly, CD3 
ζ-chain expression was found to be down-regulated in cervical carcinoma patients compared to healthy 
controls but not in precancerous lesions.  
These previous studies on T cell infiltration reported on varying cell densities and phenotypes in 
correlation with histomorphological disease stages without taking however into consideration the 
underlying biological infection status defined as non-transforming and transforming infections. 
Therefore, it has been remained unclear until now whether these changes are induced with beginning 
transforming infections in low-grade lesions or rather occur later in well-established high-grade 
lesions that have accumulated secondary genomic alterations and clonal selection. 
The density and phenotype of tissue infiltrating T cells has been reported to correlate with outcome in 
various cancer types (GALON et al., 2006) and it is conceivable that the quantity and the quality of 
immune cells in CIN is of prognostic importance.  
 
With regard to the characterization of antigen-specific T cells in HPV-related cervical precancers and 
cancers data are published for peripheral as well as for tumor-infiltrating T cells. T cells specific for 
HPV-antigens are rare, however several studies demonstrated that at low frequencies they exist.  
The immunogenicity of the viral Ll proteins that is able to induce a humoral immune response is also 
reported to contribute to proliferative T cell responses. Both T cell subtypes, CD4+ and CD8+ T cells 
were shown to contribute to the cellular immunity (PASSMORE et al., 2002). However, CD4+ T 
lymphocytes were characterized by a higher IFN-γ release upon stimulation with L1-peptides 
demonstrating that the antigen is able to induce a T helper cell type 1 (Th1) memory response that 
enhances the mechanisms of the cell-mediated immunity (SHEPHERD et al., 1996). Interestingly, T 
cell responses predominated in patients who had cleared the HPV infection or resolved precancerous 
lesions and one could speculate that CD4+ memory T cell responses are established during the battle 
against HPV infections and also provide long term protection (CHAN et al., 2011). Conversely, 
patients with advanced persisting or progressing precancerous lesions lack pro-inflammatory cytokines 
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(DE VOS VAN STEENWIJK et al., 2008) and although isolated from tumors and lymph nodes of 
cervical cancer patients CD4+ and CD8+ T cells show only low levels of IFN-γ release upon 
stimulation with HPV antigens (DE VOS VAN STEENWIJK et al., 2010).  
This again is indicative for the inability of these patients to mount an effective T cell-mediated 
immune response leading to functionally inactive or even immunosuppressive T cell fractions 
invading the tumors and circulating in the peripheral blood. Factors that might contribute to the 
impairment of the host’s cellular immune response and the inability of these patients to clear the 
infection and thus prevent malignancies will be highlighted in the following section (1.4.2).  
 
The published data imply that antigen-specific cellular immune responses is associated a successful 
establishment of immune response against HPV and clearance of the infection and thus occurred in 
patients whose immune system successfully raised an immune response against HPV. Also the lack of 
IFN-γ secretion, the cytokine directing cellular cytotoxic responses, suggests that immunosuppressive 
mechanisms inhibit the raise of an effective cell-mediated immune response and immune attack of the 
lesions and tumors. This might be an interesting starting-point for therapeutic interventions.  
 
 
1.4.2 Immune evasion strategies developed by human papillomaviruses  
Human papillomaviruses have developed different immune escape mechanisms allowing them not 
only to modulate the host’s immune response that might be raised during infection and establishment 
of precancerous lesions but also to avoid to be recognized and to remain largely invisible for the host’s 
defense mechanisms. The viral life cycle regarding the site of infection and also the viral replication 
within the epithelium is perfectly adapted to assure immune ignorance (reviewed in KANODIA et al., 
2007 and STANLEY, 2012a).  
In general, the infection site is located in the basal cell layer of the stratified squamous epithelium and 
occurs via microlesions in the tissue giving the virus access to the basal stem cells. During permissive 
infection the viral genome is maintained in that cell layer at low copy numbers which minimizes the 
antigen exposure for immunocytes that could potentially invade the epithelium from the stromal tissue 
beneath. The expression level of the viral proteins, especially the early proteins, remains very low 
during replication (Figure 1.9). The protein considered to be most immunogenic, the viral capsid 
protein L1, is not expressed in the basal, undifferentiated layers of the squamous cell epithelium. As 
only in the upper layers of the squamous epithelium, which circulating immune cells hardly have 
access to, the viral proteins become expressed at higher levels, and an effective immune response 
cannot be initiated. The low expression level of HPV proteins in epithelial layers that are closer to 
immune cells thereby represents an effective immune evasion strategy (FELLER et al., 2010). 
Furthermore, the assembled virions are released during naturally occurring cell death of differentiated 
keratinocytes arriving at the upper side of the epithelium and not due to cytolysis or necrosis of the 
infected host cells. Again, this strategy prevents stromal or epithelial immune cells from having direct 
contact with the infectious agent and also inhibits inflammation at the infection site. The non-lytic life 
cycle of HPV does not provoke release of pro-inflammatory cytokines and supports the virus’ 
invisibility to the host’s immune defense (STANLEY, 2006). Altogether the viral replication cycle is 
perfectly adapted to the differentiation of the host’s keratinocytes with the aim to reduce antigen 
exposure and pro-inflammatory mechanisms and thereby to avoid an effective immune response to be 
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raised. At a later time point, the interaction of the viral proteins E6 and E7 with host cell pathways 
regulating apoptosis and cell cycle progression contribute to the survival of the virus within 
keratinocytes by preventing apoptosis and delaying the differentiation program of keratinocytes that 
consequently remain in the proliferative phase (chapter 1.2).  
 
 
FIGURE 1.9 HPV EVADES THE HOST’S IMMUNE SYSTEM. The virus’ life cycle (left) is adapted to the host 
cells’ differentiation program and thus prevents immune recognition: there is no blood-born phase, low 
viral protein levels in the basal cell layers, no cell death for viral release. Furthermore, HPV actively 
down-regulates inflammatory processes (right) preventing thus the activation of innate and adaptive 
immune responses by different mechanisms. Adapted from (STANLEY, 2012a).  
Also the fact that the viral genome is not optimized for the mammalian translation machinery and 
shows a different codon usage that results in decreased translation rates of the viral proteins might 
explain the low expression profile of viral antigens (reviewed in ZHAO and CHEN, 2011). 
Furthermore, a mechanism that can be subsumed under the keyword “molecular mimicry” contributes 
to immune evasion by hindering recognition by and reactivity of immune cells (OLDSTONE, 1998). It 
has been demonstrated that human papillomavirus proteins display similar epitopes compared with the 
host cell proteome that leads to less effective immune response due to self-tolerance mechanisms of 
the host’s cells (NATALE et al., 2000). 
 
The immune evasion strategy of HPV does not only include adaptions to remain invisible for the 
host’s immune system but also includes strategies evolved to actively counteract immune responses 
that are raised by the host.  
Immune tolerance and immune suppression per se are important and helpful mechanisms in the 
regulation of the different arms of the immune system and balance the activation and termination of 
immune attacks. Mediators of immune suppression such as regulatory T cells are inherent to the 
immune defense and have evolved to prevent damages by excessive cytotoxic responses especially if 
they are directed against self-antigens. Adopted by tumors, however, immune tolerance or suppression 
are mechanisms that enable cancer cells to evade the host’s immune attack. They become able to 
modulate the tumor environment in order to create an immunotolerant micromilieu and thereby to 
immobilize the host’s immune responses.  
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Chemokines and cytokines are signaling molecules and the key players in the regulation of a complex 
immunologic network of activating and inhibitory immune responses. They are decisive for the 
immune cell types attracted to the lesion and the outcome of the immune response. Immune evasion 
strategies developed by tumors that involve aberrant cytokine or chemokine secretion do not only have 
singular but rather systemic effects on different immunological pathways. The most immediate effect 
of HPV infections is the down-regulation of type I IFN responses inhibiting antiviral innate immune 
defense mechanisms and also the induction of a secondary adaptive response (Figure 1.9). Type I IFN, 
especially IFN-α, is normally produced by infected cells, has anti-viral effects and also recruits 
neutrophils, macrophages, NK cells and DCs to the infection site (BASLER and GARCIA-SASTRE, 
2002). Its activation is necessary to induce both the innate and the adaptive immune response. The 
viral oncoproteins have been shown to interact with IFN signaling pathways that normally lead to 
transcriptional induction of IFN downstream target genes necessary for anti-viral defense, induction of 
immune response and cell growth regulation. Both E6 and E7 directly interfere with IFN downstream 
targets (IFN response genes, nuclear factor-kappa B (NFkB)) and signaling pathways to prevent IFN-
mediated immune responses. They inhibit among others the transcription of transporter associated 
with antigen-processing 1 (TAP-1), IFN-β and monocyte-chemoattractant-protein-1 (MCP-1) and 
interfere with the Jak-STAT-pathway that upon activation regulates DNA transcription and is also 
involved regulating the activity of immune cells (reviewed in STANLEY, 2008). Further chemokines, 
such as interleukin (IL)-8, and cytokines (IL-18, IFN-γ) are suppressed in HPV-infected cells. 
Normally involved in the onset of the inflammatory responses and attracting different sorts of immune 
cells such as monocytes, memory T cells, NK cell or being involved in the priming of CD8+ T cells 
the down-regulation of these molecules favors the persistence of the viral infection and the 
development of precancerous lesions (reviewed in STANLEY, 2012a). Changes of the polarity of the 
Th1/Th2 cytokine profile to a pronounced Th2 response has also been demonstrated to have 
immunosuppressive effects and to result in impaired cytotoxic immune responses (BAIS et al., 2005). 
Such a change is accompanied by reversal of the immune cell composition in precancerous stages and 
cancers as demonstrated by immunohistochemical analyses and also flow cytometry data (ADURTHI 
et al., 2012; SHAH et al., 2011).  
 
HPV infection also has effects on antigen presentation via HLA class I molecules. It has been shown 
several times independently that the viral early proteins E7 and E5 are associated with HLA class I 
antigen expression on keratinocytes and this impairs recognition of the infected cells by CD8+ T 
lymphocytes and the induction of a cytotoxic response (BOTTLEY et al., 2008; CAMPO et al., 2010). 
Theoretically, down-regulation of HLA class I molecules on the cell surface increases the 
susceptibility to be killed by NK cells. However, as the immunosuppressive cytokine IL-10 is also 
associated with HLA class I down-regulation (RODRIGUEZ et al., 2012), it is likely that the 
keratinocytes evade a possible NK cell-mediated immune attack due to the generally 
immunosuppressive micromilieu probably disturbing the recruitment of immune cells to the lesion. It 
could be demonstrated that E5 and the oncoprotein E7 both directly regulate HLA class I expression 
levels (reviewed in KANODIA et al., 2007). The interaction of E7 with the promoter of the HLA class 
I heavy chain gene has repressive effects on the transcription and leads to down-regulation of HLA 
class I antigen levels (GEORGOPOULOS et al., 2000). Viral E5 in contrast affects the stability and 
the transport of HLA class I complexes loaded with peptides that both depend on an acid pH: via 
interaction with the H(
+
)-ATPases (V-ATPase) it inhibits the acidification of endosomes and the Golgi 
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complex and thus massively disturbs peptide-HLA-complex trafficking to the cell membrane 
(ASHRAFI et al., 2005; SCHAPIRO et al., 2000).  
Down-regulation of type I IFN production is associated with lacking antiviral innate immune defense 
mechanisms and consequently inhibition of a secondary adaptive response. It was shown that the 
initiation of any of these responses by antigen-presenting cells (APCs) is defective because 
Langerhans cells, the specialized epithelial APCs, are decreased in number and are not activated 
during HPV-infections and uptake of L1 antigen, leading to inhibition of both innate and adaptive 
immune response (STANLEY, 2008). Different mechanisms are discussed to contribute to this lacking 
LC activation: (1) E-cadherin expression in keratinocytes which is required for APCs to migrate 
through the epithelium is down-regulated under the influence of DNA methyltransferase 1 activity 
(Dnmt1) (LAURSON et al., 2010). (2) The inhibition of a HPV-specific immune response in the 
epithelium is caused by activation of phosphoinositide-3-kinase pathway (FAUSCH et al., 2005).  
(3) Immunosuppressive cytokines (transforming growth factor (TGF)-β, Fas-ligand) may be released, 
that among other effects are responsible for the recruitment of regulatory T cells (Treg cells) that again 
change the cytokine milieu in the lesions by releasing TGF-β and IL-10. This release inhibits thereby 
the functional activity of CTLs and in the long run favor a deficient recognition of and cytotoxicity 
against HPV-infected and transformed cells and promote the outgrowth of the lesions and progression 
towards cancer.  
Altogether, these factors inhibit the influx of immune cells into the epithelial compartment, impair the 
migration and thus lead to a decreased likelihood that immune cells detect HPV and initiate an 
effective immune response.  
 
Importantly, the rates of HPV clearance and lesion regression proof that in the majority of the patients 
the immune system is able to combat the disease and that the quality of the immune system, either 
humoral (mainly against L1) or cell-mediated (against late or early viral proteins), is decisive in the 
natural course and also treatment of cervical intraepithelial neoplasia and cancers. Immunotherapeutic 
inventions therefore should aim at the activation of a strong, T cell-based immune response that may 
induce destruction of HPV infected keratinocytes by CTLs either by recognition of tumor antigens or 
tumor-associated antigens.  
Also, the composition of the T cell infiltrates and the cytokine profile in the microenvironment may be 
indicative for the clinical course of the disease and the patient’s outcome and therefore represent 
potential markers for progression or regression. They also contain information that could potentially 
be considered for treatment decisions in precancers in order to minimize unnecessary surgical 
interventions in patients that - from their immune status - are likely to overcome the disease.  
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1.5  Immunologic intervention strategies in HPV-associated 
diseases  
1.5.1  The urgent need for therapeutic interventions in HPV-associated 
precancers and cancers  
The prophylactic L1 VLP based vaccines Cervarix and Gardasil aim at the induction of a systemic 
immune response and are based on the production of neutralizing antibodies floating the whole body. 
The represent, however, HPV type-specific approaches and are considered - aside from sporadic 
reports on cross-protection - to offer protection against only two high-risk HPV types, HPV16 and 18, 
(reviewed in KAWANA et al., 2009). Also, they do not have any known advantageous effects on 
preexisting HPV infections or established lesions.  
A recently developed mathematical model can be used to estimate the impact of the prophylactic 
vaccines on the development of the incidence of HPV-associated cervical precancers and cancers and 
also anogenital warts. This model is based on epidemiological information of the natural history of 
HPV infections, the frequency and natural history of HPV-infections and resulting precancerous 
lesions and considers also cervical cancer screening program implemented in Germany. This model 
predicts that with a vaccination coverage of about 50% only, which reflects the actual situation in 
Germany, over the next 100 years about 22% of cervical intraepithelial neoplasia and 37% of cervical 
cancers will be prevented by the available prophylactic vaccines (HORN et al., 2013). 
These data demonstrate that the situation within the next 20-30 years will not substantially change and 
that cervical precancerous lesions and cancers as well as anogenital warts still are a major health 
problem to resolve. Therefore, there is a non-negligible need for secondary vaccination strategies or 
other approaches enabling the immune system to recognize and eliminate HPV-infected and 
transformed cells. In contrast to primary vaccines, secondary therapeutic intervention strategies aim at 
establishing an effective cellular immunity and especially enhancing the T cell responses to antigens 
expressed by HPV-infected cells that additionally might undergo transforming processes 
(BRINKMAN et al., 2007). A multitude of secondary vaccination approaches is under investigation in 
preclinical trials and some are investigated in clinical trials (reviewed in ALBERS and KAUFMANN, 
2009 and KANODIA et al., 2008).  
It has been reported that the majority of the therapeutic vaccination trials only sporadically induce an 
efficacious clinical response accompanied by cytotoxic cellular responses that might be able to 
overcome the viral evasion mechanisms and subvert immune suppression. Some other approaches led 
to promising results in patients with vulvar precancerous lesions but rarely in cervical intraepithelial 
neoplasia. This might be due to special features of the mucosal immunity in comparison to the 
epithelial immune reactions in VIN that hinders the induction of cellular response upon systemic 
vaccine administration (reviewed in KAWANA et al., 2012).  
For these reasons other approaches, alone or in combination with the above described therapeutic 
vaccines represent an interesting option to enhance the host immune reaction, also at mucosal sites in 
order to elicit a strong T cell mediated immune response. One of these treatment strategies involves 
immuno-modulatory agents that modify the quality of the immune response and reverse the 
immunosuppressive environment. The following chapter is dedicated to Toll-like receptors that can be 
targeted by specific immuno-stimulatory compounds. Once they are activated by these compounds 
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they are able to link innate and adaptive immune responses to finally induce a strong anti-viral and 
anti-tumoral cellular response.  
 
1.5.2  Toll-like receptors are key players in linking the innate and adaptive 
immune responses  
Discovered in the 1990s and since then subject to many functional studies Toll-like receptors were 
identified as main molecules of the innate immune system and major players of the first wall 
encountered by pathogens that enter the body. TLRs can mainly be found in immune cells of the 
innate immune system including DCs, monocytes and mast cells. They can, however, occasionally 
also be found in T and B lymphocytes as well as in NK cells (CRAIN et al., 2013). Their expression 
also was demonstrated in cells of the endothelium and epithelium and in a subset of tumor cells 
(HOLLDACK, 2014).  
 
 
FIGURE 1.10 TLRs LINK INNATE WITH ADAPTIVE IMMUNE RESPONSES. Upon recognition of pathogen-
associated molecule patterns (PAMPs) by TLRs dendritic cells release cytokines (IL-6, IL-12) that via 
complex regulatory mechanisms stimulate further innate immune cells but also adaptive immune 
responses. Adapted from (STEVENSON and RILEY, 2004)  
 
TLRs fall into the category of the so called pattern recognition receptors (PRRs) that are able to detect 
microbial infections. They bind to and recognize highly conserved microbial structures, so called 
pathogen-associated molecular patterns (PAMPs) that are common to a broad variety of infectious 
agents and comprise molecules such as lipopolysaccharides (LPS), bacterial DNA or double-stranded 
RNA (CHAN et al., 2009). Binding of PAMPs results to interaction of the TLRs with adaptor 
molecules, for example with myeloid differentiation primary-response protein 88 (MyD88) (AKIRA 
and TAKEDA, 2004). This initiates complex intracellular signaling pathways mediating the signal to 
the nucleus where NFκB becomes activated regulating the expression of downstream target genes 
including primarily pro-inflammatory cytokines such as IL-1, IL-6, IL-8, IL-12, tumor necrosis factor 
(TNF)-α, IFN-α and IFN-β. Their expression further enhances the innate immunity. Immediate 
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protection against pathogens is provided, in an antigen non-specific manner, by activation of NK cells, 
recruitment of macrophages and activation of the complement cascade (reviewed in MEDZHITOV, 
2007). The induction of the expression of co-stimulatory molecules of antigen-presenting cells such as 
CD40, CD80 and CD86 that contribute to T cell activation (ZHOU et al., 2013) as well as the created 
pro-inflammatory milieu that recruits further immune cells to the infection site enables an antigen-
specific, adaptive immune response to be raised against the tumor (Figure 1.10) (DE GIORGI et al., 
2009). Obviously, TLRs activated in locally confined regions can also induce NK cell mediated 
killing, enhance MHC class I expression on tumor cells and interfere with apoptotic pathways of the 
tumor cells leading to tissue destruction and a further release of pro-inflammatory cytokines enhancing 
the immune response (HOLLDACK, 2014). 
1.5.3  Toll-like receptor ligands have immuno-stimulatory properties  
TLR agonists represent a promising approach for the activation of the innate and adaptive immune 
response by binding to and stimulation of TLRs. In the context of this thesis TLR7 is of special 
interest which is an intracellular non-catalytic receptor that is located within the endosomal 
compartment of immune cells (CRAIN et al., 2013). The natural ligands for TLR7 are single-stranded 
RNA molecules which preferentially are rich in guanine and uridine (DIEBOLD et al., 2004). 
However, they also respond to synthetic small molecules such as imidazoquinolines and molecules 
that structurally resemble purine bases (Figure 1.11) (HEMMI et al., 2002) making them an interesting 
target for immuno-modulatory treatment strategies.  
One of these synthetic TLR ligands is the imidazoquinoline compound imiquimod that acts as an 
immune modifier by changing the immune milieu by binding to TLR7 and, to a lesser extent, to TLR8 
(TERLOU et al., 2010). Imiquimod is approved by the Food and Drug Administration (FDA) as a 5% 
cream – and as such called Aldara® - and clinically applied for the treatment of genital warts, 
superficial basal cell carcinoma and actinic keratosis (GASPARI et al., 2009). Imiquimod appears as 
important non-invasive treatment option also in patients with vulvar intraepithelial neoplasia allowing 
the conservation of the vulvar anatomy and is of special interest in multifocal VINs that show high 
rate of recurrence. Two imiquimod-treatment studies, a pilot study and the following placebo-
controlled, randomized trial, were conducted that included patients with diagnosed vulvar 
precancerous lesions (grade 2 or 3). The trials demonstrated the efficiency of locally applied (topical) 
imiquimod treatment that induces (at least partial) clinical response in the majority of the patients 
defined as reduction of the lesion size, histologic regression and HPV clearance (VAN SETERS et al., 
2002; VAN SETERS et al., 2008). 
In general, Aldara® is well-tolerated by patients if locally applied. Nevertheless, clinical studies 
demonstrated that systemic and local adverse effects cannot be avoided. They appear as fever, 
arthralgia, headache, myalgia or lymphadenopathy and all these symptoms are caused by pro-
inflammatory cytokine release in the blood stream having systemic effects (CRAIN et al., 2013).  
These observations induced chemists and biologist to search for new derivatives with an at least as 
high immune stimulatory potential as imiquimod but reduced side effects. In this context, a TLR7-
specific ligand called SM360320 (Figure 1.11) was synthesized on the basis of an adenine skeleton 
and pharmacologically evaluated. In a mouse model, this substance demonstrated to have an adjuvant 
effect in combination with DNA vaccination (DHARMAPURI et al., 2009). It could also be shown 
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that SM360320 is up to 100-fold more potent in inducing interferons compared with imiquimod 
(KURIMOTO et al., 2004).  
In order to further improve the effects mediated by SM360320 further derivative molecules based on 
this core molecules were synthesized by conjugating it to different macromolecules such as proteins, 
lipids or polyethylene glycol. These attempts gave rise to TMX-202 which is the core TLR7 agonist 
conjugated to a C-12 phospholipid (Figure 1.11).  
 
 
FIGURE 1.11 CHEMICAL STRUCTURES OF TLR AGONISTS. Shown are the chemical structures of the 
imidazoquinoline imiquimod and the purine-like TLR7 ligand SM360320 which represents the core 
molecule of TMX-202 obtained by conjugation of a C-12 phospholipid.  
In a cooperation project with a company specialized in TLR agonist, Telormedix S.A., Bioggio, 
Switzerland, we could gain access to the new TLR agonist TMX-202 and characterize its immuno-
stimulatory potential on different levels and in vitro experiments.  
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2. 
 
MOTIVATION AND RATIONALE 
 
Infections with human papillomaviruses are very common in the sexually active population and under 
certain circumstances might give rise to dysplastic abnormalities of the squamous cell epithelium – for 
example in the cervix uteri where the lesions then are called cervical intraepithelial neoplasia (CIN). 
The initial step of cervical carcinogenesis is the transition from permissive infection to transformation 
of the HPV-infected cells, induced by expression of the oncogenes E6 and E7 that interfere with 
critical host cell pathways and which can be highlighted by p16
INK4a
 overexpression. However, the 
induction of transformation is not sufficient to drive a lesion into further progression and development 
of invasive cancer, as proven by the proportion of transformed high-grade lesions that are reported to 
undergo regression. The deregulated host cell pathways lead to chromosomal instability and 
subsequent secondary genomic aberrations. These might give rise to cell clones having distinct 
features providing them with growth advantage over normal cells promoting disease progression. The 
higher progression rates in immunosuppressed or immunocompromised individuals clearly 
demonstrate the importance of the host’s immune system in HPV clearance and prevention from HPV-
related cancer. Clonally selected and expanding cells might have developed mechanisms that promote 
immune evasion and thus disease progression (see Figure 2.1 for conceptual background). These 
mechanisms might affect the immune microenvironment by creating an immunosuppressive milieu as 
well as tumor cell intrinsic features enabling tumor cells to directly evade the immune attack.  
 
 
FIGURE 2.1 CONCEPTUAL MODEL ILLUSTRATING CENTRAL QUESTIONS ADDRESSED IN THIS THESIS. 
Immune evasion mechanisms in cervical intraepithelial neoplasia might contribute to the induction of 
transforming infection and progression of cervical intraepithelial neoplasia towards invasive cancer. 
Clonal selection for tumor cells favoring immune evasion leads to the outgrowth of a so called immune 
evasion phenotype which might be reversed by proper immuno-modulatory drug intervention. Adapted 
from (DOEBERITZ and VINOKUROVA, 2009b).  
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The objective of this thesis was to gain a better understanding of the battle of the host’s immune 
system against HPV-associated precancerous lesions of different grades and also cancer. This is 
crucial to improve prognostic markers for guiding treatment decisions and also therapeutic 
interventions. Therefore, in this thesis the following two central goals were pursued:  
In the first part of this thesis, the immune evasion phenotype of cervical precancerous lesions was 
characterized to improve the understanding of the quality of possibly initiated immune responses 
against HPV-induced neoplasia and evaluate how successful the immune system battles against 
dysplastic cells. Possible immune evasion or suppression mechanisms were investigated and their 
occurrence was correlated with different time points of the disease progression. Thereby features 
observed on the immune cells’ side as well as mechanisms inherent to HPV-infected keratinocytes 
were investigated.  
 
 
FIGURE 2.2 GRAPHICAL OVERVIEW OF THE AIMS AND THE WORKFLOW OF THE PRESENTED THESIS. 
Shown are the main questions of each part (dark blue), the different aspects investigated in this context 
(grey) and the central methodological approaches (light blue).  
 
The second part of this work aimed at the development of non-invasive therapeutic strategies to 
circumvent possible immune evasion mechanisms in HPV-associated diseases. Different approaches 
aiming at immune-modulation of potentially suppressed immune responses were evaluated that 
possibly influence the balance between immune evasion and anti-tumoral immune response and thus 
might lead to an effect tumor attack.  
 
 
All these aspects of the interaction of the host’s immune system with lesion or tumor cells in HPV-
associated diseases were investigated by a broad spectrum of different approaches to address specific 
problems (outlined in Figure 2.2).  
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 Objective and standardized quantification methods for immune cell infiltrate in HPV-associated 
precancerous lesions of the cervix are lacking.  
 Development of a computational tissue analysis platform combining histological analysis and 
automated whole slide imaging allowing the objective quantification of tissue infiltrating 
immunocytes. This method is required to establish an immune-based prognostic biomarker tool 
for cervical intraepithelial neoplasia that would also allow the monitoring of the efficacy of 
tumor therapies (chapter 4.1).  
 
 It is still unclear which mechanisms trigger the infiltration of immune cells into lesions and a 
shift in immune cell densities and composition still cannot be related to any time point of the 
natural history of CIN. It is of particular interest whether this correlates with the biological 
infection status, e.g. with the shift from permissive to transforming infection.  
 Characterization of the immune cell infiltrates as CD3, CD8, GranB, Foxp3 and CD3 ζ-chain 
expressing cells in an antigen-independent way in cervical precancerous lesions of different 
grades and infection stages by immunohistochemistry. The main focus was lying on possible 
differences between permissive and transforming infections as represented by p16
INK4a
 
overexpression (chapter 4.2).  
 
 HPV might interfere with antigen-presentation mechanisms and thus contribute to immune 
evasion. Altered HLA expression is reported in cervical cancer, the time point when this occurs 
during progression of precancerous lesions however remains to be elucidated.  
 Analysis of the expression of molecules involved in antigen-processing and -presentation (HLA 
class I heavy chains and light chains, and HLA class II antigens) on keratinocytes by 
immunohistochemistry in different progression grades of cervical precancerous lesions and 
cancers (chapter 4.3).  
 
 Topical treatment with an immune-modulatory drug, imiquimod, might have effects on immune 
cell densities and composition in cervical intraepithelial neoplasia. These changes might be 
associated with the clinical outcome of patients.  
 Longitudinal characterization of the immune cell infiltrates as CD3 and CD8 expressing cells by 
immunohistochemistry in cervical precancerous lesions that were topically treated with a Toll-
like receptor agonist-based immune modulator (chapter 4.4).  
 
 Second generation Toll-like receptor agonists might have less side effects compared with 
imiquimod, however their effects on immune cells and the potential to raise an anti-tumoral 
immune response in the context of HPV-associated diseases have to be demonstrated.  
 Evaluation of the effects of a new immuno-modulatory drug (TMX-202) on TLR7 expression in 
immune cells on the transcript and protein level by quantitative real-time PCR and western blot. 
Evaluation of its efficiency to induce a pro-inflammatory cytokine milieu (as measured by IL-6 
ELISA). Investigation of its potency to enhance the immune attack against HPV-associated 
cancers by an in vitro priming experiment of naïve T cells and measurement of cytotoxic 
responses against CaSki cells monitored by CD107a degranulation assay (chapter 5.1). 
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 Models based on HPV-positive tumor cell lines and autologous immune cells for the 
investigation of immune responses against HPV-associated tumors are lacking. These, however, 
are of special importance to test immune-modulatory treatment options.  
 Generation of a HPV-associated cell line from HNSCC patients in order to establish an 
autologous model for in vitro functional analyses of tumor cell and immune cell interaction. 
Tumor samples could be obtained from HPV-positive head and neck squamous cell carcinomas 
that develop through the same tumorigenic mechanisms as cervical cancers and therefore 
represent a valuable model for HPV-related cancers (chapter 5.2) 
 
 The immunophenotypic characterization of CIN and cervical cancer revealed regulatory T 
lymphocytes as one possible contributor to HPV-related carcinogenesis and possible target for 
immuno-modulatory intervention strategies.  
 Analysis of the immunosuppressive effects mediated by regulatory T lymphocytes in HPV-
associated diseases using the established autologous tumor model and evaluating Treg depletion 
as one possible therapeutic intervention strategy to reverse immune evasion phenotype. The 
antitumoral effects of Treg depleted T cells and the total T cell fraction was compared in 
CD107a degranulation assay and impedance measurement (chapter 5.3).  
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3. 
  
MATERIALS AND METHODS 
 
 
3.1  Materials  
3.1.1   Technical equipment, instruments 
Agarose gel carriage     Tecnomara (Fernwald) 
Agarose gel running chamber SubCell GT  Biorad (Munich)  
Analytical balance BP 210D     Sartorius (Goettingen)  
Balance BP 310S      Sartorius (Goettingen) 
Bond Autostainer     Leica Microsystems (Wetzlar) 
Camera Electrophoresis Docu System 120   Kodak (Stuttgart) 
Centrifuge 5810R     Eppendorf (Hamburg) 
Digital camera Leica DFC480     Leica Microsystems (Wetzlar) 
Electrophoresis chamber (Sub Cell GT)   Biorad (München) 
Flow cytometer (FACSCalibur)    Becton Dickinson (Franklin Lakes, USA)  
Fluorometer for microtiter plates Luminex 100  Luminex (Austin, USA) 
Gel Documentation GelDoc 2000   Biorad (München) 
Incubator      Memmert (Schwabach) 
Leica Bond Autostainer II     Leica Microsystems (Wetzlar) 
Magnetic stirrer MR 2002     Heidolph (Schwabach) 
Microscope for cell culture Olympus CK40  Olympus optical CO (Center Valley, USA) 
Microscope Leica DMRBE    Leica Microsystems (Wetzlar) 
Microtiter plate reader Multiscan EX    Thermo Electron Corporation (Karlsruhe) 
Microtome Leica RM 2035    Leica Microsystems (Wetzlar) 
Microwave       Panasonic (Hamburg)  
Minishaker Vortex MS1     IKA-Works (Wilmington, NC) 
NanoZoomer 2.0-HT Scan System    Hamamatsu (Herrsching) 
PCR system (Mastercycler Gradient)    Eppendorf (Hamburg) 
PH meter (PB-11)      Sartorius (Göttingen) 
Photometer for microtiter plates GENios   Tecan (Crailsheim) 
Photometer Ultrospec 7000    GE Healthcare (Uppsala, Sweden) 
Pipettes 2-1000µl Pipetman     Gilson (Bad Camberg) 
Pipettor 8-5010      Neolab (Heidelberg)  
Power supply Power Pac 300    Biorad (Munich) 
Real-Time PCR system (StepOnePlus)    Applied Biosystems (Foster City, USA) 
Robocycler Gradient 96     Stratagene (Santa Clara, USA) 
Rolling mixer CAT RM 5     Neolab (Heidelberg) 
RTCA Analyzer W380     ACEA Biosciences (San Diego, USA) 
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RTCA SP Station 1x96     ACEA Biosciences (San Diego, USA) 
Safety cabinet Class II, SL-130 Blue Series   Kojair (Vilppula, Finland) 
Shaker for microtiter plates Titramax 100  Heidolph (Schwalbach) 
Speed Vac DNA Speed Vac 110    Savant (Holbrook, USA) 
Table top centrifuge 5424     Eppendorf (Hamburg) 
Thermomixer 5436      Eppendorf (Hamburg) 
Vacuum manifold Vacusafe Comfort    Millipore (Billerica, USA)   
Vortex (MS1 Minishaker)     IKA (Staufen) 
Water bath Grant SUB14    Grant Instruments (Cambridge, UK) 
 
3.1.2  Chemicals and Reagents 
Acetic acid 100%     Merck (Darmstadt) 
Acryl amide RotiphoreseGel 30    Roth (Karlsruhe) 
Agarose Ultra Pure     Invitrogen (Carlsbad, CA, USA) 
Albumine Bovine Fraction V pH 7.0   Serva (Heidelberg) 
Amphotericin B      Invitrogen (Karlsruhe) 
Aquatex       Merck (Darmstadt) 
B2-microglobuline (human)     Sigma Aldrich (Steinheim) 
Boric acid       Merck (Darmstadt) 
Brefeldin A       Sigma-Aldrich (Steinheim) 
Bromphenol blue      Serva (Heidelberg) 
Caseine from bovine milk     Sigma Aldrich (Steinheim) 
CellGro® DC      CellGenix Technologie Transfer (Freiburg) 
Citric acid       Merck (Darmstadt) 
DAB+ Substrate Chromogen System    Dako (Carpinteria, USA) 
Decitabine (5-Aza-2‘-deoxycytidine, DAC)   Sigma-Aldrich (Steinheim) 
Developer for photographic processing    Adefo-Chemie (Dietzenbach) 
Dimethyl sulfoxide (DMSO) 99.5%    Sigma Aldrich (Steinheim) 
Dipotassium phosphate     Gerbu (Gaiberg) 
Disodium hydrogenphosphate    VWR (Darmstadt) 
Disodium phosphate      VWR International (Leuven, Belgium) 
DMEM / Ham’s-F12     Gibco (Paisley, UK)  
DNA ladder 100 bp      Invitrogen (Karlsruhe) 
Dulbeco’s PBS (1x)     Gibco (Paisley, UK)  
Ethanol 96%      Sigma Aldrich (Steinheim) 
Ethanol 99%      Sigma Aldrich (Steinheim) 
Ethanol absolute      Sigma Aldrich (Steinheim) 
Ethanol absolute      Sigma-Aldrich (Steinheim) 
Ethylenediaminetetraacetic acid (EDTA)  Merck (Darmstadt) 
Fetal bovine      Gibco (Paisley, UK) 
Fixer for photographic processing    Adefo-Chemie (Dietzenbach) 
GelRed Nucleic Acid Stain    Biotium (Hayward, CA)  
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Gentamycin       Invitrogen (Karlsruhe) 
Glutamine       PAA Laboratories (Pasching, Austria) 
Glycerol (86%)      Carl Roth (Karlsruhe) 
Glycerol      Roth (Karlsruhe) 
Glycine      AppliChem (Darmstadt) 
GM-CSF      PromoCell (Heidelberg) 
H2O HPLC-grade      VWR (Darmstadt) 
Haematoxylin      Sigma Aldrich (St. Louis, USA) 
Hemalaun       AppliChem (Darmstadt) 
Heparin-Natrium 25000    Ratiopharm (Ulm) 
Horse serum      Vector Laboratories (Burlingame, CA) 
Human epithelial growth factor (EGF)    Sigma Aldrich (Steinheim) 
Human serum       PAA Laboratories (Pasching, Austria) 
Hydrochloric acid (HCl 37%)     Carl Roth (Karlsruhe)   
Hydrocortisone      Sigma Aldrich (Steinheim) 
Hydrogen peroxide 30%     Merck (Darmstadt) 
IMDM        Gibco (Paisley, UK) 
Imiquimod       Calbiochem (San Diego, USA) 
Insuline       Sigma Aldrich (Steinheim) 
Isopropyl alcohol     Sigma Aldrich (Steinheim) 
Luminol Reagent for Western Blot sc-2048  SC Biotechnology (Santa Cruz, USA) 
Lymphocyte Separation Medium LSM 1077  PAA Laboratories (Pasching, Austria) 
Magnesium chloride (MgCl2)     Solis Biodyne (Tartu, Estonia) 
Mercaptoethanol      Merck (Darmstadt) 
Methanol       Sigma Aldrich (Steinheim) 
Paraformaldehyde (PFA)     Carl Roth (Karlsruhe) 
PBS        Gibco (Paisley, UK) 
Penicillin/Streptomycin (100x)     Gibco (Paisley, UK)  
Ponceau S Solution 0.1%    Sigma Aldrich (Steinheim) 
Potassium chloride      Merck (Darmstadt) 
Potassium dihydrogen phosphate    Gerbu (Gaiberg) 
Precision Plus Protein Standard    Bio-Rad (Munich) 
Protease Inhibitor Cocktail      Sigma (Steinheim) 
Protein Assay Dye Reagent Concentrate   BioRad (München) 
Quantum 263 Medium for Tumor Cells   PAA Laboratories (Pasching, Austria) 
Reaction buffer BD (10 x)     Solis Biodyne (Tartu, Estonia) 
Recombinant Human Interleukin-2    PromoCell (Heidelberg) 
Recombinant Human Interleukin-4    PromoCell (Heidelberg) 
Recombinant Human Interleukin-7    PromoCell (Heidelberg) 
RIPA Buffer      Sigma Aldrich (Steinheim) 
RNase Out       Invitrogen (Karlsruhe) 
ROX size standard      Applied Biosystems (Darmstadt) 
RPMI 1640       Gibco (Paisley, UK) 
34  3. Materials and Methods  
Sodium acetate      Roth (Karlsruhe) 
Sodium carbonate     J.T. Baker (Deventer, Netherlands) 
Sodium chloride (NaCl)    Sigma Aldrich (Steinheim) 
Sodium dihydrogen phosphate dihydrate  J.T. Baker (Deventer, Netherlands) 
Sodium dihydrogenphosphate monohydrate   J.T. Baker (Deventer, Netherlands) 
Sodium heparin      Ratiopharm (Ulm) 
Sodium hydrogene carbonate     Merck (Darmstadt) 
Sodium hydroxide (NaOH)    Sigma Aldrich (Steinheim) 
Sodium thiosulfate      Gerbu (Gaiberg) 
Sodiumdodecylsulfate (SDS)    Serva (Heidelberg) 
Supplement Insulin-Transferrin-Selenium   Gibco (Paisley, UK) 
Tetramethylbenzidine (TMB)    Sigma Aldrich (Steinheim) 
Tetramethylethylenediamine (TEMED)   Sigma Aldrich (Steinheim) 
TMX-202      Telormedix (Bioggio, Switzerland) 
Tris-(hydroxymethyl)aminomethane    Roth (Karlsruhe) 
Tris-HCl       Roth (Karlsruhe) 
Trypan blue solution      Sigma-Aldrich (Steinheim) 
Trypsin-EDTA       Gibco (Paisley, UK) 
Tween 20      BioRad (München) 
Ultima Gold       PerkinElmer (Waltham, USA) 
Xylene       Merck (Darmstadt) 
 
3.1.3  Consumables 
96-well plates, U-bottom     BD Falcon (Durham, NC, USA) 
96-well plates, V-bottom    BD Falcon (Durham, NC, USA) 
Cannulas Microlance 3     Becton Dickinson (Fraga, Spain) 
Cell culture plate Cellstar (6/12/96 wells)  Greiner Bio-One (Frickenhausen) 
Cell culture plate Nunclon Surface    Nunc (Roskilde, Danmark) 
Cell strainer (100 µm)      BD Biosciences (Erembodegen, Belgium) 
Columns (LS)       Miltenyi Biotec (Bergisch Gladbach) 
Columns (MS)      Miltenyi Biotec (Bergisch Gladbach) 
E-Plate VIEW 96     ACEA Biosciences (San Diego, USA) 
Examination gloves, Sempercare® nitrile   Semperit (Vienna, Austria) 
Filter paper      Whatman (Dassel) 
Filter systems (0.22 µm)     Corning incorporated (New York, USA) 
Filter tips (10 µl, 20 µl, 200 µl, 1000 µl)   Corning Incorporated (New York, USA) 
Filter tips Tip One      StarLab (Ahrensburg) 
Freezing tubes Cryo.s with screw cap (2ml)  Greiner Bio-One (Frickenhausen) 
Laboratory film Parafilm „M“    American National Can (Greenwich) 
Microscope cover glasses     Marienfeld (Lauda-Königshofen) 
Microscope slides Superfrost Plus   Menzel (Braunschweig) 
Microscopy Aquatex     Merck (Darmstadt) 
  3. Materials and Methods  35 
Microtome blades R35     PFM Medica (Köln) 
Microwell plate NUNC 96 flat bottom   NUNC (Langenselbold) 
PCR tubes       Steinbrenner (Wiesenbach) 
Petri dishes       Greiner Bio-One (Frickenhausen) 
Petri dishes (sterile)      Nunc (Roskilde, Denmark) 
Photographic film Kodak     Sigma-Aldrich (St. Louis, USA) 
Pipet tips       Greiner Bio-One (Frickenhausen) 
Polystyrene tubes      BD Biosciences (Erembodegen, Belgium) 
PVDF membrane Hybond N+     Amersham (Buckinghamshire, UK) 
Reaction tubes (1.5 and 2 ml)    Eppendorf (Hamburg) 
Reaction tubes (15 ml and 50 ml)   Greiner Bio-One (Frickenhausen) 
Scalpel No. 11      PFM Medical (Köln) 
Serological pipette (2-25 ml)     Sarstedt (Nümbrecht)  
Serological pipette Costar Stripette    Corning (New York, USA) 
Sterile filter (0.2 µm)      Corning Incorporated (New York, USA) 
Tissue culture flasks (sterile, pyrogen-free) Cellstar Greiner Bio-One (Frickenhausen) 
Western Blotting Luminol Reagent    Santa Cruz (Heidelberg)    
 
3.1.4  Commercially available kits 
CD4
+
CD25
+
 Regulatory T Cell Isolation Kit human Miltenyi Biotec (Bergisch Gladbach) 
CINtec Plus (Cytology, Histology)   Roche (Mannheim) 
DNeasy Blood & Tissue Kit     Qiagen (Hilden) 
dNTP Set 100 mM      Invitrogen (Karlsruhe) 
Hexanucleotide mix (10 x)     Roche Diagnostics (Mannheim) 
Multiplex HPV Genotyping Kit    Diamex (Heidelberg) 
Mycoplasma detection kit MycoAlert™   Lonza (Köln) 
Pan T Cell isolation Kit II     Miltenyi Biotec (Bergisch Gladbach) 
Power SYBR Green PCR Master mix    Applied Biosystems (Foster City, USA) 
QIAamp DNA FFPE Tissue Kit    Qiagen (Hilden)   
Quantikine®ELISA Human IL-6   R&D Systems (Abingdon, UK) 
RNeasy Mini Kit      Qiagen (Hilden) 
SuperScript II Reverse Transcriptase    Invitrogen (Karlsruhe) 
Vectastain Elite ABC Kit     Vector (Burlingame, USA) 
 
 
  
36  3. Materials and Methods  
3.1.5  Antibodies 
Reactivity Clone 
Modi- 
fication 
Application  
(dil./conc.) 
Supplier 
p16
INK4a
 E6H4 none 
ready to use in 
CINtec® Plus Kit 
(Roche, Mannheim) 
CD3 PS1 none 
IHC 
(1:50) 
Acris antibodies (Herford) 
Foxp3 236A/E7 none 
IHC 
(1:50) 
eBioscience (Frankfurt a. M.) 
GranzymeB 11F1 none 
IHC 
(1:50) 
Novocastra (Newcastle upon 
Tyne, UK) 
CD8 4B11 none 
IHC 
(1:50) 
Novocastra (Newcastle upon 
Tyne, UK) 
CD3-ζ 6.B10.2 none 
IHC 
(1:200) 
Santa Cruz (Heidelberg) 
HC-10 n.a. none 
IHC 
(1:50) 
kind gift of Soldano Ferrone 
HCA-2 n.a. none 
IHC 
(1:50) 
kind gift of Soldano Ferrone 
L368 n.a. none 
IHC 
(1:50) 
kind gift of Soldano Ferrone 
LG-612.14 n.a. none 
IHC 
1:300 
kind gift of Soldano Ferrone 
mouse IgG / 
rabbit IgG  
polyclonal biotin 
IHC  
(1:50) 
Vector Laboratories 
(Burlingame, USA) 
CD4 RPA-T4 FITC 
FACS 
(1:50) 
BD Pharmingen (Heidelberg) 
CD8 RPA-T8 FITC 
FACS 
(1:50) 
BD Pharmingen (Heidelberg) 
CD25 4E3 PE 
FACS 
(1:50) 
Miltenyi Biotec (Bergisch 
Gladbach) 
CD107a n.a. PE 
FACS 
(1:50)  
BD Pharmingen (Heidelberg) 
HLA-A2 n.a. FITC 
FACS 
(1:50) 
AbD Serotec (Puchheim) 
HLA-A/B/C W6/32 FITC 
FACS 
(1:50) 
eBioscience (Frankfurt a. M.) 
epithelial 
antigen 
BerEP4 FITC 
FACS 
(1:50) 
Dako (Eching) 
isotype 
control 
IgG1 
n.a. FITC 
FACS 
(1:50) 
BD Pharmingen (Heidelberg) 
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isotype 
control 
IgG1 
n.a. PE 
FACS 
(1:50) 
BD Pharmingen (Heidelberg) 
isotype 
control 
IgG2a 
n.a. FITC 
FACS 
(1:50) 
BD Pharmingen (Heidelberg) 
isotype 
control 
IgG2b 
n.a. PE 
FACS 
(1:50) 
BD Pharmingen (Heidelberg) 
isotype 
control 
IgG2b 
n.a. PE 
FACS 
(1:50) 
BD Pharmingen (Heidelberg) 
TLR7  monoclonal none 
WB 
(1:1000) 
Abcam (Cambridge, UK) 
HPV16 E7 NM2 none 
WB 
(1:500) 
Santa Cruz (Heidelberg) 
actin n.a. none 
WB 
(1:20000) 
MP Biomedicals, Heidelberg. 
rabbit IgG n.a. HRP 
WB 
(1:2000) 
Promega (Mannheim) 
mouse IgG n.a. HRP 
WB 
(1:4000) 
GE Healthcare (Freiburg) 
n.a = not available; IHC = immunohistochemistry; WB = Western Blot  
 
3.1.6  Enzymes 
Collagenase Type IV      Sigma-Aldrich (Steinheim) 
DNase I       Sigma-Aldrich (Steinheim) 
Hyaluronidase       Sigma-Aldrich (Steinheim) 
Super Script Reverse Transcriptase (200U/µl)  Invitrogen (Karlsruhe)  
Tag DNA Polymerase (5U/µl)     Invitrogen (Karlsruhe) 
 
 
3.1.7  Peptides  
p16
INK4a
 
peptide name Amino acid positions amino acid sequence  
p16
INK4a
 peptide R1  51-59 VMMMGSARV 
The p16INK4a 9mer peptide was synthesized by the core facility for peptide synthesis, German Cancer Research 
Center, Heidelberg.  
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HPV16 L1  
peptide name Amino acid positions amino acid sequence  
HPV16 L1_2 2-11 SLWLPSEATV 
HPV16 L1_12 12-21 YLPPVPVSKV 
HPV16 L1_60 60-68 ILVPKVSGL 
HPV16 L1_67 67-75 GLQYRVFRI 
HPV16 L1_97 97-105 RLVWACVGV 
HPV16 L1_249 249-257 YLRREQMFV 
HPV16 L1_323 323-331 ICWGNQLFV 
The HPV16 L1 9mer and 10mer peptides were synthesized by Genaxxon Bioscience, Ulm.  
 
 
Influenza virus matrix protein  
peptide name Amino acid positions amino acid sequence  
viral MP  57-68 GILGFVFTL 
The virus matrix protein was synthesized by the core facility for peptide synthesis, German Cancer Research 
Center, Heidelberg.  
 
 
3.1.8  Primers 
primer name sequence (5’-3’) 
TLR7 forward AAGCCCTTTCAGAAGTCCAAGTT 
TLR7 reverse GGTGAGCTTGCGGGTTTGT 
β-actin forward ATGTGGCCGAGGACTTTGATT 
β-actin reverse AGTGGGGTGGCTTTTAGGATG 
The primers were obtained from Thermo Scientific, Ulm.  
 
 
3.1.9  Buffers and Solutions 
Agarose Gel (1.5%):    1.5 g Agarose 
100 ml TBE buffer 
1 µl Gel Red 
 
10% APS:     10 % (w/v) Ammonium persulfate in aqua bidest 
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Blotting Buffer (10x):   30.37 g Tris  
     144.13 g Glycine  
     ad 1l Aqua bidest.  
 
Blotting Buffer (1x) working solution: 100 ml 10x Blotting Buffer 
     200 ml methanol 
     700 ml Aqua bidest.  
 
10x Citrate buffer:    100 mM Citric acid monohydrate (21 g) 
     ad 1l Aqua bidest. 
     adjust pH to 6.0 with NaOH 
 
DNA loading buffer (6x):   25 ml Glycerol 
125 mg Xylenecyanol 
25 ml H2O dest. 
 
Laemmli sample buffer (4x) :   2.5 ml 1M Tris pH 8.0 (125mM) 
     8 ml 10% SDS (4%) 
     2 ml glycerin (10%) 
     2 ml β-mercaptoethanol (10%) 
     4 mg bromphenol blue (0.02%) 
     ad 20 ml H2O  
 
5 M NaOH:    100 g NaOH  
     ad 500 ml Aqua bidest  
 
10x PBS:     84 g NaCl (= 0.8 % w/v) 
     2 g KCl (= 0.02 % w/v) 
     11.5 g Na2HPO4 (= 0.1 % w/v)  
     2 g KH2PO4 (= 0.02 % w/v) 
     ad 800 ml Aqua bidest, pH 7.4 
 
4% PFA Stock Solution:   4g paraformaldehyde  
     100 ml PBS  
 
10x SDS-PAGE running buffer: 30.3 g Tris-Base 
     144 g Glycine  
     100 ml 10% SDS  
     ad 1 l Aqua bidest.  
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10x TBE:     108 g Tris  
     55 g boric acid  
     40 ml 0.5 M EDTA, pH 8.0 
     ad 1 l Aqua bidest.  
 
10x TBS:    60.55 g Tris  
     87.66 g NaCl 
     ad 1 l Aqua bidest.  
     adjust pH to 7.6 with 37% HCl  
 
1x TBS:     dilute 10x TBS 1:10 in Aqua bidest 
 
1x TBS-T for Western Blot:   dilute 10x TBS 1:10 in Aqua bidest  
     add 0.1% Tween  
 
Tris 0.5 M, pH 6.8:   20.29 g Tris  
     20 ml 10% SDS 
     ad 500 ml Aqua bidest.  
     adjust pH to 6.8, autoclave  
 
Tris 1.5 M, pH 8.8 :    90.9 g Tris  
     20 ml 10% SDS 
     ad 500 ml Aqua bidest 
     adjust pH to 8.8 with HCl, autoclave  
 
 
3.1.10 Cell culture media 
 
B cell/T cell basis medium  500 ml IMDM  
     50 ml human serum  
     6 ml L-glutamine 
     25 µg/ml gentamicin 
 
Dendritic cell medium    CellGro medium  
     1% penicillin / streptomycin 
     3% human serum  
 
Freezing medium for PBMCs  human serum  
     + 10 % DMSO  
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MACS Buffer    PBS 
5% human AB serum 
     1 mM EDTA 
     sterile filtrate 
 
Peptide-Load medium    500 ml IMDM (serum free) 
     25 µg/ml gentamicin 
 
Quantum Tumor Medium   Quantum 263 for Tumor cells  
(used for cell line generation)  5 µg/ml insulin 
     0.5 µg/ml hydrocortisone 
     10 ng/ml hEGF  
     25 µg/ml gentamicin 
 
T cell medium:    Bc/Tc basis medium 
1 x Insulin Transferrin Selenium 
10 U/ml IL-2 
10 U/ml IL-7 
 
Tumor digestion solution:   10 ml Tumor preparation solution 
1 mg/ml Collagenase Type IV 
0.1 mg/ml Hyaluronidase 
20 µg/ml DNase I 
 
Tumor preparation solution   200 ml RPMI 1640 
25 mM HEPES 
3.6 ml Penicillin/Streptomycin (100x)  
5 µg/ml amphotericin B 
2 mM Glutamin 
 
Tumor transport solution   DMEM medium  
     10% FCS 
     100 µg/ml gentamycin      
     10 µg/ml amphotericin B  
 
Tumor cell line Medium   RPMI 1640 
(used for standard cell lines)   10% FCS 
     25 µg/ml gentamicin  
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3.1.11  Cell lines  
 
cell line  origin, characteristics experiment 
CaSki HPV16 positive cervical cancer cell line killing assay (chapters 3.2.4, 5.2.4) 
Raji B cell lymphoma cell line, high TLR7 expression 
Positive control for TLR7 expression 
(chapters 3.2.4, 5.1.2) 
T2 TAP-deficient T-B lymphoblastoid hybridoma Peptide binding assay (3.2.4, 5.2.1) 
 
3.1.12  Patients’ material  
1) Cervical intraepithelial neoplasia and cervical cancer patients 
study “immune cell infiltration in relation to p16INK4a expression” (chapter 4.2) 
University Hospital, Heidelberg and Institute of 
Pathology, Mannheim, Germany 
 
period of recruitment 2003-2004 (Mannheim) and 2007-2010 
(Heidelberg) 
number of patients  69 
resected tissue  cervical cone biopsies  
stages  
CIN1 
CIN2 
CIN3 
invasive cervical carcinoma 
p16
INK4a
-positive [n, (%)] 
n = 22  13 (59.1%) 
n = 11 11 (100.0%) 
n = 19 19 (100.0%) 
n = 17  17 (100.0%) 
 
 
2) Cervical intraepithelial neoplasia and cervical cancer patients 
antigen-presentation HLA class I and HLA class II study (chapter 4.3) 
Institute of Pathology, Mannheim, Germany  
period of recruitment 2003-2004 
number of patients  n = 41 (* n = 69) 
resected tissue  cervical cone biopsies 
disease stages 
* CIN1  
CIN2 
CIN3 
invasive cervical carcinoma 
p16
INK4a
-positive [n, (%)] 
n = 19 10 (52.6 %) 
n = 9 (* n = 9)  9 (*9) 100.0% 
n = 13 13 (100.0%) 
n = 19   19 (100.0%) 
* cohort enlarged by CIN1 (n=19) and an additional subset of CIN2 (n=9) for HLA class II analysis (deriving from cohort 1)  
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3) Cervical intraepithelial neoplasia patients: 
imiquimod study (chapter 4.4) 
 
University Hospital, Vienna, Austria   
period of recruitment 2009-2010 
number of patients  10 
resected tissue  punch biopsies 
disease stages all patients had CIN2/3 at study entry  
(inclusion criterion)  
 
4) Oropharyngeal carcinoma patients 
Generation of HPV-positive tumor cell line (chapter 5.2) 
University Hospital, Giessen, Germany   
period of recruitment 2011-2014 
number of patients  58 
resected tissue  primary tumors located in the oropharynx and 
metastatic lymph nodes in the head and neck 
region 
HPV-status 
HPV-positive  
HPV-negative  
 
n = 31 
n = 27 
 
5) healthy blood donors  
TMX-202 treatment on PBMCs 
Institute of Pathology, Heidelberg, Germany   
period of recruitment 2013/2014 
number of patients  4 
Sex  
male 
female 
 
50% 
50% 
 
3.1.13  Software 
Adobe Acrobat Reader 6     Adobe (San Jose, CA, USA) 
BIMAS      (PARKER et al., 1994)   
CellQuest pro (5.2)      Becton Dickinson (San Jose, USA) 
Diskus Bilddarstellung (4.30)     Techn. Büro Hilgers (Königswinter) 
Endnote X6       Thomson Reuters (New York, NY, USA)  
Magellan Standard      Tecan Group Ltd. (Männedorf, Switzerland) 
MedCalc, version 11.5.1.0    MedCalc Software (Ostend, Belgium) 
NDP.view Software     Hamamatsu (Herrsching) 
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RTCA software  2.0.0      ACEA Biosiences (San Diego, USA) 
SPSS Statistics 22     IBM (Ehningen)   
STATISTICA (7)      StatSoft (Europe) GmbH (Hamburg) 
Statistica, version 8.0.3.6    Statsoft (Hamburg) 
StepOne (2.1)       Applied Biosystems (Foster City, USA) 
SYFPEITHI       (RAMMENSEE et al., 1999)  
TissuemorphDP™M      Visiopharm, Hørsholm, Denmark  
 
 
3.2  Methods  
3.2.1   Immunohistochemistry for archived tissue samples  
p16
INK4a 
Immunohistochemistry 
 
The identification and diagnosis of precancerous lesions of the cervix uteri is based on the biomarker 
p16
INK4a
, a cyclin-dependent kinase inhibitor which is normally involved in tumor suppression. It is a 
well-established biomarker for early oncogenic processes in HPV-related cancers, especially cervical 
cancer as p16
INK4a
 becomes markedly overexpressed in persistent HPV-infections in which the 
oncogenic transformation is induced by HPV proteins which is the first step necessary for the 
development of cervical cancer. 
 
The CINtec® PLUS Kit was used for the qualitative detection of p16
INK4a
 and the 
immunohistochemical staining procedure was carried out as proposed in the manufacturer’s protocol. 
The provided reagents were used as described in the protocol with the following exceptions: the 
substrate incubation with DAB was carried out in two consecutive steps comprising 8 minutes each. 
 
 
Immunohistochemical staining for CD3-, Foxp3-, Granzyme B- and CD8-positive cells and the 
antigen-presentation molecules HLA class I and HLA class II  
 
Different T cell markers were qualitatively and quantitatively investigated by immunohistochemical 
analyses. The global T cell infiltration in tissue specimens was analyzed by staining for CD3. T cell 
markers representing different T cell subtypes were used to characterize T cell activation (CD8, 
Granzyme B and CD3 ζ-chain) and T cell inhibition (Foxp3). Precancerous lesions and cancers were 
characterized for HLA class I heavy chain (HLA-A/B/C) and light chain (beta2-microglobuline, β2m) 
and HLA class II antigen expression.  
Formalin-fixed paraffin-embedded tissue sections were mounted on aminopropylsilane-coated slides 
and following deparaffinisation in xylene and rehydration in decreasing ethanol concentrations (100%-
70%) the slides were heated for 15 minutes in 10mM citrate buffer (pH=6) in order to retrieve antigen 
epitopes to be analyzed. Blocking of endogenous peroxidase was performed by using 0.6% H2O2 in 
methanol. In order to reduce non-specific antibody binding and background staining the tissue sections 
were then blocked with 10% horse serum in PBS before the various first antibodies were applied (for 
dilutions see section “Antibodies”) and incubated at 4°C overnight. Slides were then incubated with 
biotinylated anti-mouse/anti-rabbit IgG secondary antibodies for 30 minutes at room temperature. 
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Following the application of avidin-biotin reagent according to the manufacturer’s instructions, the 
color reaction with 3,3-diaminobenzidine (DAB+ chromogen) allowed the detection of the antigens to 
be characterized. Finally, the slides were counterstained with hematoxylin and mounted with Aquatex.  
 
Automated immunohistochemical staining protocol (CD3 and CD8) 
 
Tissue sections (2µm) were mounted on aminopropylsilane-coated slides and subject to automated 
immunohistochemical staining with the Leica-Bond II Max autostainer by applying the following 
staining protocol with reagents provided by Leica Biosystems:  
 
 
Step (solution applied)  duration temperature 
BOND Dewax Solution 30 sec 72°C 
BOND Dewax Solution 30 sec 72°C 
BOND Dewax Solution 30 sec RT 
ethanol (99%) (3 repetitions)  RT 
BOND wash solution (3 repetitions)  RT 
BOND ER Solution 1 (citrate buffer, pH 6.0) (2x)  RT 
BOND ER Solution 1 (citrate buffer, pH 6.0) 20 min 100°C 
BOND ER Solution 1 (citrate buffer, pH 6.0) 12 min RT 
BOND wash solution (3 repetitions)  37°C 
peroxide block 20 min RT 
BOND wash solution (3 repetitions)  RT 
serum block (10% goat serum in PBS) 30 min RT 
BOND wash solution (3 repetitions)  RT 
primary antibody in TBS/10% FBS) 30 min RT 
BOND wash solution (3 repetitions)  RT 
post primary (polymer penetration enhancer 
in TBS/10% FBS) 
8 min RT 
BOND wash solution (3 repetitions) 2min RT 
polymer (secondary antibody, poly-HRP-anti-mouse/anti-rabbit IgG) 8 min RT 
BOND wash solution (2 repetitions) 2min RT 
deionized water  RT 
mixed DAB Refine ??? RT 
mixed DAB Refine 10 min RT 
deionized Water (3x)  RT 
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hematoxylin counterstaining 5 min RT 
deionized Water (3x)  RT 
BOND wash solution 5 min RT 
deionized water  RT 
embed slides in Aquatex  RT 
 
 
Microscopic evaluation  
 
p16
INK4a
 staining 
 
Sections were defined to be negative in cases where no p16
INK4a
 expression was detectable or where 
p16
INK4a
-positive cells showed a focal staining pattern (patchy, restricted to single cells). Lesions with 
a strong and diffuse p16
INK4a
 staining were considered to p16
INK4a
-positive.  
 
T cell markers  
 
Immunohistochemically stained slides were analyzed independently in a blinded fashion during two 
sessions and blinded to histopathological grade. For counting and evaluation of the tumor-infiltrating 
lymphocytes, a Leica DMRBE microscope with a 10x10 ocular grid covering an area of 0.0625 mm
2
 
at a 400-fold magnification was used. In total, seven grid areas were counted in the in lesion/tumor 
and the adjacent stromal tissue, three located in the epithelium and four located in the stroma. In total, 
an area of 0.4375 mm
2
 was considered for counting.  
 
HLA class I and II  
 
Lesions and tumors that showed a strong cytoplasmic or membranous staining in more than 75% of 
cells were classified as positive for HLA class I or class II expression. Heterogeneous expression was 
defined as faint and patchy staining (cytoplasmic or membranous) observable in 75% to 25% of the 
cells of a lesion or tumor. Lesions were defined to be negative for HLA expression when the staining 
was absent or restricted to single cells (representing invading APCs) or could be identified as locally 
induced expression due to the presence of immune cells (faint staining, locally restricted in areas with 
infiltrating immune cells) and concerned less than 25% of the lesion cells. 
 
Automated evaluation of immunohistochemically stained slides 
 
The establishment of an automated immune cell quantification platform and the adaption of the 
underlying imagine analysis algorithms were a major goal of this thesis and are described in detail in 
chapter 4.1. The major steps of the workflow are automated staining, whole-slide-imaging and 
computational image analysis and were carried out under the supervision of PD Dr. Niels Grabe and 
Dr. Bernd Lahrmann, TIGA Center, Heidelberg.  
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3.2.2   Molecular Biology Methods  
Isolation of genomic DNA from cells or tissue 
 
DNA was isolated from either FFPE tissue sections or from cultured cells deriving from fresh tumor 
tissue following the manufacturer’s instructions.  
Briefly, for the purification of genomic DNA (gDNA) from fresh or frozen cells, the pellet was 
resuspended in 200µl PBS and 20µl proteinase K were added. Then 200µl Buffer AL were added and 
the sample was incubated at 56°C for 10 min before it was resuspended in 200µl ethanol and loaded 
on a spin column by centrifuging at 8000 rpm for 1 min. After having washed the column with bound 
DNA two times with the provided wash buffers AW1 and AW2, DNA was eluted with Buffer AE in 
two subsequent steps and by using 30µl buffer only for each step to increase the final DNA 
concentration without losing to much of the maximum DNA yield.  
For the isolation of gDNA from formalin fixed paraffin-embedded tissue sections, samples had to be 
pretreated by xylene to remove paraffin. Following centrifugation and removal of the supernatant by 
pipetting, ethanol was added to the pellet to remove residual xylene. Ethanol was removed by 
pipetting following centrifugation. This step was repeated once before the pellet was dried in the 
SpeedVac at 37°C for 15 min, resuspended in 180µl buffer ATL and completely lysed by adding 20µl 
Proteinase K at 56°C (minimum 1 hour until overnight incubation). Then the samples were incubated 
at 90°C for 1 hour before 200 µl Buffer AL and 200µl ethanol were added to the sample. The lysate 
was transferred and the provided QIAamp MinElute column which – following binding of DNA to the 
column – was washed twice with Buffers AW1 and AW2. Finally, following complete drying of the 
membrane by centrifugation at full speed, DNA was eluted in two steps with 30µl buffer in each step.  
The concentration of eluted gDNA was determined by measuring the absorbance at 260 nm with the 
elution buffer used as blank for the zero adjustment.  
 
 
GP5+/6+ PCR for Luminex® -based HPV-Genotyping 
 
amount reagent 
26.75 µl H2O 
5.0 µl  10x PCR Buffer 
7.0 µl 50 mM MgCl2 
1.5 µl 10 mM dNTPs 
2.0 µl primer set 1 
0.5 µl primer set 2  
0.25 µl Taq polymerase 
7.0 µl  template 
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Temperature profile:  
 
94°C 10 min initial denaturation  
94°C 30 sec denaturation  
38 °C 30 sec primer annealing 40 x 
72°C 80 sec primer extension  
72°C 6 min final extension  
4°C forever  
 
 
HPV genotyping based on Luminex® technology  
 
Luminex Technology based on polystyrene beads with various but specifically identifiable absorption 
spectra allow the multiplexed detection of different factors. Specifically amplified DNA from tumor 
samples is bound to the beads that are coupled to HPV specific oligonucleotide probes. By this 
approach 24 of the most common HPV types (15 high-risk and 6 low-risk and 3 putative high-risk 
types) can be detected simultaneously in one sample by reporter fluorescence. For the assay procedure 
the manufacturer’s protocol was followed:  
First, 40µl/well of the Bead Mix were pipetted to each required sample well of a 96 well Hybridization 
Plate. As a negative control 10 µl H2O, 10µl Hybridization Control (1:10 diluted in H2O) ad 10µl PCR 
product per sample well were pipetted. The PCR plate was covered tightly with a seal foil and 
incubated at 95°C for 10 min in a preheated PCR machine. The plate was then incubated on ice for 1 
min and then for hybridization subsequently transferred to the PCR machine and incubated at 41°C for 
30 min. In the meantime a filter plate was equilibrated by pipetting 100 µl Assay Buffer in each well 
and incubating the plate for 30min at room temperature. Wash Buffer was removed by vacuum 
filtration and the Bead Mix PCR samples were transferred to the filter plate after having the samples 
mixed vigorously by pipetting up and down and with the hybridization plate still being located in the 
PCR machine. Liquid is removed from the filter plate by vacuum filtration and the plate was washed 
twice with 100µl/well Assay Buffer. 70µl Staining solution were added to each well and incubated 
protected from light for 30min at room temperature under slight agitation. Then the liquid was again 
removed by vacuum filtration and the plate was washed trice with 100µl/well Assay Buffer 
respectively. The beads were then resuspended in 100µl Assay Buffer and transferred to a 96 lock-
microtiter plate to measure samples then in the Luminex analyzer.  
 
 
RNA extraction from cultured cells 
 
RNA purification from human cells was performed with RNeasy Mini Kit from QIAgen with slight 
modifications to the manufacturer’s protocol. All centrifugation steps were carried out at 10000 rpm if 
not indicated otherwise. Cells were disrupted by adding Buffer RLT and β-mercaptoethanol (1:100) to 
the cells and vortexed. The lysate was homogenized by adding 70% ethanol and vigorous vortexing or 
pipetting. Then 700µl of the sample were transferred onto the membrane of an RNeasy spin column 
and centrifuged for 90 s. The flow-through was discarded. For DNA elimination 350 µl Buffer RW1 
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were added to the spin column, centrifuged for 90 sec to wash the membrane and the flow-through 
was discarded. DNase 1 incubation mix (consisting of 62µl H2O, 7µl 10xDNase Buffer + 1µl DNase 1 
(Invitrogen) per sample) was added onto spin column membrane and incubated for 15 min at RT. 
350µl Buffer RW1 were added to the membrane, centrifuged for 90 sec at 10000 rpm and the flow-
through was discarded. To wash the spin column membrane, 500µl Buffer RPE were then added to the 
membrane, centrifuged for 90 sec and the flow-through was discarded. This washing step was repeated 
once by centrifuging the spin column for 3 min. The spin column was then dried by centrifuging it at 
14000 rpm for 2 min and was then placed in a new 1.5 ml reaction tube. Then, 50µl RNase-free water 
were pipetted on the spin column membrane, incubated for 7 min on ice and then centrifuged at 10000 
rpm for 2 min to elute the RNA. This step was repeated to increase the overall RNA yield 
accompanied however by decreased RNA concentration.  
DNA concentration was measured at 260nm wavelength via photometer and RNA purity was assessed 
as the ratio of absorbance measured at 260nm to the absorbance measured at 280nm wavelength.  
 
 
Reverse Transcription  
 
Isolated RNA underwent reverse transcription for the generation of complementary DNA (cDNA). 
Complete RNA samples or a negative control (H2O HPLC-grade) were used for reverse transcription 
in addition with the following components: 
 
amount reagent 
11.0 µl RNA (1 µg, prediluted with H2O) 
4.0 µl 5 x First-Strand Buffer 
2.0 µl  0.1M DTT 
0.5 µl Oligo-dT-nucleotide 
0.5 µl Hexanucleotide Mix (1:10 pre-diluted) 
1.0 µl 10 mM dNTPs 
1.0 µl Reverse Transcriptase (200U/µl) 
 
The First-Strand Buffer, DTT and the Reverse Transcriptase (all contained in the SuperScript II 
Reverse Transcription Kit) were mixed with remaining reagent and RNA as listed above. The mixture 
was incubated at 70°C for 10 min, the briefly put on ice, incubated at 37°C for 15 min and finally at 
42°C for 60 min. The reverse transcription was completed with a denaturation step carried out at 90°C 
for 5 min. As the resulting cDNA concentration was assumed to equal the initial RNA concentration, 
cDNA was diluted based on RNA concentrations to 20ng/µl in H2O (HPLC-grade). The samples were 
either stored at -20°C until further usage or immediately used in quantitative real-time PCR.  
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Real-time quantitative PCR  
 
Quantitative Real-time RT-PCR was performed with primers to detect human toll-like receptor 7 
(TLR7) gene expression. The human β-actin gene expression was used as a normalization control 
(primer sequences listed in section 3.1.8). Quantitative real-time PCR was performed in triplicates in a 
96-well plate format. Power SYBR Green Master Mix (5µl), the corresponding forward and reverse 
primers (final concentration 150 nM) and cDNA template (5µl) or water for the non-template controls 
were mixed. The cycling conditions are shown in the table below.  
 
 
 Temperature Duration Number of cycles  
Enzyme activation 95°C 15 min 1 cycle 
Denaturation 95°C 15 sec  
Annealing 60°C 30 sec 40 cycles 
Extension 72°C 30 sec  
 
 
 
Calculation of TLR7 mRNA levels  
 
The threshold cycle PCR values (Ct) were obtained during exponential amplification. The calculation 
of relative changes in TLR7 mRNA levels was based on the ∆∆Ct method, which means that TLR7 
gene expression – in relative units – was calculated by comparing the Ct values of the target gene with 
the normalization control gene. The Ct values for β-actin and TLR7 of technical triplicates of each 
sample were averaged. Standard deviations (threshold cycle differences) between triplicate reactions 
less than 0.5 cycles were considered to be acceptable and the Ct values were used for further 
calculation. The relative expression level of TLR7 mRNA was calculated in comparison to β-actin 
mRNA expression. In a first step, ∆Ct-values were calculated for TLR7:  
 
∆Ct gene =Ct target – Ct control cDNA 
 
Then, the ∆∆Ct value for each treated samples was calculated by subtracting the ∆Ct of the control 
(untreated or DMSO-treated) from the ∆Ct of the sample.  
 
∆∆Ct = ∆Ct gene (treated) - ∆Ct gene (untreated/control)  
 
The fold exchange in TLR7 expression was then obtained by calculation 2
-∆∆Ct
 and visualized as bar 
graphs in a log2 scale.  
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3.2.3 Biochemical Methods 
 
Whole cell lysates  
 
Whole cell lysates were prepared by resuspending cell pellets containing a defined numbers of cells in 
4x Laemmli buffer and heated for 10 min at 95°C before subjected to gel electrophoresis.  
 
Protein lysates and Bradford assay  
 
Cell pellets were resuspended in 50µl RIPA Buffer containing Protease Inhibitor Cocktail and 
incubated for 20 min on ice. Samples were centrifuged at 13000rpm for 15 min at 4°C and 
supernatants were transferred in new 1.5 ml reaction tubes for further processing. Protein 
concentrations were determined using Bradford protein assay, a photometric method based on the dye 
Coomassie Brillant Blue changing its color from red to blue if complexes with proteins are formed. 
For the quantification of protein concentrations a 10 mg/ml aqueous BSA solution was serially diluted 
to produce a standard curve ranging from 0.0 mg/ml to 2.0 mg/ml BSA. The samples to be tested were 
diluted 1:20 in water and Bradford Reagent which was filtered with a 0.22µm sterile filter was diluted 
1:5 in water. 5 µl of the standards and the diluted samples were pipetted into a 96 well flat bottom 
plate and 250 µl of the Bradford solution were added to each well and incubated for 5 min at room 
temperature while shaking until measurement. The absorbance was measured at 595 nm without 
wavelength correction and the protein concentrations of the samples were determined by using the 
formula of the best-fit curve for the standard values. Samples were either directly used for SDS-PAGE 
or stored at -20°C for further analysis.  
 
Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Protein separation was performed with polyacrylamide gel electrophoresis based on the method by 
Laemmli. Proteins are denatured and negatively charged after binding of the detergent SDS. In an 
electric field the negatively charged proteins migrate towards the anode and are thus separated 
according to their molecular weight.  
For TLR7 SDS-PAGE whole cell lysate were used, while for HPV16 E7 electrophoresis protein 
lysates as described above were used 
Dependent on the size of the protein of interest, the resolving gels were produced with different 
percentages of acrylamide contained in the formulation to vary the pore size for protein separation. For 
the early protein of HPV16, E7, a 20% resolving gel was used, whereas for the separation of TLR7 
protein a 7% gel was required.  
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 stacking gel resolving gels 
 5% gel 7% gel 20% gel 
Aqua dest. 2.9 ml 5.1 ml 0.73 ml 
Tris Buffer 
1.25 ml 
(0.5 M Tris, pH 6.8) 
2.5 ml 
(1.5 M Tris, pH 8.8) 
2.5 ml 
(1.5 M Tris, pH 8.8) 
Bis-Acrylamide 
(30%) 
0.85 ml 2.3 ml 6.67 ml 
10% APS 50 µl 100 µl 100 µl 
Temed 5 µl 10 µl 10 µl 
 
Dependent on the required total protein amount, protein lysates were mixed with 4x Laemmli sample 
buffer and water and adjusted to a total volume of 50 µl. The samples are cooked for 10 minutes at 
95°C for protein denaturation and then loaded on the gel. Gels were run at 200V, 250 mA and 50W for 
about 50 minutes.  
 
Western Blot  
 
Filters and sponges for the Western Blot chamber were treated with blotting buffer before use. The 
PVDF membrane was prewetted with 100% methanol for 30 seconds before use and was then washed 
in Blotting Buffer. The membrane and the acryl amide gel were stuck between three filter papers and 
one sponge from both sides. The blot was performed in Blotting Buffer at 400mA, 50W for 60-90 
minutes. After the blotting step the membrane was stained with Ponceau Red solution indicating the 
success of the protein transfer. After removing of the color by applying distilled water, the membrane 
was blocked with 5% casein solution (in TBS buffer) for one hour at room temperature on the rolling 
mixer and was then incubated over night at 4°C with first antibody diluted in 5% casein solution (for 
antibody concentrations see Table). The next day, the membrane was washed 3 times for 10 minutes 
with TBS containing 0.1% Tween before incubated with the corresponding secondary antibody diluted 
in 5% casein solution. After another washing step (3x10 minutes in TBS-T) the membrane was 
incubated with the premixed ECL substrate (solution A and B) for 1 min before the antigens could be 
detected by developing the photographic films exposed to luminescent light in the darkroom. Exposure 
time was variable ranging from 10 seconds to 1 hour depending on the strength of the signal.  
 
 
3.2.4  Cell culture methods 
Flow cytometry analysis  
 
In order to characterize the phenotypes of different primary cells as well as to monitor the generation 
of tumor cell lines and purification of different cell types from the whole PBMC fraction, flow 
cytometry analysis was performed. Therefore living cells were stained with directly fluorochrome-
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labeled antibodies specific for extracellular antigens expressed by different cell types. The light 
emitted by the fluorochromes following absorption is three-dimensionally scattered and registered as 
forward scatter representing the cell size and as sideward scatter representing the cell granularity. Not 
only the percentage of positive cells can be determined, but also the mean fluorescence intensity 
providing information about the levels of antigen expression can be measured.  
Depending on their availability an average of 2.5 x10
5 
cells were used per staining. Cells were 
harvested, washed twice in PBS by centrifugation for 10 min at 4°C and 1200 rpm. Incubation with 
directly labeled primary antibodies (each diluted 1:50 in PBS) was carried out on ice for 30 min and 
protected from light. If double staining was performed, the second antibody was applied in a second 
incubation step following an additional washing step to remove the first antibody. Additionally, for 
every staining an isotype control based on an antibody directed against the corresponding IgG subtype 
(diluted 1:50 in PBS) was included. Following the incubation with the antibodies, cells were washed 
twice again in PBS by centrifuging at 4°C and 1200 rpm for 8 min and finally fixed in 1% PFA 
solution and stored in the dark until measurement. The samples were analyzed in a FACSCalibur and 
fluoresce data obtained were evaluated using CellQuest Pro Software.  
 
 
Density gradient centrifugation for the isolation of mononuclear cells from peripheral blood 
 
For immunological studies peripheral blood mononuclear cells (PBMCs) were isolated by density 
gradient centrifugation. PBMCs are comprise different cell types such as lymphocytes, monocytes and 
macrophages that can be used directly or following further separation in different immunological 
approaches. Density gradient centrifugation allows isolating PBMCs from whole blood and is carried 
out with a ficoll-based separation medium that contains a hydrophilic polysaccharide of a distinct 
density. Centrifugation of overlaid blood leads to the separation of the whole blood sample into 
plasma on the top of tube, PBMCs (middle fraction), and a fraction mainly consisting of erythrocytes 
on the bottom of the tube.  
For extraction of PBMCs heparinized blood samples were diluted with equal amounts of RPMI 1640 
medium and the mixture was carefully layered on 15ml lymphocyte separation medium. Density 
gradient centrifugation was carried out at 2500 rpm for 15 minutes with inactivated brake. The 
supernatant containing plasma was taken off and stored at –20°C. Then the interphase containing 
peripheral blood mononuclear cells (PBMCs) was collected and cells were washed twice in RPMI 
1640 medium by centrifugation at 1800 rpm and 1500 rpm (15 min each) to purify PBMCs from 
eventually contaminating separation medium and also from thrombocytes. Following the washing 
steps the pellet was resuspended in 20 ml RPMI 1640 medium and cells were counted with trypan blue 
solution. PBMCs then were either directly used in experiments or stored at -80°C in human serum 
containing 10% DMSO.  
 
 
Tumor preparation and tumor tissue culture  
 
Tumor samples of HNSCC patients were sent overnight within 16-24 hours after surgical resection 
while lying in transport medium and on ice packs. All washing steps were performed with cooled 
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solutions and at 4°C. The tumor sample deriving from primary tumor of different localizations (base of 
the tongue, edge of the tongue, tonsils) or lymph node metastasis were transferred into a sterile 50 ml 
tube and washed twice in 10 ml tumor preparation solution by centrifuging for 10 min at 1200 rpm. 
Then the tissue was transferred to a sterile petri dish and eventually necrotic tissue, fatty tissue 
surrounding lymph nodes and larger blood vessels were removed mechanically. Following two 
additional washing steps in a new 50 ml tube the samples were again transferred to a new petri dish 
and cut into very small pieces (≥ 1 mm2) with a scalpel. The tissue pieces were again transferred into a 
new 50 ml tube with the help of forceps and 10 ml pipettes washed twice in a new 50 ml tube with 
tumor preparation solution and then digested overnight (16-20 hours depending on the size of tissue 
pieces) by applying 5 ml tumor digestion solution. Due to the limited size of tumor tissue, isolation of 
tumor infiltrating lymphocytes was not carried out and the complete amount of digested tumor tissue 
was used for generation of HNSCC tumor cell lines. The next day the tissue was washed twice in 
RPMI 1640 medium by centrifuging for 10 min at 1200 rpm and finally resuspended either in 
Quantum medium or FAD medium and cultured in cell culture flasks or plates. Cultures with adherent 
and outgrowing tumor cells were checked regularly via flow cytometry for the proportion of tumor 
cells. Cultures with at least 10% tumor cells were further cultured, whereas cultures with less tumor 
cells and those containing only fibroblasts were discarded. Sequential trypsinization of fibroblasts 
from young tumor cell cultures was performed to remove fibroblasts and if necessary a second 
trypsinization step of the remaining adherent tumor cells was carried out to detach single cells from 
tumor cell clusters and allow these areas to expand.  
 
 
T2- peptide binding assay  
 
The human T2 cell line deriving from T-B lymphoblast hybrids was used to test the binding affinities 
of different L1 peptides that were synthesized based on epitope prediction algorithms. T2 cells are 
transporter associated with antigen processing (TAP1/TAP2) deficient and therefore defective in 
loading human leukocyte antigen (HLA) class I molecules with endogenous peptides. However, HLA 
class I molecules of T2 cells can be loaded exogenously with peptides present in the medium, whereby 
different epitopes bind to HLA class I molecules with higher or lower affinities. Only peptide-HLA-
complexes are stable and can be detected by flow cytometry analysis following staining with a HLA 
class I specific antibody whereas free HLA class I molecules not bound to any peptide are instable and 
degraded and therefore cannot be detected. The higher the affinity of predicted epitopes to HLA class 
molecules, the more stable is the complex formed and the higher is the fluorescence intensity 
measured. 
T2 cells were harvested and resuspended in T2 medium at a density of 0.5x10
6
 cells/100 µl. 100 
µl/well was pipetted into a 96-well round bottom plate. Then β-2-microglobulin at concentration of 5 
µg/ml as well as the newly synthesized peptides to be analyzed for their binding affinity (at 50 µg/ml) 
were added to each well. Peptides already known to have a high affinity to HLA class I were included 
as positive controls and determined the cut-off (viral MP, p16_R1, L1_323). All antigens were tested 
in quadruplicates. The plate was incubated over night at 27°C for 17 hours. Following the 17 hours 
incubation period the plate had to be incubated another 2.5 hours at 37°C, 5% CO2. Then cells were 
harvested and transferred into a 1.5 ml reaction tube. They were washed one with PBS and then 
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stained with directly labeled HLA-A2 antibody. Finally, samples were washed twice with PBS, fixed 
with 1% PFA and stored at 4°C in the dark until measurement.  
 
For analysis the MFI values for all antigens were recorded and compared with the positive controls 
after background subtraction (obtained by measuring T2 cells incubated in absence of any antigen). 
Peptides were considered to have sufficient binding capacity to HLA-A2 if the MFI was significantly 
higher as negative controls and at the same time exceed the lowest MFI measured for the positive 
controls. Peptides that fulfilled both criteria were considered to form stable peptide-HLA-complexes 
and to be suitable for simulation experiments.  
 
 
IL-6 ELISA 
 
Enzyme-linked immunosorbent assay (ELISA) allows the detection and quantification of antigen by 
specific antibodies. The ELISA used for measuring IL-6 levels is a classical “sandwich” ELISA with 
the antigen contained in a sample being attached to the surface of wells coated with a first antigen-
specific antibody. Bound antigens are detected by a second specific antibody linked to an enzyme 
allowing the detection of antigen-antibody complexes via a color reaction after adding the 
corresponding substrate for the enzyme. Antigen concentrations can be calculated by comparing the 
measured optical density values with those of defined standard concentrations. For measuring the 
interleukin-6 release following PBMC stimulation, a commercially available IL-6 ELISA was used 
providing pre-coated and blocked plates. The assay was performed following the manufacturer’s 
protocol and all standards, samples and controls were tested in duplicate. Briefly, after having 
prepared an IL-6 standard dilution series, the assay diluent provided was added to the wells, followed 
by 100µl/well of standard, sample or control. After 2 hours incubation, wells were washed, 200µl/well 
of IL-6 conjugate was added, incubated for another 2 hours and washed again. Substrate solution 
(200µl/well) was added, incubated for 20 minutes protected from light and then the color reaction was 
stopped by adding 50µl/well of stop solution. The optical density was determined at a wavelength of 
450nm and the reference wavelength for wavelength corrections was 540nm. A standard curve was 
created by plotting the mean absorbance for each standard against the concentrations and drawing a 
best fit curve through the data points which allowed the concentration of the samples to be calculated.  
 
 
Generation of dendritic cells from monocytes 
 
Dendritic cells are the most potent antigen-presenting cells and play an important role in the raise of an 
antigen-specific immune response as the process and present antigens to T cells. Except from culturing 
dendritic cells from hematopoietic progenitor cells they also can easily be generated using CD34-
positive monocytes circulating in the peripheral blood. Generation of dendritic cells requires external 
granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4 contained in the media.  
The standard protocol requires PBMCs freshly isolated from peripheral blood. They were washed in 
serum free CellGro medium and resuspended in CellGro medium supplemented with 3% human 
serum. After one hour of adherence in a 10cm cell culture plate at 37°C the non-adherent cells were 
56  3. Materials and Methods  
detached by tapping to avoid clumping and the cell culture flask was then incubated overnight at 37°C, 
5 % CO2. The next day, the non-adherent cells were removed and the remaining adherent monocytes 
were cultured to generate mature dendritic cells. To stimulate the differentiation of monocytes into 
dendritic cells, the monocytes were cultured in CellGro medium containing GM-CSF (1000U/ml) and 
IL-4 (667 U/ml) for 6 days at 37°C and 5% CO2 in a humified atmosphere. The standard maturation 
cocktail was supplemented by addition of TMX-202 to the medium (treatment schedule see below) on 
days 0, 2, 4 and 5 of the culture. Cells were harvested on day 6 by using 0.05% EDTA solution and a 
cell scraper. Cells were immediately used for immunoassays. For the T cell in vitro priming DCs 
generation with cells from the same donor was repeated weekly (every 6 days) and used as fresh cells 
for T cell re-stimulation.  
 
 
Isolation of T lymphocytes from PBMCs  
 
In order to obtain total T cells from the whole PBMC fraction, isolated mononuclear cells were subject 
to plastic adherence for 4 hours in RPMI containing 5% human serum as described for the generation 
of dendritic cells. T cells then were isolated from the non-adherent cell fraction by Pan T cell isolation 
based on magnetic depletion of non-T cells. Therefore floating cells were harvested, passed through a 
40µm cell strainer to avoid clumping, counted and washed once in MACS Buffer. T cells were 
purified from that fraction by using MACS Pan T cell Isolation Kit II from Miltenyi Biotec following 
the manufacturer’s protocol. Briefly, cells were resuspended in 40 µl MACS buffer per 107 cells and 
then incubated for 5 minutes with 10 µl per 10
7
 cells of the biotin-antibody cocktail (containing 
monoclonal antibodies against CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and 
CD235a) targeting non-T cells. Following addition of 30 µl MACS buffer and 20 µl anti-biotin 
microbeads per 10
7
 cells to the sample and incubation for 10 minutes, T cells could be isolated by 
magnetic separation. The specific binding of magnetic microbeads to labeled cells allows the depletion 
of the non-target cells by retaining them in the magnetic field of the MACS column while unlabeled T 
cells pass through. Eluted T cells were counted and immediately used in immunoassays. T cells were 
cultured in T cell medium containing IL-2 and IL-7.  
 
 
Isolation of regulatory T cells from PBMCs (Regulatory T cell depletion)  
 
Treg depletion was performed in order to compare the effects of T cell mediated killing of tumor cells 
between the total T cell fraction (including regulatory T cells) and T cells that are depleted from 
regulatory T cells. Tregs were depleted from the total CD3+ T cell fraction by using MACS 
technology based on magnetic labelling of CD25
+
 T cells with CD25 MicroBeads and isolation of the 
labelled cells by positive selection over a MACS column in a magnetic field. Tregs were depleted in 
two successive steps following the manufacturer’s protocol and comparable to the procedure describe 
for T cell isolation. In the first step non-CD4 positive cells were magnetically labelled and separated 
from CD4+ T cells to enrich the CD4+ T cell fraction. These cells were eluted from the column and 
stored for the experiments. In the second step, CD4+CD25+ regulatory T cells were labelled and 
separated from the remaining CD4+ T cell population over a column. Briefly, the cell pellet of CD4+ 
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T cells was resuspended in 90 µl MACS buffer per 10
7
 cells and 10 µl of anti-CD25 microbeads per 
10
7
 cells were added and incubated for 15 minutes on ice. Cells were then washed twice in 2 ml of 
MACS buffer by centrifuging at 1200 rpm for 10 minutes and finally resuspended in 500 µl of MACS 
buffer. Cells were then subject to magnetic separation for positive selection of labeled CD25+ cells 
while unlabeled cells pass through the column. Non-CD4+ T cells separated in first step were 
combined with the CD4+ enriched and Treg depleted fraction and used for further experiments.  
 
 
In vitro priming of T cells with HPV16 L1 and p16
INK4a
 peptides  
 
The induction of a specific T cell response depends on the recognition of the antigen via MHC 
complex and the activation by co-stimulatory molecules. The activation of naïve T cells after the 
recognition of antigens presented by antigen presenting cells and their development into effector T 
cells is called “priming” and can be simulated in vitro to monitor the ability of peptides to induce a 
cell-mediated immune response in naïve individuals giving rise to T cells that are able to recognize 
and target tumor cells that express the protein.  
In order to induce a primary cell-mediated immune response against HPV16 L1-peptides and a 
p16
INK4a
-peptide naïve T cells of a HLA-A*0201 positive healthy donor were stimulated with 9mer 
and 10mer L1 and p16
INK4a
 peptides predicted for HLA-A2 and validated in peptide binding assay.  
Dendritic cells as potent antigen-presenting cells were used to prime naïve T cells to the peptides and 
were generated in 4 cycles as described above. T cells were obtained by T cell isolation from PBMCs 
as described above. The ratio between DC and T cell during stimulation was 1:10.  
 
 
FIGURE 3.1  TMX-202 AND DMSO TREATMENT SCHEDULE FOR DENDRITIC CELLS AND T CELLS 
DURING THE IN VITRO PRIMING APPROACH. 
 
Dendritic cells were harvested and loaded with peptides by incubating them in peptide-load medium 
with 20µg/ml of each peptide and in presence of Lipofectamine 2000 for 2.5 hours at 37°C, 5% CO2. 
Cells were irradiated with 30 Gray after loading and washed twice. They were then added to T cells in 
a 12-well plate in T cell medium and were co-cultured until the next restimulation 6 days later. For 
restimulation T cells were harvested, washed and counted and the required amounts of DC were 
loaded again with peptides by repeating the procedure described above. In total, T cells had four 
stimulation cycles over 24 days (Figure 3.1). The experiment was based on two distinct T cell 
fractions that were treated with either TMX-202 or DMSO during the complete duration of the 
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experiment (4 treatments per cycle) and also were stimulated with either TMX- or DMSO-treated 
dendritic cells. The treatment schedule is shown in Figure 3.1. 
 
 
PBMC treatment with TMX-202 
 
PBMCs were obtained by density gradient centrifugation as described above and cultured in 24-well 
plates in medium for T cells. PBMCs were cultured for 3 days and were treated daily with either 1 µM 
TMX-202, 10µM TMX-202, 30µM imiquimod or the same amount of DMSO as added with the 
substances as control. Cells were harvested after 72 hours. Due to the adherence capacities of 
monocytes two distinct cell fractions had to be harvested: non-adherent peripheral blood lymphocytes 
(PBLs) and adherent monocytes that were harvested by using a cell scraper. Cells were washed and 
pellets were stored at -20°C until used for further analyses. Supernatants were also harvested, 
centrifuged to remove cells and stored at -80°C for cytokine analysis.  
 
 
Tumor cell line maintenance  
 
Tumor cell lines were cultured in the corresponding tumor cell media listed above. Adherent tumor 
cell lines were split when confluent. Prior to use in killing assays tumor cells were treated with 1 µM 
DAC following a standard treatment protocol to increase antigenicity of the tumor cells which was 
developed in the department: tumor cells were treated for 96 hours, with daily change of half of the 
media and addition of 1 µM final concentration with the supplemented media. Cells were then 
harvested and used in the corresponding experiments.  
 
 
xCELLigence Impedance Measurement  
The xCELLigence system is based on a microelectronic readout using electronic cell sensor array 
technology and allows for real-time monitoring of cellular processes without requiring labeling of 
cells with additional compounds and therefore being less invasive and allowing more physiological 
conditions. The assay principle is based on changes of the electrode impedance by adherent cells 
(Figure 3.3) As the measurement reflects the entire duration of the assay, the conditions can be 
monitored in real-time allowing the characterization of the kinetic response of cells within an assay, 
prior and following certain treatments. Thereby information regarding the biological status of the cell 
(growth rate, growth arrest, morphology, apoptosis) can be obtained rendering the assay also suitable 
for the quantification of compound-mediated or cell-mediated cytotoxicity. The assay principle is 
based on the measurement of changes of the electrode impedance due to cell-electrode interactions, as 
adherence of cells onto the electrodes affects the local ionic environment at the electrode/solution 
interface. Impedance increase is dependent on the numbers of cells attached to the electrodes but also 
on the quality of the interaction between cells and electrodes. The electrode impedance is represented 
by a dimensionless value, termed cell index, which indicates the relative change in measured electrical 
impedance and thus the cell status. It contains information about cell viability, cell growth or growth 
arrest, apoptosis, morphology and adhesion degree (Figure 3.3). 
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FIGURE 3.2  PRINCIPLE OF THE xCELLigence TECHNOLOGY. Adherence of cells to the electrodes affects the 
electrode impedance (Z cell) compared with the baseline impedance (no cells, non-adhered cells) by 
changing the local ionic environment at the electrode/solution interface). Adapted from 
www.aceabio.com. 
Without cells or cells not adhered to the electrodes the cell index is zero. Under the same conditions, 
cell index values increases with adherence of cells to the electrodes, and even more increases if cells 
spread over the electrodes or become more strongly attached to them. The values decrease with cells 
detaching from the electrodes due to apoptosis or cytotoxicity.  
 
FIGURE 3.3 CHANGES OF THE CELL INDEX REPRESENTATIVE OF THE ELECTRODE IMPEDANCE OVER 
TIME UNDER DIFFERENT CONDITIONS. A) Electrode and cell index (CI) is zero if no cells or only 
non-adherent cells are contained in the wells and B) increases with adherence of cells to the electrodes. 
The CI positively correlates with C) the cell number and D) the strength of adherence. E) Detaching cells 
due to apoptosis or cytotoxicity lead to decreasing CI values. Adapted from www.aceabio.com. 
electrode without cells
Z
Z
Z = Z0
Z = Z cell
baseline
impedanceelectrode with attached cell
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The xCELLigence system was used to compare and quantify the effects of depletion of regulatory T 
lymphocytes from the total T cell fraction on the killing rate of tumor cells. It served as platform to 
characterize the cell-mediated cytotoxicity in an autologous tumor model.  
The 96 well E-plate was prepared by adding 100 µl PBS in all interspaces between the wells to reduce 
evaporation of the medium and drying-out of the plate. Then, 75 µl/well Quantum tumor cell medium 
were added in well (150 µl/well in the wells designated for medium control). The plate then was 
incubated for 30 min at RT, put onto the SP station for measurement and impedance was measured for 
determination of the background (sequence 1). Per well, 25000 tumor cells were seeded in a volume of 
150 µl Quantum tumor cell medium and were grown for 96 hours while pre-treated with 1 µM DAC 
following the standard treatment protocol developed in our laboratory (see above). Therefore the 
measurement was interrupted every 24 hours until day 4 (96 hours) when effector cells were added. 
This was done by changing half of the media and adding 25000 T cells per well in 75 µl T cell 
medium. The plate was then measured for an additional period of 96 hours without interruption while 
T cells and tumors were co-incubated. Throughout whole experiment the electrode impedance was 
measured every 30 minutes leading to approx. 48 time points measured for each 24 hours-interval and 
approx. 190 time points recorded during the tumor cell growing and the co-incubation phase.  
 
CD107 degranulation assay  
Cytotoxic T lymphocytes (CTLs) can get activated upon contact with and recognition of target cells. 
In the activated state during the CTL-target interaction they start to release cytotoxic granules which is 
accompanied by the mobilization of CD107a (lysosomal-associated membrane protein-1, LAMP-1) to 
the cell surface which is normally present in vesicle membranes. The CD107a surface expression thus 
correlates with the cytotoxic activity of T cells and the killing rate of target cells and can be 
quantitated by flow cytometry analysis. This method allows also for the simultaneous staining with 
other markers to gain further information about T cell phenotypes. The assay principle is displayed in 
Figure 3.4. 
CD107a mobilization assay was used in two different settings: for the analysis of the killing potential 
of T cells after in vitro priming under treatment with immune modulators and of the killing effect of T 
cells after Treg depletion in an autologous setting.  
The specific conditions and setups for each of these assays are demonstrated in Tables x and x. In 
general, 2.5x10
5 
T cells (effectors) were co-incubated with tumor cells (targets) in a 1:1 ratio. 
Following isolation of fresh cells or harvesting of cultured cells, T cells were washed once in RPMI 
medium and adjusted to 2.5x10
6
 cells per 100 µl in T cell medium. Effector cells and target cells were 
co-incubated in a total volume of 200µl in a 96-well round bottom under sterile conditions. As the 
experiment was demonstrated in previous approaches to provide reliable results with small standard 
deviations between quadruplicates it was performed in duplicates as T cell numbers were restricted. As 
controls for spontaneous CD107a release and background reactivity T cells were incubated without 
tumor cells. To the corresponding wells (except those where only T cell markers were investigated or 
served as isotype controls), 10 µl of fluorescent-labeled anti-CD107a antibody were added (see Table 
“Antibodies” section 1.3.5).  
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FIGURE 3.4 PRINCIPLE OF THE CD107A DEGRANULATION ASSAY. Effector cells (T cells) are co-incubated 
with target cells (tumor cells) and an antibody against CD107a is added to the culture (A). Upon T cell activation CD107a is 
mobilized to the cell surface with the release of cytotoxic granules and can be bound by the antibody. CD107a surface 
expression can then be analyzed by flow cytometry analysis (B).  
 
The plate was then incubated at 37°C in a humidified atmosphere with 5% CO2. After 1 hour of co-
incubation, brefeldin A at a final concentration of 5µg/ml was added to each well and the plate was 
incubated for further 4 hours. The plate was then centrifuged (1200 rpm, 10 minutes, room 
temperature) and the supernatant was removed. T cell/tumor cell conjugates were dissolved by 
resuspending the pellets in 200 µl PBS/0.5mM EDTA buffer and cells were then transferred into a 1.5 
ml reaction tube. The wells were washed a second time with 200 µl PBS/0.5mM EDTA buffer and 
remaining cells were also transferred into the tubes. After centrifugation (1200 rpm/10 minutes/ 4°C), 
cells were washed once with FACS-PBS and samples were either directly fixed with 1% PFA solution 
(CD107a single staining) or subjected to FACS staining (isotype control and T cell markers as single 
staining or in double staining with CD107a) by applying the FACS staining protocol described above., 
Finally, cells were fixed with 1% PFA solution and transferred into FACS tubes for measurement.  
During FACS analysis, T cells could be distinguished from tumor cells in the FSC/SSC based on their 
size and granularity. The corresponding FITC and PE isotype controls allowed the definition of 
quadrant borders and single stains for CD107a and T cell markers were used to adjust the fluorescence 
compensation for the measurement of double stains. Samples containing only tumor cells were used to 
verify that with the instruments settings and gates chosen for analysis only T cells are included in the 
analysis and tumor cells are excluded from the quantitation. Then the samples of co-incubated T cells 
and tumor cells for the analysis of the killing rate were measured in duplicates by applying the same 
settings and conditions.  
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In vitro priming of T cells with subsequent CaSki killing 
sample no Tc untreated Tc treated tumor cells anti-CD107a FACS-stain 
1 yes no no none IgG1-FITC 
2 yes no no none IgG1-PE 
3 yes no no yes none 
4 yes no no none CD8 
5 yes no no yes  CD8 
6 no yes no none IgG1-FITC 
7 no yes no none IgG1-PE 
8 no yes no yes none 
9 no yes no none CD8 
10 no yes no yes CD8 
11 no no yes none IgG1-FITC 
12 no no yes none IgG1-PE 
13 no no yes yes none 
14 no no yes none CD8 
15 no no yes yes CD8 
16-17 yes no yes no CD8 
18-19 yes no yes yes none 
20-21 yes no yes yes  CD8 
22-23 no yes yes no CD8 
24-25 no yes yes yes none 
26-27 no yes yes yes CD8 
Samples 1-5 represent controls for untreated T cells, samples 6-10 controls for treated cells. Controls for tumor 
cells are represented by samples 11-15. The killing experiment (co-incubation of T cells with tumor cells) is 
represented by samples 16-23.  
Treg depletion with subsequent killing of the autologous cell line HN038M 
sample no Tc total  Tc depleted tumor cells anti-CD107a FACS-stain 
1 yes no no none IgG1-FITC 
2 yes no no none IgG1-PE 
3 yes no no yes none 
4 yes no no none CD4 
5 no yes no none IgG1-FITC 
6 no yes no none IgG1-PE 
7 no yes no yes none 
8 no yes no none CD4 
9 no no yes yes none 
10 no no yes none CD4 
11 no no yes yes yes 
12-13 yes no yes yes yes 
14-15 no yes yes yes yes 
Samples 1-4 represent controls for total T cells, samples 5-8 controls for Treg depleted T cells. Controls for 
tumor cells are represented by samples 9-11. The killing experiment (co-incubation of T cells with tumor cells) 
is represented by samples 12-15.  
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Mycoplasma detection assay  
Mycoplasma are the simplest prokaryotes and a major problem in cell culture as contamination is very 
common and may influence the cell proliferation of cell lines but also their gene expression patterns 
which might be a problem for different assays. To exclude infections with mycoplasma, cell lines, 
especially those of primary cell culture, were regularly tested with the MycoAlert™ assay. This assay 
is a rapid and easy method to detect mycoplasma contamination in cell cultures and is based on the 
selective biochemical analysis of the activity of special mycoplasma enzymes. Mycoplasma contained 
in the culture are lysed and set free enzymes that react with the MycoAlert substrate catalyzing the 
conversion of ADP to ATP. The ATP levels measured in a sample before and after the substrate is 
added allow the calculation of a ratio that indicates presence or absence of mycoplasma. The 
underlying biochemical reaction is based on the oxidation of Luciferin in presence of ATP by 
Luciferase and allows the quantification of emitted light.  
 
The intensity of the emitted light is linearly related to the ATP concentration and can be measured by a 
luminometer. The assay was performed following the manufacturer’s protocol. Briefly, 2 ml of cell 
culture supernatant or cell culture were transferred into a reaction tube and any cells contained in the 
sample were pelleted at 1500 rpm for 5 minutes. 100 µl of the cleared supernatant were transferred 
into a luminometer cuvette and 100 µl of MycoAlert reagent were added to each sample and incubated 
for 5 minutes. The cuvette was placed in the luminometer and read (with a program set to 1 minute 
integrated reading) to obtain a value for Reading A. Then 100 µl of the MycoAlert substrate were 
added to each sample and incubated for 10 minutes before the cuvette was measured again (Reading 
B). The ratio “Reading B/Reading A” was calculated and interpreted as follows:  
 
Ratio Interpretation 
< 0.9 negative for mycoplasma 
0.9 - 1.2 borderline: quarantine cells and retest in 24 hours  
> 1.2 mycoplasma contamination 
 
 
3.2.5  Statistical Methods 
 
For the comparison of continuous data between two groups either Student’s t-test or Mann-Whitney U 
test for non-parametrical data were used.  
For the estimation of differences in categorical in terms of between two groups chi-square test was 
used.  
For all tests, differences were considered to be significant if the calculated p-value was 0.05 or less.  
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4. IMMUNE CELL INFILTRATES 
AND POSSIBLE IMMUNE 
EVASION MECHANISMS IN 
CERVICAL LESIONS 
 
The present chapter deals with the immunological characterization of cervical intraepithelial neoplasia 
and cancers. Final goal of this part is to gain a better understanding of the clinically heterogeneous 
behavior of the precancerous lesions in terms of regression and progression rates.  
In the first part a central methodological approach of histological analyses of immune cell infiltrates in 
CIN was established using a computer-based tool for the standardized quantification of immune cell 
infiltrates in cooperation with the TIGA Centre Heidelberg (chapter 4.1).  
In the following part immune cell infiltrates were investigated in CIN to find out if samples of 
different infection stages are different in terms of immune cell phenotypes. Changes in immune cell 
densities and composition might be a hint for either underlying immune-regulatory mechanisms or 
effective anti-tumoral immune responses. In this context, the time point of when changes in the 
immune cell infiltration become apparent during the natural history of CIN lesions and a possible 
association with the initiation of the transforming infection stage as represented by p16
INK4a
 
overexpression are of special interest. Therefore different T cell markers of which most are well-
characterized, and which are representative of T cell activation and also of immuno-regulatory 
mechanisms were investigated (chapter 4.2).  
To better understand to which extent intrinsic features of the epithelial cells play a role in the 
pathogenesis of cervical cancer the antigen-presentation capacity of the lesion cells was investigated. 
Antigen presentation might be influenced by HPV infection and alterations regarding the expression of 
the involved molecules probably promote disease progression by causing immune escape despite the 
presence of infiltrating lymphocytes (chapter 4.3).  
Finally, the immune infiltrates of patients with CIN who were topically treated with the clinically 
approved immuno-modulatory substance imiquimod, were characterized in a longitudinal approach 
(chapter 4.4). These analyses aim at a better understanding of how the immune cell composition could 
be positively influenced and how these changes might correlate with the clinical course of the disease.  
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4.1  Development of an automated quantification system for the 
computational profiling of cervical intraepithelial neoplasia 
and its microenvironment  
 
4.1.1 Scanning and digitalization of stained tissue sections 
As the analysis of immune cell infiltrates in the lesions and the adjacent stroma was based on 
digitalized images of the tissue sections, the slides were scanned after having been fully automated 
stained with monoclonal antibodies against CD3 and CD8. The tissue sections were automatically 
imaged with the Hamamatsu NanoZoomer 2.0-HT Scan System (Figure 4.1) at 20-fold magnification 
resulting in a resolution of 0.46µm/pixel. The scan system is equipped with three 4096x64 pixel Time 
Delay and Integration (TDI) CCD (charge-coupled device) sensors enabling imaging based on a three-
dimensional XYZ-zoom technology (ROJO et al., 2006). This type of sensor allows multilayer 
scanning and is not restricted to one single, two-dimensional layer. The resulting virtual slides can 
then be analyzed in a similar manner as using classical microscopy allowing focusing through 
different layers of the tissue, dependent on the number of layers that were scanned and the distance 
between them. With a total capacity of 210 slides per batch and a scanning speed of 60 seconds for a 
tissue sample sized 15x15mm² the system allows for high-throughput scanning, digitalization and 
archiving of tissue samples. While scanning a glass slide, the system automatically detects the region 
of interest defined by presence of any tissue and also automatically chooses the correct and valid focal 
plane for the scanning processing. The file size of the virtual slides resulting from the digitalization 
process originally is up to 20 GB as uncompressed files and depends on the total size of the scanned 
area, the number of scanned layers and the magnification used during scanning. The file size 
retroactively can be reduced (approximately by the factor 25) by applying lossless JPEG compressing 
algorithms reducing for example a 16.3 GB slide to a 636 MB JPEG file.  
 
  
FIGURE 4.1  THE NANOZOOMER 2.0-HT SCAN SYSTEM USED FOR DIGITALIZATION OF STAINED 
SLIDES AND THE USER INTERFACE OF THE NDP SLIDE SERVER. With the NDPView software 
digitalized slides can be analyzed on a computer and allows the user to navigate through the slide in all 
three dimensions. Slides can be annotated, screenshots can be made and parameters such as intensity of 
the color channel, contrast and brightness can be adapted.  
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The scanned slides were made accessible on the TIGA’s Slide Server (http://tigacenter.bioquant.uni-
heidelberg.de/ndp-slide-server.html) for all cooperation partners and thus facilitated the exchange of 
data and information. This tool was also used for the definition of the lesion based on the p16
INK4a
 
staining and in cases of unclear morphology in low-grade lesions served as a platform for the 
pathologist’s review of the tissue (Figure 4.1).  
 
 
4.1.2 Development of an image processing tool adapted to cervical 
intraepithelial neoplasia 
The algorithms used for image processing have been developed using TissuemorphDP™M from 
Visiopharm, a company specialized in tissue analysis. The image processing software applied in this 
project was based on different algorithms and developed in cooperation with the TIGA Center, 
Heidelberg. An overview of the user interface of the Visiopharm image processing software with 
exemplary tools developed in the frame of this project that are applicable to the analysis of immune 
cells infiltrates in cervical intraepithelial neoplasia is given in Figure 4.2.  
 
 
FIGURE 4.2  OVERVIEW OF THE USER INTERFACE OF THE VISIOPHARM IMAGE PROCESSING 
SOFTWARE. Tools were developed for the annotation of the lesion and basal membrane, generation of 
ROIs, clearance of non-ROIs before starting the processing for cell segmentation.  
  
   4. Results I  67 
Image processing was developed and adapted to CIN lesions using the Visiopharm image processing 
software before algorithms could finally be applied to the digitalized slides. Image processing is 
performed in four distinct steps.  
(i) Automated tissue detection  
The fully automated detection of all analyzable tissue contained on the glass is the first step towards 
the cell quantification in the lesion and its microenvironment. The region of interest (ROI) is defined 
as the tissue area that shall be subjected to further analysis. ROI detection was performed on the whole 
slide after converting a color overview image (RGB) into a greyscale image. By applying simple 
thresholding methods on the grey scale image as described previously (OTSU, 1979), ROIs could be 
separated from the background regions of the slides. Thereby the background representing any non-
tissue regions is separated from the relevant tissue regions which can then be subject to further image 
processing steps and analysis (Figure 4.3 A). As a post-processing step for the ROI detection, areas 
that cannot be analyzed because they are too small or inappropriate such as small tissue fragments, 
folded tissue, staining artifacts or dust particles were removed (Figure 4.3 B) by applying 
morphological operations like opening or closing (GONZALES, 2009). These are standard imaging 
operations to remove small disturbing objects from the image or to remove small holes contained in 
the tissue.  
 
FIGURE 4.3  EXAMPLE OF THE ROI DETECTION PROCESS. A) Regions of interest are detected automatically 
using thresholding methods to separate the tissue from the background (green line). B) Post-processing 
steps remove artifacts and areas (indicated by arrows) that are too small for further analysis.  
(ii) Manual annotation of the lesion and the basal membrane and automated generation of 
different invasive margins in the stroma  
In a second step the regions to be analyzed had to be defined which was done partially by manual 
annotation and partially by automated generation of regions that were then subjected to further 
analysis. Due to the high tissue heterogeneity in CIN and the resulting difficulties to separate normal 
tissue from the lesion and also the presence of p16
INK4a
-positive and p16
INK4a
-negative lesion areas 
among the low-grade lesions renders fully automated computational image processing challenging. 
One major concern is that p16
INK4a
-negative low-grade lesions would not have been identified as such 
by the established automated annotation algorithm and would have falsely been annotated as “normal” 
tissue. Therefore in this first approach for the establishment of the basic method, automated 
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tumor/lesion-identification was replaced by manual annotation based on a comparison with the 
p16
INK4a
-stained reference slide. Lesions positive for p16
INK4a
-overexpression were visually identified 
and the corresponding region was annotated manually in the slides stained for the defined T cell 
markers (white line, Figure 4.4). In unclear cases due to aberrations between the histological stage 
given by the pathologist and the morphology of the lesion, tissue sections were reviewed by the 
pathologist again. The manual approach described here also allowed for the separate investigation of 
p16
INK4a
-positive and -negative lesion areas within the same sample. In the second step the basal 
membrane underneath the annotated lesion was also manually marked. These annotation steps are the 
prerequisite to proceed to the next step that divided the adjacent stromal tissue into several distinct 
areas (invasive margins). The algorithms applied for region growing are used from the baseline (basal 
membrane/lamina) and separate the tissue into specific regions by growing in fixed and determined 
directions. Starting at the basal lamina, the first region grows with a distance of 100µm into the 
surrounding tissue of the epithelial region (yellow line, Figure 4.4). Then the second defined region 
grows with further 400µm into the tissue (border at 500µm, pink line) and is followed by the last 
growing with 500µm (border at 1000µm) leading finally to the last margin with a maximal distance of 
1000µm located from the basal membrane (green line, Figure 4.4). After processing the slides were 
manually inspected and regions that did not represent typical stromal tissue (artifacts such as 
disruptions, or glandular tissue, endothelial cells and cavities of large blood vessels) and that therefore 
had to be excluded from further processing were removed manually from the regions by annotating 
them as regions to be cleared (Figure 4.4).  
 
FIGURE 4.4  EXAMPLES OF PROCESSED SLIDES WITH AND THE CLEANING POST-PROCESSING STEP. 
The regions of interest (ROIs) are visualized by color-coded lines and represent the epithelium (white), 
margin 100 (yellow), margin 500 (pink) and margin 1000 (green). Cleared regions are marked by an 
asterisk. 
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(iii) Cell segmentation 
During the last image processing step positively stained and unstained cells were detected by cell 
segmentation and subsequently the expression level (determined as brown (positive) or non-brown 
(negative)) is determined. The segmentation of the cell nuclei was performed separately in all 
determined stromal ROI generated in the previous step and also of all nuclei in the epithelial region. 
The segmentation of all nuclei (brown and blue) is based on a watershed segmentation described 
elsewhere (BEUCHER, 1992; JUNG and KIM, 2010) on the IHS (Intensity, Hue, Saturation)-S color 
band. The basic principle of watershed segmentation is the transformation of an intensity image into a 
three-dimensional topographic image. The intensity of each pixel of an image thereby is represented 
by the altitude of the relief. Watershed algorithms then are applied, the relief is “floated” and the 
watersheds around peaks can be interpreted as borders defining different components which can thus 
be segmented from each other.  
 
FIGURE 4.5  EXAMPLE OF THE CELL DETECTION STEP. Shown is the annotated tissue (A) before cell 
segmentation and (B) after cell segmentation. DAB-negative cells are displayed in green, DAB-positive 
cells in red. 
Finally, the DAB-positive (brown stained) cells were detected within a HDAB-DAB color band, 
provided by a color deconvolution algorithm (RUIFROK and JOHNSTON, 2001). In dependence on 
the DAB staining signal of the surrounding membranes nuclei were categorized into two groups by 
simple thresholding, namely blue nuclei with brown (DAB-positive) membranes and blue nuclei 
without brown staining signal (Figure 4.5). In a post-processing step nuclei detected that were defined 
as being too small where removed by an area-filter. An overview of all image processing steps is given 
in Figure 4.6.  
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FIGURE 4.6  EXAMPLE OF THE SUCCESSIVE STEPS OF THE AUTOMATED QUANTIFICATION PROCESS. 
Based on the p16INK4 reference slide (1) on which the lesion was marked after reviewed by a pathologist 
(1*) the slides stained for CD3 (left side, (A)) and CD8 (right side, (B)) were annotated by demarking the 
epithelium and the basal membrane (2). Then the different invasive margins with 100 µm, 500 µm and 
1000 µm reaching into the stromal compartment were generated (3). Finally, cells stained for the 
corresponding immune cell markers (red) and those that are negative (green) are detected and quantified.  
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4.1.3  Calculation of cell densities from the output data  
The successive application of image processing steps described above resulted in different output 
variables comprising number and area of the nuclei for every staining category (negative = blue, 
positive = brown) and, in addition, the white areas surrounding the nuclei and representing cytoplasm. 
All output variables are listed below in table 4.1. 
ROI 001 RO002 ROI 003 ROI 004 
epithelium margin 100 margin 500 margin 1000 
counts of negative nuclei inside the corresponding ROI (blue signal) 
counts of positive nuclei inside the corresponding ROI (brown signal) 
area covered by negative nuclei inside the corresponding ROI  
area covered by positive nuclei inside the corresponding ROI 
remaining (non-nuclei) area inside the corresponding ROI (white area) 
TABLE 4.1 OVERVIEW OF THE OUTPUT VARIABLES OBTAINED FOR ALL DEFINED REGIONS OF 
INTEREST (ROI) FOLLOWING APPLICATION OF IMAGE PROCESSING STEPS.  
 
The output data comprise cell counts of positive and negative cells and the areas that are covered by 
cell in a distinct ROI. Single values are given for the negative nuclei, positive nuclei and the white 
surroundings representing cytoplasm. The total areas of all compartments, ROIs, could then be 
calculated from these values. This was done for each compartment separately (margin 100, margin 500 
and margin 1000), but also for the continuous regions that reach from the basal membrane up to the 
500µm and the 1000µm borders. The ratios between cell counts in a distinct ROI and the 
corresponding area of this compartment were calculated in order to obtain the cell densities as 
“positive cells/mm2”) from the output data.  
 
 
4.2  The local immune cell infiltration in cervical intraepithelial 
neoplasia in relation to p16
INK4a
 expression 
 
The study presented in this chapter adresses the question whether changes in the composition and 
densities of immune cell markers are correlated to p16
INK4a
 overexpression in cervical dysplasia, as a 
marker stratifying CIN into two infection states (permissive infections, p16
INK4a
-negative, and 
tansforming infections, p16
INK4a
-positive). The correlation of possible changes in immune cell density 
and composition with p16
INK4a
-defined biologic stages may reveal import insights into the immune 
control and changes of these mechanisms during cervical carcinogenesis.  
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For the investigation of a possible link between the infection stage and infiltrating immune cells in 
CIN mainly well-characterized standard T cell markers were chosen (for details see Introduction 
chapter 1.4.1).  
A mixture of activation and inhibition markers should allow to investigate to which extent T cells 
present in the lesion microenvironment are in an activated state and possibly able to combat the HPV 
infection and transformed cells or are inhibited. The global T cell infiltration was characterized by 
CD3-expressing cells while CD8 and Granzyme B were used as markers for cytotoxic T lymphocytes 
(CTLs) and activated CTLs displaying lytic activity. Forkhead box transcription factor 3 (Foxp3), a 
marker for regulatory T cells and thus representing the suppressive state of immune cells was also 
included. CD3-ζ was included as a marker for the susceptibility of T cells for activation upon antigen 
recognition. 
 
4.2.1  p16
INK4a
-expression status of the lesions 
As a marker highlighting transforming HPV infections (BERGERON et al., 2014; VON KNEBEL 
DOEBERITZ et al., 2012) p16
INK4a
 was used to biologically define the different lesion grades that 
were available for this study. Immunohistochemical staining for 16
INK4a
 (chapter 3.21) revealed that all 
cervical carcinoma samples and all high-grade CIN (CIN2/3) were p16
INK4a
-positive. However, low-
grade CIN (CIN1) could be classified into two groups with 9 of 22 lesions being p16
INK4a
-negative 
(permissive infection) and 13 of 22 lesions being p16
INK4a
-positive representing the early transforming 
infection stage in CIN (Table 4.2).  
 
 CIN1 CIN2 CIN3 CxCa Overall population 
number of patients 22 11 19 17 69 
p16
INK4a
-positive 
samples: n (%) 
13 (59.1%) 
11 
(100.0%) 
19 
(100.0%) 
17 
(100.0%) 
60 
(86.96%) 
TABLE 4.2 SAMPLE CHARACTERISITCS REGARDING THE HISTOLOGICAL CLASSIFCIATON AND THE 
TRANSFORMING INFECTION STAGE AS REPRESENTED BY THE p16INKa STATUS.  
 
4.2.2  Comparison of T cell infiltrates in p16
INK4a
-positive and p16
INK4a
-
negative low-grade CIN 
In terms of histomorphological classification CIN1 lesion are regarded as a uniform group. 
Biologically they are, however, more diverse with a proportion of these lesions being already in the 
early transforming infection stage which is highlighted by beginning p16
INK4a
-overexpression.  
T cell infiltrates of all phenotypes were compared between p16
INK4a
-negative and p16
INK4a
-positive 
low-grade lesions (representative examples for the immunohistochemical characterization of 
infiltrating immune cells are given in Figure 4.7).  
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FIGURE 4.7  REPRESENTATIVE DETAILS OF IMMUNOHISTOCHEMICAL STAININGS (AT 200x 
MAGNIFICATION) FOR p16INK4a, CD3, CD8, GRANB, CD3ζ AND FOXP3. Representative areas of 
the epithelium (upper part of the tissue) and the adjacent stroma (lower part) are shown and examples of 
positive cells are indicated by arrows.  
Low-grade lesions (all CIN1 irrespective of the p16
INK4a
 expression state) and the adjacent stromal 
compartment had generally lower total numbers of infiltrating immune cells compared with the higher 
grade CIN (mean cell numbers, ranges and standard deviations are summarized in Table S9.1). 
Nevertheless, the comparison of p16
INK4a
-negative and p16
INK4a
-positive samples within the group of 
low-grade CIN did not reveal significant differences regarding the infiltration densities of the five 
investigated T lymphocyte phenotypes (4.8 and Table S9.1). The ratio between epithelial and stromal 
cell numbers representing the percentage of T cells invading from the lesion-adjacent stroma into the 
lesion neither did reveal significant differences between p16
INK4a
-negative and p16
INK4a
-positive CIN1 
lesions (Figure 4.8 and Table S9.1). Furthermore, the ratios of all T cell subtypes to CD3+ cell counts 
were calculated for both compartments as a measure for the proportion of distinct T lymphocyte 
phenotypes among all present T cells. Here again, no significant differences between p16
INK4a
-negative 
and p16
INK4a
-positive low-grade lesions were observed (Figure 4.9 and Table S9.2). 
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FIGURE 4.8 DISTRIBUTION OF T CELL SUBTYPES IN DIFFERENT COMPARTMENTS IN p16INK4a-
NEGATIVE LOW-GRADE LESIONS COMPARED WITH p16INK4a-POSITIVE LOW-GRADE 
LESIONS. A) Absolute T cell counts per 0.0625mm² in the lesion and lesion-adjacent stroma. B) Ratio 
between the lesion and lesion-adjacent stroma for all T cell phenotypes. The dot in the center of each box 
represents the median value of the distribution; the borders of the box represent the upper and lower 
quartiles (25%-75%). Significant levels are indicated by asterisks:  
  * p<0.05 (significant) 
  ** p<0.01 (very significant) 
  ***  p<0.001 (extremely significant) 
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FIGURE 4.9 RATIOS OF T CELL SUBTYPES TO CD3+ T CELLS PRESENT IN THE LESION AND LESION-
ADJACENT STROMA IN p16INK4a-NEGATIVE LOW-GRADE LESIONS COMPARED WITH 
p16INK4a-POSITIVE LOW-GRADE LESIONS. The dot in the center of each box represents the median 
value of the distribution; the borders of the box represent the upper and lower quartiles (25%-75%). 
Significant levels are indicated by asterisks:  
  * p<0.05 (significant) 
  ** p<0.01 (very significant) 
  ***  p<0.001 (extremely significant) 
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4.2.3 T cell infiltrates in p16
INK4a
-positive high-grade CIN 
The high-grade CIN (CIN2/3) were all p16
INK4a
-positive indicating true transforming HPV infection in 
these lesions that furthermore probably have acquired secondary genomic alterations. 
The comparison of T cell counts between high-grade CIN (CIN2/3, all p16
INK4a
-positive) and all low-
grade CIN (of which n=13 were p16
INK4a
-positive and n=9 were p16
INK4a
-negative) revealed that the 
number of total T cells represented by CD3+ cells significantly was increased in high-grade lesions 
compared with low-grade CIN in both the epithelium (p=0.0273) and the stromal compartment 
(p<0.0001). This general increase is also reflected by the higher stromal infiltration of Foxp3+ T cells 
(p=0.0076), the higher infiltration with GranB+ T cells in the epithelium (p=0.0028 for the epithelium 
and p=0.0014 for the stromal), of CD8+ T cells (p=0.0012 for the epithelium and p<0.0001 for the 
stroma) and also of CD3ζ+ T cells (p=0.0286 for the epithelium p=0.0022 for the stroma) (Figure 
4.10, Table S9.1). With regard to the epithelial to stromal cell number ratios a trend for decreased 
ratios was found for CD3+ cells (p=0.0799) and also CD3ζ+ cells (p=0.0672) in high-grade CIN 
compared to low-grade lesions (Figure 4.10 and Table S9.1). Again, the ratios for all T cell 
phenotypes to CD3+ T cell counts were calculated and were found to be significantly increased in 
high-grade CIN for GranB+ T cells (p=0.0041) and for CD8+ T cells (p=0.0258) in the epithelium. 
The ratio calculated for CD3ζ+ T lymphocytes showed the inverse correlation and tended to be 
decreased in the stromal compartment of high-grade CIN (p=0.0700) (Figure 4.11 and Table S9.2).  
Interestingly, the absolute T cell numbers but also the ratios calculated for different T cell subtypes to 
CD3+ T cells are very heterogeneous in high-grade lesions (Figures 4.10 and 4.11) and within a 
distinct histomorphological category (Table S9.1) and span wide ranges. Epithelial numbers for CD8+ 
T cell for example range from 3.7 to 32.3 cells per 0.0625mm² in CIN2 lesions. These enormous 
variances can also be observed for epithelial Foxp3+ T cell numbers in CIN2 lesions ranging from 2.0 
to 17.0 cells per 0.0625mm
2 
(Table S9.1). 
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FIGURE 4.10 DISTRIBUTION OF T CELL SUBTYPES IN DIFFERENT COMPARTMENTS IN LOW-GRADE 
(LG) LESIONS COMPARED WITH HIGH-GRADE (HG) LESIONS. A) Absolute T cell counts per 
0.0625mm² in the lesion and lesion-adjacent stroma. B) Ratio between the lesion and lesion-adjacent 
stroma for all T cell phenotypes. The dot in the center of each box represents the median value of the 
distribution; the borders of the box represent the upper and lower quartiles (25%-75%). Significant levels 
are indicated by asterisks:  
   * p<0.05 (significant) 
   ** p<0.01 (very significant) 
   ***  p<0.001 (extremely significant) 
 
78     4. Results I 
 
FIGURE 4.11 RATIOS OF T CELL SUBTYPES TO CD3+ T CELLS PRESENT IN THE LESION AND LESION-
ADJACENT STROMA IN LOW-GRADE (LG) LESIONS COMPARED WITH HIGH-GRADE (HG) 
LESIONS. The dot in the center of each box represents the median value of the distribution; the borders 
of the box represent the upper and lower quartiles (25%-75%). Significant levels are indicated by 
asterisks:  
  * p<0.05 (significant) 
  ** p<0.01 (very significant) 
  ***  p<0.001 (extremely significant) 
 
4.2.4 T cell infiltrates in cervical carcinomas 
With regard to the total T cell numbers the infiltration is even higher in cervical carcinoma samples in 
comparison to high-grade CIN for most of the different T cell phenotypes (mean cell numbers, ranges 
and standard deviations are shown in Table S9.1). Especially the stromal compartment showed an 
enhanced T cell infiltration where significant differences compared to the high-grade lesions could be 
found for the global T cell infiltration with CD3+ T lymphocytes (p=0.0414), GranB+ T cells 
(p=0.0095) and also Foxp3+ T cells (p=0.0243). The higher total cell numbers were accompanied by 
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decreased epithelial to stromal ratio for GranB+ (p=0.0467) and Foxp3+ T lymphocytes (p=0.0464). 
For the other cell types (CD3+, CD8+ and CD3ζ+ T lymphocytes) no significant differences in the 
epithelial/stromal ratio could be observed (Table S13.x). Also most of the ratios calculated for all T 
cell subtypes to CD3+ cell counts as a measure for the proportion of distinct cell phenotypes among all 
T lymphocytes, were decreased in cervical carcinomas compared to high-grade CIN. The decrease was 
significant for the intraepithelial CD8/CD3 ratio (p=0.0090) and the stromal CD3ζ/CD3 ratio 
(p=0.0090), which represents the lowest CD3ζ/CD3 ratio of all stages. The only exception is the 
significantly higher GranB/CD3 ratio (p=0.0418) in cervical carcinoma samples compared to high-
grade lesions.  
 
In summary, cervical precancerous lesions displayed generally increasing T lymphocyte densities with 
worsening lesion grade from low-grade lesions to high-grade lesions and towards cancer. Thereby, T 
cell densities in the transforming infection stage of low-grade CIN were not yet different form non-
transforming CIN1 lesions. Although the increase of immune cell densities could be observed for 
different T cell markers, the presence of regulatory T cells could be identified in all lesion stages and 
is more pronounced in the stroma than in the epithelium. Based on the data shown in Table S9.1 an 
increase from low-grade lesions (stromal mean cell density for both non-transforming and 
transforming low-grade lesions together: 10.8 cells/0.0625 mm
2
) to CIN3 (mean 19.3 cells/0.0625 
mm
2
) could be observed (p=0.0076). The Foxp3+ T cell density was further increased in invasive 
cancer with a mean density of 42.1 cells/0.0625 mm
2
 compared with high-grade lesions (p=0.0243). 
The ranges of densities were remarkable in all diseases stages with 0.0-20.0 cells/0.0625 mm
2
 in low-
grade lesions, 1.5-16.8 cells/0.0625 mm
2 
in high-grade lesions and 3.3-97.8 cells/0.0625 mm
2 
in 
cervical cancers.  
 
 
4.3  Alterations of human leukocyte antigen expression in 
cervical intraepithelial neoplasia and cancers 
As shown in section 4.2 there is a striking contradiction between high numbers of infiltrating 
lymphocytes in high-grade cervical dysplasia and carcinomas indicating that immune cells are 
attracted to the lesion site. However, these lesions obviously have progressed to finally become an 
established and morphologically visible high-grade lesion demonstrating that despite the presence of T 
cells in the microenvironment a certain number of already established high-grade lesions cannot be 
completely eradicated and will further progress to become invasive tumors. High T lymphocyte 
infiltration of both CD4+ and CD8+ T lymphocytes in association with cancer development has also 
been observed in other tumor entities (HAN et al., 2014; MATKOWSKI et al., 2009).  
These observations might imply that tumor cells under the immunoselective pressure evolve strategies 
that provide protection from recognition and elimination by cytotoxic T cells (GARCIA-LORA et al., 
2001). Indeed, as adaption to the host’s immune system and in order to circumvent an immune attack 
tumor cells are able to modulate the immune response by changing their own characteristics. One of 
these changes represent the alteration of the expression and function of human leucocyte antigen 
(HLA) class I and class II on the surface of tumor cells. In comparison with the modification of the 
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tumor microenvironment by changes in the cytokine milieu and immune cell composition, is a much 
more immediate mechanism. In the context of HPV-associated diseases this might also be of 
importance: transforming cervical lesions and carcinomas constitutively express the viral oncoproteins 
E6 and E7 which could be degraded for antigen processing and subsequent presentation by HLA class 
I molecules and might be recognized by effector cells such as cytotoxic T lymphocytes. As outlined in 
chapter 1.4.2 alterations in antigen-presentation pathways might result in a less effective presentation 
of viral and tumor-associated antigens and prevents the tumor from being recognized by the host T 
cells.  
 
HLA class I antigens are composed of a heavy chain (glycoprotein) which is encoded by genes within 
the HLA regions of chromosome 6p (HLA-A, -B, -C) and a light chain (β2m) encoded by a gene 
located on chromosome 15q. HLA class I antigens are normally expressed on all nucleated cells of the 
body. HLA class II antigens are also heterodimeric molecules composed of an alpha and a beta chain. 
This class of antigen-presenting molecules is usually expressed by professional antigen-presenting 
cells of the immune system. Tumors of different origins have been reported to show altered human 
leucocyte antigen expression which can be gradual and range from down-regulation to total loss of 
classical HLA class I antigens but also gradual induction of de novo expression of HLA class II 
antigens.  
 
The project described in this chapter aims at the characterization of altered HLA class I antigen and 
HLA class II antigen expression profiles in cervical intraepithelial neoplasia and cancers to answer the 
question if these modifications might contribute to cervical carcinogenesis. Some reports on altered 
HLA class I expression are conflicting and it remains still unclear whether HLA class I antigens are 
completely lost during cervical carcinogenesis – suggesting a strong selection pressure for negative 
cell clones, or whether their expression is only reduced – suggesting functional impairment, but 
potentially enabling re-expression by drug intervention, vaccination or immune modulation.  
Cervical lesions of different grade, CIN2 (n=9), CIN3 (n=13) and invasive squamous cell carcinoma 
(SCC) samples (n=19) were analyzed by immunohistochemical staining for HLA class I antigen heavy 
chains (HLA-A, HLA-B and HLA-C) and the light chain (beta-2-microglobuline, β2m) and also HLA 
class II antigens in order to find out if these molecules are differentially expressed in increasing 
histomorphological lesion grades. 
 
 
4.3.1  Altered HLA class I antigen expression in cervical intraepithelial 
neoplasia and cervical carcinoma  
 
For the characterization of HLA class I antigen expression a panel of antibodies was used as described 
previously (KLOOR et al., 2005) to determine the expression levels of the HLA class I heavy and light 
chains separately. The monoclonal antibodies HC-10 and HCA-2 recognize different epitopes of the 
HLA class I heavy chains: while HC-10 recognizes a determinant expressed on β2m-free HLA-A10, 
HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32 and HLA-A33 heavy chains and on β2m-free 
   4. Results I  81 
HLA-B and HLA-C heavy chains the monoclonal antibody HCA-2 binds to a determinant expressed 
on β2m-free HLA-A (excluding HLA-A24), HLA-B7301 and HLA-G heavy chains.  
To determine the expression of the HLA class I light chain the monoclonal antibody L368 recognizing 
β2m was used.  
Importantly, HLA class I complexes are denatured by formalin fixation during the tissue processing 
and dissociate into the heavy chain and the light chain. Therefore, it is not possible do detect intact and 
functionally active HLA class I complexes. Thus only a combination of antibodies can allow the 
distinction between free heavy chains or β2m molecules respectively and those assembled to HLA-
class I heavy chains/β2m complexes transferred to and located on the cell surface. Membranous 
localization of HLA heavy chains (A/B/C) indicated intact HLA class I complexes transferred to the 
tumor cell surface. In contrast, altered expression or complete loss of membranous β2m staining and 
disturbances in membranous HLA class I heavy chain staining is a sign for defects in the antigen 
presentation pathway being either impaired or non-functional.  
Lesions were classified as having normal, heterogeneous or negative HLA class I staining pattern 
based on criteria summarized in Table 4.3.  
 
score staining pattern 
% cells positive within 
lesion/tumor 
positive strong, homogeneous overall expression  > 75% 
heterogeneous faint and patchy, weak overall expression 25-75% 
negative  
absent or restricted to single cells (immune cells or locally 
induced expression)  
< 25%  
TABLE 4.3 SCORING SYSTEM FOR THE EVALUATION OF HLA CLASS I AND II STAINING PATTERNS. 
Examples of staining pattern are shown in Figure 4.12 for the HCA-2 antibody. 
 
 
FIGURE 4.12  REPRESENTATIVE HCA-2 STAINING PATTERNS OBSERVED IN CIN AND CERVICAL 
CANCER SAMPLES (200x MAGNIFICATION). Shown are examples for A) positive staining (strong 
and membranous) in normal, non-dysplastic epithelium, B) positive staining of invasive SCC, C) 
heterogeneous expression pattern and D) invasive SCC with negative HCA-2 staining pattern.  
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Cytoplasmic and membranous staining of cells of the normal, non-dysplastic epithelium, precancerous 
lesions and tumors was recorded separately and are summarized in Table 4.4. Representative staining 
results for p16
INKa
 and all HLA class I antigen markers are shown in Figure 4.13.  
 
 
TABLE 4.4  HLA CLASS I ANTIGEN EXPRESSION IN CIN2, CIN3 AND INVASIVE SCC. Data for HC-10 and 
HCA-2 heavy chain antibodies and β2m are shown for the cytoplasmic and membranous separately.  
Normal, non-dysplastic epithelium if present and analyzable on the same slide was characterized for 
HC-10, HCA-2 and β2m staining patterns. In total, n=19 regions could be found that were adjacent to 
CIN2 or CIN3 lesions. The normal epithelial regions showed positive staining in 100.0% of the cells 
and also a clear membranous staining for all three antibodies.  
In cervical precancerous lesions and cancers a high frequency of HLA class I alterations could be 
observed.  
 
All samples investigated for HLA class I antigen expression were p16
INK4a
-positive. The staining 
results for HC-10 showed that all CIN2 samples displayed normal expression in both cytoplasm and 
membranous localization (100.0%). A heterogeneous membranous staining could be observed in 3 of 
13 (23.1%) of CIN3 lesions and 3 out of 19 samples (15.8%) of invasive SCC. Lesions totally negative 
for membranous HC-10 staining were rare and represented 1of 13 (7.7%) of CIN3 and 1 of 19 (5.3%) 
of invasive SCC.  
The HCA-2 staining demonstrated that heterogeneous or absent cytoplasmic staining occurred more 
frequently in comparison with HC-10 antibody staining. Positive HCA-2 cytoplasmic staining could 
only be observed in 6 of 9 (66.7%) of CIN2, in 6 of 11 (54.5%) of CIN3, and 8 of 17 (47.1%) of 
invasive SCC samples. Conversely, heterogeneous expression and total losses were frequent: 
regarding the membranous expression more than half of CIN2 (5 of 9, 55.6%) and CIN3 (6 of 11, 
54.5%), and 11 of 17 (64.7%) of invasive SCC are negative for membranous HCA-2 staining.  
 
non-neoplastic epithelium
positive (%) 19 100.0% 19 100.0% 19 100.0% 15 78.9% 19 100.0% 19 100.0%
heterogeneous (%) 0 0.0% 0 0.0% 0 0.0% 4 21.1% 0 0.0% 0 0.0%
negative (%) 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Samples analyzed 19 19 19 19 19 19
CIN 2 
positive (%) 9 100.0% 9 100.0% 6 66.7% 1 11.1% 9 100.0% 9 100.0%
heterogeneous (%) 0 0.0% 0 0.0% 1 11.1% 3 33.3% 0 0.0% 0 0.0%
negative (%) 0 0.0% 0 0.0% 2 22.2% 5 55.6% 0 0.0% 0 0.0%
Samples analyzed 9 9 9 9 9 9
CIN 3 
positive (%) 12 92.3% 9 69.2% 6 54.5% 2 18.2% 12 92.3% 8 61.5%
heterogeneous (%) 1 7.7% 3 23.1% 2 18.2% 3 27.3% 1 7.7% 4 30.8%
negative (%) 0 0.0% 1 7.7% 3 27.3% 6 54.5% 0 0.0% 1 7.7%
Samples analyzed 13 13 11 11 13 13
invasive SCC
positive (%) 16 84.2% 15 78.9% 8 47.1% 2 11.8% 16 84.2% 8 42.1%
heterogeneous (%) 2 10.5% 3 15.8% 4 23.5% 4 23.5% 3 15.8% 6 31.6%
negative (%) 1 5.3% 1 5.3% 5 29.4% 11 64.7% 0 0.0% 5 26.3%
Samples analyzed 19 19 17 17 19 19
HLA class I heavy chain HLA class I light chain
HC-10 cytoplasm HC-10 membrane* HCA-2 cytoplasm HCA-2 membrane* β2m cytoplasm β2m membrane*
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FIGURE 4.13  EXEMPLARY STAINING RESULTS FOR ALL MARKERS IN A CERVICAL CANCER SAMPLE 
(SCC) AT 200x MAGNIFICATION. Shown are the p16INK4a-staining and the slides stained for all three 
HLA class I antigen markers (HC-10, HCA-2 and L368).  
 
Regarding the staining for β2m the results demonstrated the vast majority of cervical precancers and 
cancers are positive for cytoplasmic β2m (100.0% of CIN2, 92.3% of CIN3 and 84.2% of invasive 
SCC). Heterogeneous expression is found in a small proportion of CIN3 and invasive SCC (7.7% and 
15.8%) and none of the samples is negative for cytoplasmic β2m expression. Regarding the 
membranous expression of β2m all CIN2 samples displayed normal expression (100.0%) while CIN3 
and invasive SCC to a certain extent display altered membrane staining. However, still 61.5% of CIN3 
and 42.1% of invasive SCC are positive for membranous β2m.  
 
The correlation analyses between expression intensities (negative, homogenous and positive) and stage 
of the disease showed that the HC-10 membranous staining was differently distributed between all 
precancerous lesions (CIN2 and CIN3) and invasive cancers (SCC) with p<0.0001. CINs lesion more 
often showed a positive staining (in 13/22 samples) while in SCC more often a heterogeneous staining 
pattern could be observed (in 15/19 samples). Regarding the HCA-2 staining no differences between 
the two groups could be shown for the membranous staining, but the overall cytoplasmic expression 
was different between CIN and SCC: CIN lesions more frequently showed positive staining patterns 
(in 9 out of 20 CINs), while 9 of 17 SCC samples were negative for HCA-2 staining (p=0.0005). For 
membranous β2m-expression a strong trend towards more positive staining pattern in CIN (17 of 22 
samples) in comparison to SCC samples (8 of 19 samples) could be observed. In contrast, SCC 
samples showed a higher tendency to be negative for membranous β2m-expression (5 of 19 samples) 
compared with CIN samples (1 out of 22).  
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4.3.2  Human leucocyte antigen class II expression in cervical intraepithelial 
neoplasia and cervical cancer 
HLA class II antigens are normally expressed on professional antigen-presenting cells (APCs), but 
have also been reported to be expressed by distinct solid tumors (ALTOMONTE et al., 2003; 
DENGJEL et al., 2006). The mechanisms involved in the expression of HLA class II antigens and 
their role in the interaction of the tumor cells with the host’s immune system as well as the role of 
immunoselection in HLA class II antigen loss are largely unknown. To investigate the role of HLA 
class II antigen expression in the development of cervical intraepithelial neoplasia and progression 
towards cancer, cervical lesions were stained with a monoclonal antibody against HLA class II chains 
DR, -DQ, -DP (LGII-612.14).  
The analysis was performed in the cohort used for the characterization of HLA class I antigen 
expression. With CIN2 already displaying strong HLA class II antigen de novo expression the 
question arose whether or not low-grade CIN (CIN1) also showed this expression pattern. To 
explicitly address this question the cohort was enlarged by an additional set of CIN1 samples (n=19) 
and a further subset of CIN2 samples (n=9). In parallel to the study of immune cell infiltrates in 
different infection stages of low-grade CIN lesions (chapter 4.x) the HLA class II expression pattern 
was correlated with the p16
INK4a
 status of these additionally included lesions.  
The same categories of staining patterns were applied as for HLA class I antigen staining (Table 4.3). 
Examples of the different HLA class II antigen staining patterns are shown in Figure 4.14.  
 
 
FIGURE 4.14  EXEMPLARY LGII.612-14 STAINING PATTERNS OBSERVED IN CIN AND CERVICAL CANCER 
SAMPLES. Shown are A) normal, non-dysplastic epithelium which is negative for HLA class II antigen 
expression B) the transition from adjacent normal epithelium to a CIN lesion with a strongly positive 
staining pattern, C) positive invasive SCC and D) heterogeneous staining pattern in invasive SCC with 
areas negative and positive for LGII.612-14 staining. 
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The results of HLA class II antigen expression were recorded separately for the cytoplasm and the 
membranous localization and are summarized in Table 4.5.  
Again, if normal non-dysplastic epithelium adjacent to the lesions was present, it was also analyzed 
for HLA class II antigen expression (n=29). Positive staining was completely absent in the normal 
stratified cervical epithelium or restricted to single cells in the epithelium only. However, HLA class II 
antigen expression can frequently be detected in dysplastic epithelium as shown in Figure 4.14.  
Interestingly, 15 of 18 investigated CIN2 samples showed cytoplasmic HLA class II antigen 
expression (heterogeneous or positive staining) in the lesion and only 3 of 18 (16.7%) were negative 
for staining with the LGII.612-14 antibody. Importantly, more than half of the CIN2 lesions (55.6%) 
(10 out of 18 cases) displayed strong and positive HLA class II antigen expression. This suggests that 
HLA class II antigen expression is a very common event during the initial steps of transforming HPV 
infection.  
 
 
TABLE 4.5 HLA CLASS II ANTIGEN EXPRESSION IN NORMAL EPITHELIUM, CIN1, CIN2, CIN3 LESIONS 
AND INVASIVE SCC. Data are shown for the cytoplasmic and membranous expression separately.  
In CIN3 lesions 84.6% (11 out of 13 samples) of the lesions were found to be positive for HLA class 
II antigens with more than half of them (53.8%) being strongly stained and considered positive. The 
same trend could also be observed in invasive cancers. Here, a positive HLA class II staining pattern 
could be observed in 11 of 19 cases (57.9%).  
LGII-612.14 membrane*
non-neoplastic epithelium
positive (%) 0 0.0% 0 0.0%
heterogeneous (%) 0 0.0% 0 0.0%
negative (%) 29 100.0% 29 100.0%
Samples analyzed 29 29
CIN 1
positive (%) 6 31.6% 3 15.8%
heterogeneous (%) 4 21.1% 4 21.1%
negative (%) 9 47.3% 12 63.1%
Samples analyzed 19 19
CIN 2
positive (%) 10 55.6% 8 44.4%
heterogeneous (%) 5 27.8% 6 33.3%
negative (%) 3 16.6% 4 22.3%
Samples analyzed 18 18
CIN 3 
positive (%) 7 53.8% 5 38.4%
heterogeneous (%) 4 30.8% 6 46.2%
negative (%) 2 15.4% 2 15.4%
Samples analyzed 13 13
invasive SCC
normal (%) 11 57.9% 10 52.6%
heterogeneous (%) 5 26.3% 6 31.6%
negative (%) 3 15.8% 3 15.8%
Samples analyzed 19 19
HLA class II 
LGII-612.14 cytoplasm
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The observation that the majority of CIN2 lesions displayed HLA class II antigen expression prompted 
the idea to characterize low-grade CIN1 lesions - included retrospectively - for the expression of HLA 
class II antigens in order more precisely determine the time point of the induction of its expression.  
Again, in a non-negligible proportion of samples (10 of 19, 52.7%) HLA class II expression could be 
observed. In comparison with high-grade lesions (CIN2/3) and cancers, however, the percentage of 
negative lesions was relatively high (47.35%).  
 
As for the immune cell infiltrates (chapter 4.2) the low-grade lesions were stratified for their p16
INK4a
-
status representing thus non-transforming (p16
INK4a
-negative) and transforming (p16
INK4a
-positive) 
CIN1 in order to estimate a possible correlation of HLA class II with the biological infection stage.  
 
 
FIGURE 4.15  REPRESENTATIVE STAININGS FOR THE CORRELATION OF (A) P16INK4A EXPRESSION AND 
(B) HLA CLASS II ANTIGEN EXPRESSION IN LOW-GRADE CIN (CIN1). Shown are examples for 
1) perfectly matching p16INK4a-positive areas with HLA class II positive regions 2) a p16INK4a-positive 
lesion that is HLA class II negative and C) a p16INK4a-negative (focal p16INK4a-expression) that is HLA 
class II positive.  
Among CIN1 9 out of 19 (47.4%) were p16
INK4a
-negative and 10 out of 19 (52.6%) were p16
INK4a
-
positive. A possible association between p16
INK4a
 expression reflecting the infection stage and HLA 
class II antigen expression in CIN1 lesions could not be found when HLA class II antigen expression – 
cytoplasmic or membranous – and the p16INK4a expression status in low-grade lesions were correlated. 
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This result confirmed the observations made during the microscopic evaluation with regard to the 
occurrence of all possible combinations of p16
INK4a
 expression with HLA class II antigen presence or 
absence (Figure 4.15). The distribution HLA class II antigen expressing lesions among p16
INK4a
-
negative and p16
INK4a
-positive CIN1 is shown in Table 4.6.  
 
p16
INK4a
 status  LGII-612.14 negative  LGII-612.14 positive 
p16
INK4a
-negative 3/9 (33.3%)  6/10 (60.0%) 
P16
INK4a
-positive 6/9 (66.6%)  4/10 (40.0%) 
p-value   p=0.245  
TABLE 4.6  DISTRIBUTION OF HLA CLASS II EXPRESSION IN p16INK4a-NEGATIVE AND p16INK4a-POSITIVE 
CIN1 LESIONS.  
The distribution of HLA class II antigen expression was also correlated to the grade of the disease by 
comparing all precancerous lesions with the invasive cancer samples: no correlation could be observed 
between the membranous HLA class II antigen expression and the disease stage represented by all 
CIN lesions and invasive SCC samples (p=0.182). The comparison of single, unpooled CIN stages 
(CIN1, CIN2 and CIN3 separately) and SCC samples with each other revealed that membranous HLA 
class II antigen expression was significantly different lower in CIN1 lesions than all high-grade lesions 
(CIN2, CIN3) and cancers (p=0.019).  
  
In order to find out if there was a correlation between HLA class II expression and the alterations of 
HLA class I antigen expression reported in the previous section (4.3.1) the samples that were initially 
included in the study (CIN2, CIN3 and invasive SCC) before enlargement by CIN1 and further CIN2 
samples and for which both staining data sets were available, were investigated. A significant 
association between HLA class II and class I antigen expression was not observed. The presence and 
absence of HLA class II expression was correlated with the HC-10 staining pattern (p=0.996) and 
HCA-2 staining (p=0.532) and also β2m expression (p=0.361). A significant association between HLA 
class II and class I antigen expression was not observed.  
 
While the normal, non-dysplastic epithelium was negative for HLA class II staining, a strong and 
uniform staining pattern was observed in glandular cells and the columnar epithelium of the 
transformation zone of the cervix uteri (Figure 4.15 3B).  
 
 
4.4 Immune cell infiltrates under immuno-stimulatory 
treatment  
 
It has been demonstrated that immune modulation by topical treatment with imiquimod, a TLR-
agonist, might positively influence the local immune response and lead to regression of dysplastic 
lesions (TERLOU et al., 2010).  
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The efficacy of topical imiquimod treatment in patients with cervical intraepithelial neoplasia has been 
tested for the first time in the frame of a phase I (double-blind randomized, placebo-controlled) trial 
conducted in Austria (GRIMM et al., 2012). The treatment protocol and the clinical outcome of the 
patients analyzed in the here presented study are summarized in Figure 4.16.  
The patients included in the Austrian trial represent an exceedingly precious cohort. Although the 
sample size is relatively small, the included biopsies represent a precious source of tissue of non-
excised lesions that were treated with an immuno-modulatory agent and observed for 20 weeks. This 
cohort therefore provides highly important longitudinal information about the influence of immuno-
modulatory agents on the immune cell composition and the clinical behavior of these lesions.  
 
 
 
FIGURE 4.16  SCHEME OF THE AUSTRIAN IMIQUIMOD TRIAL WITH TIMING OF THE OBTAINED PUNCH 
BIOPSIES. Procedure is shown for the 10 patients of the imiquimod arm that were analyzed in the 
presented study.  
 
4.4.1  Characterization of the study cohort 
 
In a cooperation project with the Medical University of Vienna, Austria samples of the above 
described imiquimod trial could be obtained for immunological characterization. 10 patients with a 
CIN2/3 diagnosis that had received a 16-week imiquimod treatment were included in the analysis each 
providing cervical biopsies before (week 0), during (week 8) and after (week 20) treatment. Tissue 
sections of the biopsies were stained for p16
INK4a
, CD3 and CD8. Image annotation and processing 
were performed based on the method described in section 4.1 and blinded to the patient ID and the 
clinical outcome. All patient related information at this stage of the analysis was subjected to 
pseudonymisation except the histomorphological classification (lesion grades) as the lesion grade that 
led to the diagnosis was needed for the definition of the region to be analyzed on the p16
INK4a
 reference 
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slide as well as for the annotation of the slides stained with T cell markers. Once the immune cells 
were quantified the clinical parameters were uncovered: 6 of the patients had regressing disease 
(defined as CIN1 or less) and 4 of the patients had persistent disease or had even progressed (defined 
as CIN2 or CIN3). The characteristics of all 10 patients are listed in Table 4.7.  
 
 
patient 
week 0 
(CIN grade) 
week 8 
(CIN grade) 
week 20 
(CIN grade) 
clinical outcome 
1 CIN2 (no CIN) CIN3 progression 
2 CIN2 CIN1 no CIN regression 
3 CIN3 CIN2 CIN1/no CIN regression 
4 CIN2 no CIN CIN1/no CIN regression 
5 CIN2 n.a CIN2 persistence 
6 CIN2 n.a CIN2 persistence 
7 CIN2 CIN1 no CIN regression 
8 CIN 3 CIN3 CIN3 persistence 
9 CIN2 no CIN CIN1 regression 
10 not available no CIN no CIN regression 
TABLE 4.7  OVERVIEW OF THE CHARACTERISITICS OF THE PATIENTS SELECTED FOR THIS 
APPROACH. All patients received a 16-week imiquimod treatment; n.a = not analyzable. Histologic CIN 
grades were recorded to evaluate the treatment efficacy for CIN2/3 patients which was defined as 
histologic regression of the initial high-grade lesions to histologically proven CIN1 or less (normal 
epithelium). 
 
4.4.2 T cell infiltrates in non-responders and responders to imiquimod 
before treatment 
 
Immune cell infiltrates, as CD3+ and CD8+ T cells, were quantified by application of the automated 
quantification method presented in chapter 4.1. The lesions were annotated as described previously on 
the basis of the p16
INK4a
 reference slide. The areas for all regions of interest as well as the T cell 
densities in these regions were calculated. Cell densities of both T cell phenotypes were compared 
between patients that had persistent or progressing disease and did not respond to the imiquimod 
therapy (“non-responders”) and patients whose lesions had regressed during the treatment 
(“responders”). Densities for each phenotype separately as well as ratios of CD8+ T cells to all CD3+ 
cells in the different regions were compared in week 0 and week 20 biopsies.  
Before treatment (week 0 biopsy) the infiltration with CD3+ T cells is very high in patients who did 
not respond to the imiquimod therapy (progressing/persistent lesions) compared with patients whose 
lesion had regressed after imiquimod therapy (Figure 4.17). The mean cell density of CD3+ T cells in 
the epithelium of non-responders is much higher (537.0 cells/mm
2
) compared with responders (160.8 
cells/mm
2
). However, these differences are not statistically significant (p=0.190). This trend can also 
be observed in the stromal compartments where again non-responders had higher CD3+ T cell 
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numbers (1883.9 cell/mm
2
) compared with non-responders (945.9 cells/mm
2
) (p=0.190) (margin 500) 
(supplementary Figures S9.1 and S9.2 and supplementary Table S9.3). 
Interestingly, with regard to CD8+ T cell infiltrating the lesion and the stroma the densities are higher 
in responders than in non-responders in week 0 before treatment is started. The mean cell densities for 
CD8+ T cells in the epithelium of non-responders is 82.1 cells/mm
2
 compared with 113.8 cells/mm
2
 in 
responders (p=0.730). The difference in the stromal compartment margin 100 is even more 
pronounced (394.2 vs. 973.3 cells/mm
2
, p=0.286) (supplementary Figures S9.1 and S9.2). The same 
trend could also be observed for the more distant stromal compartments and also for the CD8/CD3 cell 
ratios in all regions of interest (supplementary Figures S9.1 and S9.2 and supplementary Table S9.4).  
 
 
FIGURE 4.17 CD3+, CD8+ CELL COUNTS AND CD8/CD3 RATIO IN THE INITIAL BIOSPSY (WEEK 0) IN 
NON-RESPONDERS AND RESPONDERS. Results are shown as Box-Whisker-Plots for A) the 
epithelium and B) the first stromal compartment (margin 100). The line in the center of each box 
represents the median value of the distribution; the borders of the box represent the upper and lower 
quartiles (25-75%). 
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4.4.3  T cell infiltrates in non-responders and responders to imiquimod after 
treatment 
In the biopsies taken 4 weeks after the treatment (week 20 biopsy) CD3+ T cell densities are 
comparably high in non-responders and in responders to imiquimod in the lesion and stromal 
compartment (Figure 4.18 and supplementary Figures S9.3 and S9.4). For example, in the epithelium 
the mean cell density is 287.8 cells/mm
2
 in non-responders and 371.1 cells/mm
2
 in responders 
(p=0.429) (supplementary Table 9.3).  
 
 
FIGURE 4.18  COMPARISON OF CD3+, CD8+ CELL COUNTS AND THE CD8/CD3 RATIO IN THE INITIAL 
BIOSPSY (WEEK 0) AND THE LAST BIOPSY (WEEK 20) IN NON-RESPONDERS AND 
RESPONDERS. Results are shown as box-whisker-plots for A) the epithelium and B) the first stromal 
compartment (margin 100). The line in the center of each box represents the median value of the 
distribution; the borders of the box represent the upper and lower quartiles (25-75%).  
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As the direct comparison between week 0 and week 20 shown in Figure 4.18 demonstrates the 
assimilation of responders and non-responders in terms of T cell densities is caused by an increased 
CD3+ T cells densities in responders compared to non-responders. This can be observed in the 
epithelium and the stroma of responders is also reflected by the comparison of the mean cell densities 
of week 0 and week 20 (see also supplementary Figures S9.6 and S9.7 and supplementary Table S9.3).  
With regard to CD8+ T cells the direct comparison of both time points (week 0 and week 20) for non-
responders and responders revealed that CD8+ T cell densities also slightly increase over time in 
patients responding to the treatment but not in non-responders (Figure 4.18 and supplementary Figures 
S9.6 and S9.7). Non-responders in contrast show decreasing CD8+ T cell densities in week 20 
compared with week 0 which results in a more pronounced difference between the groups at the end of 
the treatment. In week 20 the CD8 mean cell density in the epithelium of non-responders is 58.2 
cells/mm
2
 compared with 174.1 cells/mm
2
 in responders (p=0.643).  
 
To get a better insight in how the T cell infiltrates develop during the treatment in the two groups, the 
mean cell densities of every single patient at each time point is shown in a line chart and both groups 
(non-responders vs. responders) were directly compared (Figure 4.19). This contrasting juxtaposition 
revealed that the majority of the responders’ infiltrate densities is located above the highest value of 
the non-responders’ T cell densities in week 20. However, the groups are different in the middle of 
treatment were non-responders show an increase and responders a decrease in T cell densities. 
Interestingly, these differences are completely reversed in the last weeks of the treatment until week 
20. T cell densities in non-responders show a massive decrease while those of responders continuously 
increase. The majority of responders therefore quit the treatment with clearly higher T cell densities 
compared with non-responders 
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FIGURE 4.19  DEVELOPMENT OF CD8+ T CELL DENSITIES OVER TIME IN NON-RESPONDERS COMPARED 
WITH RESPONDERS. Results for non-responders (red) and responders (green) are shown as line chart 
for A) the epithelium and B) the first stromal compartment (margin 100). The dashed line represents the 
highest count of non-responders in week 20.  
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5. 
 
  TREATMENT OPTIONS FOR 
HPV-ASSOCIATED 
PRECANCERS AND CANCERS 
 
 
Despite important advances in the prevention of HPV infections and screening programs the world-
wide incidence rates for cervical and other HPV-associated ano-genital precancerous lesions and 
cancers are not expected to decrease significantly within the next 15 to 20 years. On the contrary, the 
incidence is expected to increase in developing countries. The introduction of the prophylactic 
vaccines was demonstrated to reduce the risk for HPV infections for young girls. However the 
currently available vaccines provide protection against four HPV types of 14 considered to be 
potentially carcinogenic. Although protection might be provided by herd immunity, this effect requires 
a certain vaccination coverage and young women already infected with HPV do not necessarily benefit 
from subsequent vaccination and still might develop cervical cancer twenty years later. Screening 
programs based on Pap test in developed countries are well established, but getting women to attend 
the cervical cancer screening in developing countries remains a major concern. In the light of all these 
factors there is still a need for therapeutic intervention strategies. Different approaches are 
conceivable, many of them are based on therapeutic vaccines based on RNA, DNA, peptides or full-
length proteins of diverse HPV-antigens.  
In this part of the thesis, based on the insights that could be gained in the first part of this thesis, two 
different intervention strategies involving immune modulation of the cancer environment will be 
investigated. The first strategy aims at local application of a newly developed substance that might 
enhance the local immune response by induction of inflammatory processes. In a second approach the 
effect of regulatory T cell depletion on the efficiency of immune attack towards autologous tumor cells 
shall be investigated.  
 
 
5.1  Effects of TLR agonist treatment on immune cells 
It has been shown in the past that TLR-agonists act as immune modifiers that, locally applied, can 
positively influence the immune response and potentially reverse immune suppression. The substance 
imiquimod is a well characterized immune stimulatory agent that is approved for the treatment of 
condylomata accuminata, actinic keratosis and basal cell carcinoma, but is also tested in patients with 
vulvar intraepithelial neoplasia. Within the scope of this thesis the potency of a new, second-
generation immune modifier was evaluated. The substance called TMX-202 was obtained from 
Telormedix SA, Bioggio, Switzerland and is a modified purine base derivative that is supposed to be 
even more potent than actually available immuno-stimulatory agents such as imiquimod.  
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TMX also is a TLR7 agonist and was tested in vitro by measuring the effects on PBMCs of healthy 
donors. It has been demonstrated in the past that TLR-9 agonist treatment increased the expression of 
the corresponding TLR-9 on B cells (BOURKE et al., 2003). It is conceivable that the new TLR 
agonist TMX also positively correlates with TLR expression on peripheral immune cells and thus 
further enhances the innate and adaptive immune response by a positive feedback loop between 
stimulation and activation of TLRs and their expression. To gain a better understanding of its mode of 
action and its potency to induce immune responses the effects of TMX-202 on TLR7 mRNA and 
protein levels were investigated (chapters 5.1.1 and 5.1.2). 
The down-stream effect of TLR stimulation is the induction of inflammation that provokes the 
attraction of further immune cells to the treated site and thus stimulates both the innate and the 
adaptive immune response. To gain insight in the potency of the new TLR-agonist to induce 
inflammation the cytokine release was measured (chapter 5.1.3).  
As a long term goal, the TLR-agonist should be included in a combinatory drug composed of TMX-
202 and other immune modifiers that could be locally applied and thus is suitable for non-invasive 
anogenital lesions.  
 
 
5.1.1  The effect of TLR7 agonist treatment on the TLR7 mRNA expression 
levels in PBMCs 
To characterize the effects of the second-generation TLR7 agonist TMX on PBMCs a total number of 
4 healthy donors were tested. Peripheral blood mononuclear cells were isolated from freshly drawn 
blood and cultured for 72 hours in the presence of imiquimod, TMX or the vector control DMSO (as 
described in 3.x). The expression of TLR7 was first measured on the transcript level by quantitative 
real-time PCR. Possible effects of the substances on mRNA levels were compared between the 
compounds. An additional negative control is represented by untreated cells that were frozen at day 0 
and not subjected to in vitro culture. Furthermore, cells that were not treated with any substance but 
cultured under the same conditions as those that received the treatment were included in the analysis. 
For normalization purposes controls were included that were treated with the same amounts of DMSO 
that were added with substance (dissolved in DMSO) to TMX-treated cells. Each treatment 
experiment was normalized with the corresponding DMSO concentration in order to take into account 
the effect of DMSO.  
 
The mRNA levels in PBMCs that were frozen on day 0 before treatment was started were similar to 
those of cultured, but untreated cells (data not shown). Therefore the values obtained for DMSO-
treated cells were normalized against these untreated cells cultured under the same conditions. The 
DMSO controls were then used to normalize the corresponding values obtained for PBMCs treated 
with the immuno-modulatory agents by matching the DMSO concentrations used during stimulation.  
In the first approach involving the first two donors, the effects of the new TLR7 agonist TMX-202 at a 
concentration of 10 µM was compared with imiquimod at a concentration of 30 µM. This 
concentration was reported previously in the context of immune cell in vitro vaccination approach 
(FAHEY et al., 2009) while the TMX-concentration was based on preliminary in vitro data 
communicated by Telormedix.  
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The results of the TLR7 quantitative real-time PCR for donors 1 and 2 (Figure 5.1) demonstrated that 
imiquimod in both donors induced higher mRNA levels compared to the DMSO control. Donor 1 
displayed high fold changes of TLR7 mRNA after treatment with both of the substances, imiquimod 
and TMX-202, but mRNA expression was more up-regulated after TMX treatment. Donor 2 also 
showed increased TLR7 mRNA after imiquimod treatment expression, while TMX treatment did not 
show an effect on TLR7 mRNA levels. Here again, following imiquimod treatment higher fold-
changes could be measured.  
 
 
FIGURE 5.1 TLR7 mRNA EXPRESSION IN PBMCS TREATED WITH TMX AND IMIQUIMOD. Changes of 
mRNA levels in comparison to the DMSO control are displayed on the y-axis (fold-change). The 
experimental groups are displayed on the x-axis. The bars represent the results for the tested groups.  
Two further donors were tested to compare the effects of TMX-treatment administered in different 
concentrations. The 10µM dosage from the first experiment was compared with a reduced TMX-202 
concentration (1µM). Furthermore, another aspect was investigated in this second experiment, as not 
only the PBL fraction but also the adherent cell fraction representing mainly monocytes was analyzed 
separately. Thus, changes in TLR7 mRNA levels were measured under two different TMX-202 
concentrations separately for monocytes and lymphocytes (PBLs) (Figure 5.2). Donor 3 displayed 
down-regulation of TLR7 mRNA expression in all cases except for the 1 µM concentration in the 
monocyte fraction. Donor 4 showed a general TMX-induced up-regulation of TLR7 mRNA 
expression levels compared with the corresponding DMSO controls. The 1µM dosage had a higher 
effect on mRNA levels than the 10µM in both of the cell types, monocytes and PBLs. 
 
 
FIGURE 5.2  TLR7 mRNA EXPRESSION IN MONOCYTES AND LYMPHOCYTES (PBLs) TREATED WITH 
DIFFERENT TMX CONCENTRATIONS. Changes of mRNA levels in comparison to the DMSO 
control are displayed on the y-axis (fold-change). The experimental groups are displayed on the x-axis. 
The bars represent the results for the tested groups.  
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5.1.2 The effect of TLR7 agonist treatment on the TLR7 protein expression 
in PBMCs 
A second fraction of the same PBMCs that were tested for TLR7 mRNA expression levels was 
subjected to TLR7 Western Blot in order to investigate the effect of TLR7 agonist treatment on the 
protein level. As a positive control for TLR7 expression a B cell lymphoma cell line (Raji) was 
included. Whole cell lysates of the same samples were tested, including the DMSO controls, the d0 
uncultured PBMCs and PBMCs under treatment. As a loading control actin expression was 
investigated.  
The results for donors 1 and 2 treated with imiquimod and TMX-202 are shown in Figure 5.3.  
The baseline TLR7 expression in uncultured and immediately stored PBMCs (d0) was difficult to 
evaluate for both donors. No effects of any of the treatments (neither controls nor substances) could be 
observed in donor 1. Donor 2 showed comparable TLR7 protein levels for the DMSO controls and 
TMX, however, also less expression in imiquimod-treated cells.  
 
 
FIGURE 5.3  TLR7 PROTEIN EXPRESSION IN PBLs TREATED WITH TMX AND IMIQUIMOD. Shown are the 
results of the anti-TLR7 western blots of donor 1 (left) and donor 2 (right). TLR7 expression of treated 
PBMCs is compared with uncultured control PBMCs (PBMCs d0), DMSO controls and the TLR7 
positive control (Raji cells).  
 
The results for donors 3 and 4 treated with two different TMX concentrations (1µM and 10µM) are 
shown in Figure 5.4. Donor 3 showed slight baseline TLR7 expression and similar intensities of the 
protein bands for the DMSO control and 1µM TMX. A strong signal for 10µM TMX treated PBLs 
could be observed which might not be related to the treatment as a stronger signal can also be 
observed for actin. Although lacking baseline TLR7 expression in donor 4 could be explained by very 
protein concentration in the sample due to the lacking actin signal, the comparison between the highest 
DMSO control (4 µl) and the TMX-treated samples revealed an induction of TLR7 protein expression 
following treatment.  
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FIGURE 5.4 TLR7 PROTEIN EXPRESSION IN PBLs TREATED WITH TMX AND IMIQUIMOD. Shown are the 
results of the anti-TLR7 western blots of donor 3 (left) and donor 4 (right). TLR7 expression of treated 
PBMCs is compared with uncultured control PBMCs (PBMCs d0), DMSO controls and the TLR7 
positive control (Raji cells).  
In summary, the effects of different treatment approaches on the TLR7 expression on the protein level 
that has been investigated in the PBMCs of 4 healthy individuals remained inconclusive. In most cases 
no changes in protein expression could be observed – or could not definitively be related to the 
treatment – and the observed protein expression was not concordant with changes in TLR7 mRNA 
levels during treatment. The only exception is donor 4 who displayed higher protein levels for both 
TMX concentrations compared to the DMSO controls. This is in concordance with the increase in 
mRNA levels measured following treatment with TMX-202.  
 
5.1.3  Release of the pro-inflammatory cytokine IL-6 of PBMCs upon 
treatment with TLR7 agonists  
 
Following the investigation of mRNA and protein levels induced by TLR agonist treatment, another, 
more functional readout to investigate the effects of TMX-202 treatment was chosen based on the 
quantification of interleukin (IL)-6 released by immune cells. IL-6 is a potent inducer of inflammation 
and therefore indicative for the initiation of innate and adaptive immune responses. The supernatants 
from PBMCs cultures that were treated with imiquimod, TMX-202 and the controls were tested in IL-
6 ELISA.  
 
Although the effects of TMX treatment on mRNA and protein expression in the four tested donors 
remained inconclusive, it could be shown by ELISA that the IL-6 release was consistently induced by 
TMX treatment (Figures 5.5 and 5.6). The IL-6 release of stimulated PBMCs into the cell culture 
medium was significantly higher than under DMSO control treatment. Massive IL-6 release was 
induced with 1µM TMX compared with the DMSO control in donors 3 and 4 (p=0.0036 and 
p<0.0001), but further increased in dose-dependent manner with 10µM TMX compared with the 1µM 
TMX treatment (p=0.0002 and p=0.0004) (Figure 5.6). The IL-6 concentrations released under 
imiquimod treatment in donors 1 and 2 did not exceed the IL-6 release measured in the DMSO 
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controls or untreated cells (Figure 5.5). Interestingly, in one donor (donor 4) DMSO equally induced a 
slightly higher IL-6 release compared with the untreated control cells (p=0.0247). 
 
 
 
FIGURE 5.5  IL-6 SECRETION BY PBMCS TREATED WITH IMIQUIMOD AND TMX-202. The IL-6 
concentration (pg/ml) is presented on the y-axis. The experimental groups for donors 1 and 2 are 
displayed on the x-axis. The colored bars represent the means for the tested groups, standard deviations 
are shown as black whiskers (comparison by unpaired t-test, p-values are indicated). 
 
FIGURE 5.6  IL-6 SECRETION BY PBMCS TREATED WITH DIFFERENT TMX-202 CONCENTRATIONS. The 
IL-6 concentration (pg/ml) is presented on the y-axis. The experimental groups for donors 3 and 4 are 
displayed on the x-axis. The colored bars represent the means for the tested groups, standard deviations 
are shown as black whiskers (comparison by unpaired t-test, p-values are indicated). 
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5.2  Effects of TMX-202 treatment on the in vitro priming of 
naïve T lymphocytes with HPV-associated and host cell 
antigens and the generation of antigen-specific T cells  
 
The potency of the new TLR agonist was investigated on a functional level in a large experiment 
based on the in vitro priming of naïve T cells with HPV-related antigens that were loaded on dendritic 
cells for antigen-presentation. This experimental setup allowed the effects of TMX-202 to be 
investigated for both of the arms, the innate and the adaptive immunity. The final read-out of the 
treatment, however, focused on the adaptive immune response as was evaluated by the potency of 
stimulated T cells to kill tumor cells. This was measured in a heterologous system based on PBMCs of 
a healthy HLA-A2 positive donor and CaSki cells. TMX-202 treatment was applied during the 
complete procedure starting with the generation of dendritic cells from monocytes and continued 
during the stimulation of T cells with the antigen-presenting cells until the end of the experiment. As 
potentially relevant antigens in HPV-associated cancers p16
INK4a
, strongly overexpressed in HPV-
associated tumors, and HPV16 L1, one of the most immunogenic HPV antigens, were chosen.  
While for p16
INK4a
 a peptide was available that has been demonstrated in previous experiments to bind 
to HLA-A2 antigens, potential HPV16 L1 peptides had to be evaluated for their binding capacities to 
HLA molecules in a T2 cell based peptide binding assay.  
 
5.2.1  Determination of L1 peptides bound to HLA class I antigens with 
high affinity for stimulation assays  
 
In order to define out of a panel of predicted L1 peptides (for sequences see chapter 3.1.7, for 
predicted peptide panel see supplementary Table S9.8) those that have the highest binding affinity to 
HLA class I antigens and therefore being suitable for in vitro priming of T cells they were tested in 
peptide-binding assay based on T2 cells. The mean fluorescence intensities (MFIs) for each peptide 
were measured and compared with the negative and positive controls. As negative control served T2 
cells incubated in absence of any peptide thus defining the baseline fluorescence intensity. To compare 
the effect of beta2-microglobuline (β2m) on the MFI the negative control was performed with and 
without β2m added to the culture. It could be shown that the addition of β2m to the cells, required for 
stabilizing the complex built of HLA class I antigens and peptide, did not increase the MFI in absence 
of any peptides (Figure 5.7). Peptides that were reported to have high binding affinities (L1_323) or 
were evaluated before in the context of other experiments (p16_R1 and viral MP) were included to 
obtain reference MFIs as positive controls. The values for all three positive controls (L1_323, p16_R1 
and viral MP) were significantly higher than the negative control (Figure 5.7). 
For the T cell in vitro priming the peptides with highest MFIs were chosen by applying the following 
inclusion criteria: Only peptides that fulfilled two distinct criteria, having significantly higher MFIs 
compared with the negative control and with a MFI at least as high as the positive control with the 
lowest MFI. The L1-peptides L1_2, L1_12 and L1-97 had MFIs that were significantly higher than the 
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negative control (all p<0.0001). Furthermore, the MFIs of the L1 peptides were significantly higher 
than the control peptide with the lowest MFI which was viral MP (Figure 5.7).  
 
 
FIGURE 5.7 MEAN FLUORESCENCE INTENSITIES (MFIs) MEASURED FOR DIFFERENT HPV16 L1 
PEPTIDES IN A T2-CELL BASED PEPTIDE BINDING ASSAY. 
The peptide binding assay was repeated once and the result obtained in the first assay could be 
confirmed. Again, the peptides L1_2, L2_12 and L1_97 were revealed to be the best binding ones and 
therefore chosen for subsequent T cell in vitro priming (supplementary Figure S9.8).  
 
 
5.2.2  The effect of TMX treatment on dendritic cell maturation  
 
The generation of antigen-specific T lymphocytes was based on an autologous system that involved 
antigen-presenting cells of the same healthy donor from whom also T cells were obtained. Being the 
most potent antigen-presenting cells, dendritic cells (DCs) were generated from the adherent PBMC 
fraction, the monocytes, under the influence of a basic cytokine cocktail including GM-CSF and IL-4. 
To test the potency of the immune modulatory agent TMX on the innate immune system, involving 
maturation of dendritic cells from monocytes, and also on the adaptive immunity in terms of 
interacting with T cells and priming them towards the chosen antigens, TMX was added to the 
dendritic cell culture. Following the standard protocols for dendritic cell generation from monocytes 
the cells require a “maturation cocktail” consisting of different pro-inflammatory cytokines including 
IL-1β, TNF-α, PGE-2 and IL-6. As TMX leads to IL-6 secretion of peripheral immune cells creating a 
strongly pro-inflammatory milieu as shown in section 5.1.3 one could hypothesize that TMX treatment 
also might have an influence on dendritic cell maturation and that the endogenous IL-6 production 
could replace the exogenously added cytokine cocktail. The effect of TMX on monocytes and 
generation of dendritic cells was evaluated by the cell counts obtained after dendritic cell culture, 
morphology of the growing cells and expression of co-stimulatory molecules CD80 and CD86 on 
dendritic cells which is a sign for DC maturation.  
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The cell counts of harvested monocytes and dendritic cells – although varying between different 
cycles of DC generation - demonstrate that the numbers of harvested cells depends on the treatment. 
Cell numbers were calculated as the percentage of full PBMCs that could be harvested after 6 days 
culture period. Obviously the number of monocytes that became adherent and thus were separated 
from the non-adherent lymphocytes varied from one generation cycle to another. However, out of the 
cells that initially became adherent, more cells could be obtained after TMX stimulation compared 
with DMSO controls. The difference was most pronounced after the second and third round of 
dendritic cell generation with a 1.8- and 2.1-fold increase in cell numbers (Figure 5.8).  
 
 
 
FIGURE 5.8  CELL NUMBERS OBTAINED DURING THE FOUR DENDRITIC CELL GENERATION CYCLES. 
The percentage of dendritic cells that could be harvested from total PBMCs subjected to adherence for 
monocyte isolation is displayed on the y-axis. The 4 cycles of DC generation are shown on the x-axis 
with the bars representing the different tested groups (DMSO and TMX). 
Also, the morphology of monocyte culture is indicative for the maturation of dendritic cells: while 
newly adhered monocytes are regular and round, growing and maturing dendritic cells display the 
typical, longish and branched, dendrite-like morphology. The cultures that obtained TMX treatment in 
comparison with the DMSO controls showed faster, at an earlier time point, and to a higher extent 
cells with a dendrite-like morphology. The morphologic changes became obvious 48 hours after 
treatment with TMX had started and could be observed in more cells than in the culture containing 
DMSO treated cells. After 96 hours under TMX treatment the monocyte culture displayed clear 
morphologic signs of dendritic cells. Still, these cells were more frequent than in the DMSO-treated 
culture (Figure 5.9). These effects could be observed in all 4 successively established DC cultures, 
independently of the cell density and the rate of yield of monocytes from full PBMCs. 
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FIGURE 5.9  REPRESENTATIVE MICROSCOPIC IMAGES OF THE MORPHOLOGY OF DENDRITIC CELLS 
GENERATED FROM MONOCYTES UNDER THE INFLUENCE OF CONTROL SUBSTANCE 
DMSO (A) AND TMX (B). Shown are examples for 1) early dendritic cell culture (48h) at 20x 
magnification and 2) a later time point of dendritic cell generation (96h) at 40x magnification.  
 
The expression of CD80 and CD86 is indicative for activated antigen-presenting cells – B cells and 
monocytes. They are co-stimulatory molecules that bind to CD28 and CTLA-4, which are the 
corresponding ligands on T cells. CD80 and CD86 together play an important role in T cell activation 
and priming towards distinct antigens. They are up-regulated during the activation of monocytes and 
maturation of dendritic cells (CD86 is a marker for early maturation, while CD80 is a marker for 
mature DC). While morphology and cell numbers were recorded for all DC cultures the expression of 
co-stimulatory molecules could only be investigated in one out of 4 DC cultures because there was not 
a decent amount of cells available in the other cycles. The cell numbers were limited and in most cases 
all available DC had to be used for the T cell stimulation to assure the ratio of 1:10 between antigen-
presenting cells and T cells. FACS analysis of the available DCs revealed that culturing monocytes in 
presence of TMX in comparison with DMSO treatment leads to higher expression of CD80 (28.8% vs. 
19.92%) and CD86 (41.95% vs. 28.8%). The results are shown in Figures 5.10 and 5.11.  
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FIGURE 5.10  RESULTS OF THE FACS ANALYSIS FOR CD80 EXPRESSED ON DENDRITIC CELLS. The results 
are shown for DC generation under DMSO treatment (top) and TMX treatment (bottom). The 
fluorescence intensities for CD80 are given on the x-axis. Region borders (R2) were defined based on the 
isotype control with the FI for mouse IgG1 given on the x-axis. The percentage of cells that are CD80+ is 
given in R2.  
 
 
FIGURE 5.11  RESULTS OF THE FACS ANALYSIS FOR CD86 EXPRESSED ON DENDRITIC CELLS. The results 
are shown for DC generation under DMSO treatment (top) and TMX treatment (bottom). The 
fluorescence intensities for CD86 are given on the y-axis. Region borders (R2) were defined based on the 
isotype control with the FI for mouse IgG2b given on the y-axis. The percentage of cells that are CD86+ 
is given in R2.  
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5.2.3  The effect of TMX treatment on stimulation of naïve T cells with 
HPV-associated antigenic peptides  
 
The priming of naïve T cells with peptide-loaded dendritic cells was carried out in 4 cycles over 24 
days. Functional analyses during the stimulation period were not possible as T cell numbers were 
limited and all available cells were used for the final killing assay.  
However, the appearance of the T cells in culture and their morphology was recorded. Also, after each 
stimulation cycle that has been completed, T cell numbers were determined upon harvesting and 
reseeding cells with newly generated dendritic cells. From the photos taken of the T cell cultures 
(Figure 5.12) it becomes obvious that, although the same T cell numbers were initially seeded, T cells 
under TMX developed differently from those treated with DMSO only. On day 10 of the stimulation T 
cells that were treated with DMSO were less dense compared with the TMX-treated T cells (Figure 
5.12. 1A and 1B). Although they seemed to recover until day 21 they still appeared to be less close to 
each other and more scattered over the well than the T cell culture treated with TMX (Figure 5.12 2A 
and 2B).  
 
 
FIGURE 5.12  APPEARANCE OF T CELLS DURING STIMULATION WITH PEPTIDE-LOADED DENDRITIC 
CELLS UNDER THE INFLUENCE OF CONTROL SUBSTANCE DMSO (A) AND TMX (B). Shown 
are examples for 1) an earlier time point of T cell priming (day 10) and 2) a later time point of T cell 
stimulation (day 21) at 20x magnification.  
The morphologic appearance of the T cell cultures was confirmed by the cell numbers recorded upon 
harvesting and re-stimulation. Figure 5.13 demonstrates the development of T cell numbers over time 
during the stimulation. While T cells stimulated under TMX treatment with TMX-generated DCs 
continuously grew until day 17, T cells numbers under DMSO conditions decreased until day 11. 
Nonetheless, they recovered until day 21 and finally both cultures were harvested with more than 
3x10
6
 cells and thus globally showed a positive growing tendency.  
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FIGURE 5.13  DEVELOPMENT OF T CELL NUMBERS DURING THE IN VITRO PRIMING. Shown are the cell 
numbers for T cells stimulated in presence of TMX and in presence of the control substance DMSO.  
 
5.2.4  The effect of TMX treatment on the killing potency of stimulated T 
cells against CaSki cells  
 
The final read-out of the T cell in vitro priming was the killing assay of CaSki cells in a heterologous 
tumor cell – immune cell system. To minimize the reactivity of T cells against tumor cells due to HLA 
mismatching, a PBMC donor expressing the HLA-A2 allele was chosen.  
The reactivity of T cells stimulated with peptides against L1 and p16
INK4a
 and cultured either under 
TMX or DMSO treatment was compared. Therefore they were co-incubated with tumor cells and the 
degranulation rate as measured by CD107a expression on the cell surface was evaluated.  
First, the gate for T cells was defined by T cell cultured alone. Its suitability was also checked for T 
cells that were co-incubated with CaSki cells (Figure 5.14). Then two gates containing CD8+CD107a+ 
T cells (R2) and the total fraction of CD8+ cells irrespective of CD107a expression (R4) were defined. 
The percentage of cells that upon co-incubation with tumor cells expressed CD107a on their cell 
surface and that simultaneously expressed CD8 (cytotoxic T lymphocytes) were higher in the T cell 
culture that had undergone a treatment with TMX compared with the cells that were treated with 
DMSO (p=0.1353). In a second step the degranulation rate of CD8+ T cells measured upon co-
incubation with CaSki cells was calculated by diving the fraction of CD8+/CD107+ T cells by total 
amount of CD8+ T cells measured in the corresponding well. The percentage of CD107a-expressing 
CTLs among all CD8+ T cells again tended to be higher in TMX-treated T cells (8.26%) compared 
with DMSO-treated T cell culture (6.75%) (p=0.2202) (Figure 5.15).  
In conclusion, a slightly higher CD107a release could be obtained by TMX-treatment compared with 
untreated cells. This is true for CD8+CD107a+ T cells and the fraction of CD107a+ T cells among all 
CD8+ T cells (degranulation rate of CD8+ T cells).  
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FIGURE 5.14  EXEMPLARY RESULTS OF THE FACS ANALYSIS FOR CD8 AND CD107A. The gating strategy in 
the FSC/SSC is shown for A) T cells and B) T cells with CaSki cells. One of the duplicates is shown for 
C) the co-incubation of T cells with CaSki cells under DMSO treatment and D) TMX treatment. The 
fluorescence intensities for CD8 (x-axis) and CD107a (y-axis) are given. Region borders were defined 
based on the isotype controls (not shown). The percentage of cells that are CD8+CD107a+ is given in R2 
and the percentage of CD8+ cells in R4.  
 
 
FIGURE 5.15  EVALUATION OF THE CD8+ T CELLS FOR THE DEGRANULATION MARKER CD107A AND 
DEGRANULATION RATE. The percentage of positive cells is presented on the y-axis. The 
experimental groups are displayed on the x-axis. The blue bars represent the results for the tested groups, 
standard deviations are shown as black whiskers (comparison by Student’s t-test, p-values are indicated).  
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5.3 Establishment of an autologous system for the development 
and evaluation of therapeutic intervention strategies in 
HPV-associated diseases  
 
The previous results (chapter 4.2) demonstrated that regulatory T cells might play a role in the 
carcinogenesis of cervical cancers and that immuno-modulatory treatment might reverse the 
immunosuppressive state of the host’s immune system and lead to better killing of cervical cancer 
cells (CaSki) (chapter 5.2.4). Other strategies, such as cell-based approaches, might also be of 
importance in the battle against HPV-cancers and will be considered in this thesis. For the 
investigation of immunological questions autologous models based on tumor cells and immunocytes 
deriving from the same donor are of special interest as they provide advantages in terms of avoidance 
of cross-reactivity and cytotoxicity due to unmatched HLA allelic phenotypes. However, autologous 
HPV-associated tumor models for the cervix as well as for other sites are lacking. One major part of 
this thesis therefore was to establish a HPV-positive tumor cell line for these purposes. This was based 
on tumor samples of head and neck squamous cell carcinoma (HNSCC) patients that could be 
obtained from collaboration partners of the University Hospitals Giessen and Muenster. As cervical 
cancer and HPV-positive HNSCC have the same underlying mechanisms of tumorigenesis, HNSCC 
tumor might also function as a reliable model for HPV-related diseases.  
In the course of this project, one HNSCC cell line from a HPV-positive patient could be established 
and used for further immunological studies.  
 
5.3.1  The cell line HN038M: general features and patient’s characteristics 
In the course of this project tumors samples of 31 HPV-positive HNSCC patients, primary tumors 
together with or without the corresponding metastatic lymph nodes, were obtained. The tissue was 
prepared and cultured as described in section 3.2.4. After many attempts, one cell line out of these 31 
primary cultures could successfully be established by explant culture. This cell line derives from a 
lymph node metastasis of a male patient who underwent his first surgery in March 2013.  
The patient’s and the tumor’s characteristics as well as the clinical course of the disease are 
summarized in Table 5.1.  
The tissue of the primary tumor and the metastasis was prepared as described in section 3.2.4. 
Following the enzymatic digestion of the tissue two tumor explant cultures were initiated, one 
containing the primary tumor cells and the other containing the metastatic cell material. Regular 
microscopic evaluation showed that the culture containing the primary tumor cells in contrast to the 
metastasis seven weeks after tumor preparation still did not contain adherent and growing tumor cell 
cluster and therefore was discarded. 
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Parameter Description 
Sex male  
Age 58 years at diagnosis (march 2013) 
exposure to noxa heavy smoker 
primary tumor  
HPV-association p16
INK4a
 status as determined before surgery: positive 
localization oropharyngeal cancer of the palatine/lingual tonsil 
Size resected mucosal tissue (7,5 x 5,5 x 1,5 cm
3
), with a ulcerous area 
of about 2,1 x 1,5 cm
2
 in the center of the tissue  
cTNM staging cT3, cN2b, cM0 
pTNM staging pT2, pN2b (14/18), L1, V0  
metastatic LN 10 of 11 lymph nodes on the right side affected (level IIb)  
4 of 7 lymph nodes on the right side affected (Level V) 
grade of malignity G2 
 R0 
ICD-O code 8070/3 
further clinical course recurrent disease, relapse within one year: detection of multiple 
metastases 
beginning of January 2014  second surgery: macroscopically recurrent disease could not 
be observed; removal of a lymph node conglomerate 
 lymph node metastasis could be identified  
 partially necrotic tissue, moderately differentiated (G2) 
 squamous cell epithelium 
 ICD-O-Code: 8070/6 
end of January 2014  third surgery with removal of further lymph nodes 
 in 1/25 “metastasis of the known primary tumor” 
 poorly differentiated (G3) 
 ICD-O-Code: 8070/6 
TABLE 5.1  OVERVIEW OF THE MAIN CHARACTERISITCS AND THE CLINICAL COURSE OF THE 
PATIENT FROM WHOM THE CELL LINE IS DERIVED.  
The explant culture of the metastasis after 3 weeks has already shown macroscopically and 
microscopically detectable tumor cell clusters within the fibroblast layer (Figure 5.16 A). After the 
fibroblasts had undergone apoptosis, the tumor cell nests remained stably attached to the cell culture 
flask. However, they did not further expand across their initial “borders” determined by the outer cells 
and, although cells proliferated, only the minority of the newly generated cells adhered to the free 
space of the bottom of the flask (Figure 5.16 B). In this state the tumor cells remained stable over 11 
months. The culture was subjected to repeated trypsinization in order to detach the cells from the 
bottom and allow them to adhere again but in a more homogeneously distributed pattern.  
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Finally, cell proliferation and adherence of newly generated cells to the flask could be stimulated by 
this treatment (Figure 5.16 C and D). The culture after 13 months became 90% confluent, could be 
split and analyzed by FACS staining and cytometry analysis in order to determine the content of 
epithelial cells (Figure 5.17).  
 
FIGURE 5.16  MORPHOLOGIC APPEARANCE OF THE CELL LINE HN038M. Shown are A) an initial tumor cell 
nest (arrow) embedded in fibroblasts (week3), B) expanded tumor cell nest (month 8) and C) tumor cells 
of the established cell line at 100x magnification and B) at200x magnification.  
The analysis revealed that the culture contained ~ 99% of BerEP4+ cells, a marker for epithelial cells 
that have been stable for more than 13 months and still proliferate autonomously. The FACS results 
could be confirmed several times and the tumor cells were subjected to further characterization which 
is described in sections 5.3.2 to 5.3.4 
To date the culture is stable, continuously growing and has until now undergone 43 passages.  
 
 
FIGURE 5.17 EXAMPLARY RESULTS OF THE FACS ANALYSIS FOR BEREP4 OF THE NEWLY GENERATED 
TUMOR CELL LINE. One of the replicates of tumor cells harvested at confluence (passage x) is shown. 
The fluorescence intensity (FI) for BerEP4 is given on the x-axis. Region borders (R2) were defined 
based on the isotype control with the FI for mouse IgG1 given on the x-axis. The percentage of cells that 
are BerEP4+ is given in R2.  
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5.3.2  Determination of the HPV-status and oncogene activity  
To further characterize the established cell line and to validate the clinical finding in terms of HPV-
association of the tumor, the formalin-fixed paraffin-embedded tissue of the metastasis was ordered to 
compare the characteristics of the tumor cell line with the archived tumor material. Therefore, tissue 
sections were stained for p16
INK4a
 to confirm the original diagnosis of the pathologist. The original 
FFPE material of the lymph node metastasis showed a strong and diffuse staining for p16
INK4a 
(Figure 
5.18).  
 
FIGURE 5.18  p16INK4a IMMUNOHISTOCHEMISTRY OF FORMALIN-FIXED PARAFFIN-EMBEDDED 
METASTATIC TUMOR TISSUE OF THE PATIENT FROM WHOM THE CELL LINE IS DERIVED. 
Shown is A) on overview of the lymph node metastasis at 20x magnification and B) details at 40x 
magnification (p16INK4a-positive tumor is marked by an arrow).  
In order to assure that the cultured cells still have this feature equally and were not selected for 
p16
INK4a
-negative cell clones, p16
INK4a
 cytology staining on cultured cells was performed. Therefore, 
tumor cells were harvested and spun down onto a microscopy glass slide. The p16
INK4a
 staining for 
cytological preparations revealed that virtually all cells contained in the sample strongly stained for 
p16
INK4a
 indicating viral oncogene activity (Figure 5.19 A,B).  
 
FIGURE 5.19  p16INK4a CYTOLOGY OF THE HNSCC CELL LINE HN038M AND HPV DNA STATUS 
VISUALIZED BY GP5+/6+ LUMINEX PCR. A) and B) Staining of tumor cells of the HN038M cell line 
(passage 14) shows a clear p16INK4a-staining (brown signal). C) Agarose gel following GP5+/6+ PCR 
shows amplification of HPV DNA in the HN038M tumor cells and in the positive controls (HeLa and 
SiHa) but not in the negative controls.  
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In order to proof the underlying HPV-infection in the cells and the oncogene activity the tumor cells 
were subjected to HPV-genotyping and viral oncoprotein expression of HPV16 E7.  
The GP5+/6+ PCR demonstrated that HPV DNA was amplified (Figure 5.19 C) and the subsequent 
Luminex-based HPV genotyping revealed that the sample was positive for HPV16 DNA. The HPV 
status was also compared with the original FFPE tissue samples of the primary tumor and the 
metastases to validate these findings. HPV genotyping demonstrated that the archived tumor material 
also harbored HPV16 DNA (supplementary Table 9.9).  
 
In order to examine whether p16
INK4a
 overexpression was linked to viral oncogene activity, the viral 
oncogene expression was investigated by western blot analysis for HPV16 E7 expression.  
For the characterization of the protein expression the viral oncoprotein E7 was investigated. Samples 
of different subcultures that have undergone varying numbers of passages (7 and 16 passages) were 
analyzed for viral oncoprotein E7 expression and compared with each other. They were also compared 
with HPV16-positive SiHa cells which were used as positive control for HPV oncoprotein expression. 
As shown in Figure 5.20 the tumor cell line HN038M displayed a strong staining for the viral 
oncoprotein E7 (located at 17 kDa) at earlier passages as well as at a later time point when the tumor 
cell had undergone more passages. 
 
FIGURE 5.20  WESTERN BLOT ANALYSIS OF DIFFERENT FRACTIONS OF THE HNSCC CELL LINE HN038M 
FOR HPV16E7. Tumor cells of different passages (passage 16 and passage 7) were tested and compared 
with HPV16-positive cell line SiHa used as control.  
The tumor cell line was further characterized for HLA class I antigen expression, which is an 
important factor for immunological studies. Expression of HLA class I antigens is the prerequisite for 
the recognition of cells by T cells and therefore required for by CD8+ T cells.  
Tumor cells of the cell line HN038M were characterized for HLA class I expression by flow 
cytometry analysis. It could be demonstrated in two independent experiments that virtually all cells 
were positive for HLA class I antigens (Figure 5.21).  
 
   5. Results II  113 
 
FIGURE 5.21  REPRESENTATIVE RESULTS OF THE FACS ANALYSIS FOR HLA CLASS I ANTIGENS OF THE 
NEWLY GENERATED TUMOR CELL LINE. One of the replicates of tumor cells harvested at 
confluence (passage x) is shown. The fluorescence intensity (FI) for HLA class I antigens is given on the 
x-axis. Region borders (R2) were defined based on the isotype control with the FI for mouse IgG1 given 
on the x-axis. The percentage of cells that are HLA class I positive is given in R2.  
 
5.3.3  Cell line validation via short-tandem-repeat profiling 
 
The detection of misidentification of standard cell lines and the increasing awareness of the danger for 
cross-contamination, the proof of authenticity of established and newly generated cell lines that are 
used in experiments has become indispensable. Short-tandem-repeat (STR) profiling is a DNA 
fingerprinting method based on the characterization of hypervariable DNA sequences, so called 
microsatellites, and recommended for cell line authentication. It allows the determination of a unique, 
cell-line specific profile based on 8 different STR loci. The comparison with database comprising all 
characterized and registered cell lines allows to authenticate the cell line and to exclude cross-
contamination with other cell lines.  
Cell line authentication was carried out by Multiplexion GmbH, Heidelberg. STR profiling and 
comparison with database revealed that the newly generated HNSCC cell line HN038M has a unique 
sequence, showing only 90% identity with already known cell lines (less than 96% identity is defined 
as a cell line being not identical with the compared “best hit” cell line). The search for the best hit 
among cell lines registered in the database identified the cell line UACC-257. This is a melanotic 
melanoma cell line of non-epithelial origin which is not in use in our laboratory. The established 
HNSCC cell line has not been present in database to date and shows a genotype code that is unique to 
this cell line and does not match to any of the cell lines contained in the database.  
 
best database hit identity genotype code 
UACC-257 90% AATTAAAAAATTAAAAATAAAWA 
TTTTTTTAAWTWTATTTAATTATWT 
(W= uncertain signal) 
TABLE 5.2  CHARACTERISITICS OF THE TUMOR CELL LINE HN038M.  
114      5. Results II 
All these characteristics revealed by cell line characterization exclude cross-contamination of the 
primary culture with additional cells from other cell line (established cell lines). In conclusion, the 
identity of the cell line was confirmed with a unique sequence being revealed for the sample. 
Furthermore, the characteristic genotype code, which represents a 48-letter code for 24 single 
nucleotide polymorphism (SNP) locations, was identified. The main characteristics are summarized in 
Table 5.2, for more detailed information provided by the company see also supplementary Figure 9.9.  
As the newly generated cell line is currently not present in the Multiplex Cell Authentication (MCA) 
database (CASTRO et al., 2013) and does not show identity with any other cell lines reported therein, 
the novelty could be proofed and cross-contamination was excluded.  
 
 
5.4  Effect of regulatory T cell depletion on the cellular immune 
response against autologous tumor cells 
 
The presence of regulatory T cells in low-grade lesions and their increasing frequencies in high-grade 
lesion and invasive cervical cancer (chapter 4.2) is a hint for the role they play in all steps of cervical 
carcinogenesis. Their contribution to tumor progression and metastasis and the resulting poor 
prognosis for patients has been, apart from cervical cancer, also been demonstrated in other tumor 
entities (reviewed in HALVORSEN et al., 2014). With the availability of the above described 
autologous model system that could successfully be established the idea was prompted to test the 
immunosuppressive effects of Tregs in vitro and measure the cell-mediated cytotoxicity in presence 
and absence of Tregs. Therefore, peripheral blood lymphocytes could be obtained from the patient 
who gave rise to the cell line that were subjected to Treg depletion and used for the killing assay.  
 
5.4.1  T cell purity and Treg depletion 
The efficiency of Treg depletion was monitored by flow cytometry analysis by comparing the total 
(undepleted) T cell fraction with the T cells following Treg depletion. The results are shown in Figure 
5.22 and demonstrate that depletion of CD25+ T cells by magnetic labelling decreased the amount of 
CD4+CD25+ T cells from 1.93% in undepleted T cells to 0.75% in Treg depleted T cells.  
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FIGURE 5.22  RESULTS OF THE FACS ANALYSIS OF CD4+CD25+ T CELLS CONTAINED IN THE T CELL 
FRACTIONS USED FOR CD107a DEGRANULATION ASSAY BEFORE AND AFTER MAGNETIC 
DEPLETION OF TREG CELLS. The gating strategy in the FSC/SSC is shown in the upper part of the 
figure and was applied for both T cell fractions. The frequencies of Tregs before (total T cells) and after 
Treg depletion are shown in lower part of the figure. The fluorescence intensities for CD4 (x-axis) and 
CD107a (y-axis) are displayed. The percentage of cells that are CD4+CD107a+ are given in R5.  
 
5.4.2  Characterization of the effect of Treg depletion on the killing potency 
of autologous T cells against the tumor cell line HN038M 
The cytotoxic effect of T cells against tumor cells that were either depleted from regulatory T cells or 
not was measured by CD107a expression on the cell surface as described in section 3.x. CD107a 
degranulation in T effector cells is induced upon recognition of and activation by tumor cells. As the 
Treg depletion via magnetic labelling (chapter 3.2.4) targets the CD4+ T cell population of T cells 
isolated from PBMCs the killing effect also was measured by analyzing the CD4+ T cell population. 
Although an additional staining for CD8+ T cells was not possible due to restricted cell numbers, the 
fraction of non-CD4+ T cells can be considered to reflect effects of CD8+ T cells. The gating was 
performed on T cells as shown in chapter 5.2 and the defined gate was then also checked for samples 
consisting of T cells co-incubated with tumor cells. T cells were analyzed by plotting CD107a 
expression against CD4 expression and defining a gate for CD107a+ cells among the CD4+ and non-
CD4+ T cells respectively which represented two clearly distinguishable cell populations (Figure 
5.23). The values for CD4+CD107a+ T cells were obtained by applying the same gates for all 
samples.  
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FIGURE 5.23  RESULTS OF THE FACS ANALYSIS FOR CD4 AND CD107A. One of the duplicates is shown for the 
co-incubation of autologous tumor cells with total T cells (left) and Treg depleted T cells (right). The 
fluorescence intensities for CD4 (x-axis) and CD107a (y-axis) are given. Region borders were defined 
based on the isotype controls (not shown). The percentage of cells that are CD4+CD107a+ are given in 
R2 and the percentage of CD4-CD107a+ cells in R3.  
The results obtained from the comparison between Treg depleted and total T cells are shown in Figure 
5.x. Treg depleted T cells compared with total non-depleted T cell fraction showed a slightly better 
killing effect as measured by the percentage of CD107+ cells among the CD4+ T cells as defined by 
region R2. Interestingly, this effect can also be observed in the non-CD4+ T cell fraction (R3).  
 
 
FIGURE 5.24  EVALUATION OF THE CD4+ AND NON-CD4+ T CELLS FOR THE DEGRANULATION MARKER 
CD107A. The percentage of positive cells is presented on the y-axis. The experimental groups are 
displayed on the x-axis. The blue bars represent the results for the tested groups, standard deviations are 
shown as black whiskers (comparison by Student’s t-test, p-values are indicated).  
 
In summary, a higher degranulation rate could be observed in the CD4+ T cell fraction and also in the 
non-CD4+ T cell population after Treg depletion. The effect was even more pronounced in the non-
CD4+ T cell fraction where the proportion of CD107a+ T cells following Treg depletion was 3 times 
higher compared with the total T cell fraction.  
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5.4.3 The killing capacities of T cells co-incubated with autologous tumor 
cells can also be monitored in real-time 
 
The effect of Treg depletion on tumor cell killing was monitored by a second experimental approach. 
Thereby changes in impedance caused by cytotoxic effects mediated by T cells against tumor cells 
were measured as explained in section 3.2.4. These effects are displayed as cell indices, a unit that 
reflects changes in size and morphology of the cells, grade of adherence of the cells to the plate as well 
as cell density (PEPER et al., 2014). The results obtained from this measurement are shown in Figure 
5.x. While the ascending curves represent the growing phase of tumor cells during the first 96 hours 
(represented by the dotted line), the descending curves represent the co-incubation of tumor cells with 
the effector cells during the following 96 hours (continuous line). T cells were added following the 
adherence and growing of tumor cells, 96 hours after the experiment has been started (marked by an 
arrow).  
 
 
FIGURE 5.25  DYNAMIC REAL-TIME MONITORING OF T CELL-MEDIATED CYTOTOXICTY AGAINST 
AUTOLOGOUS TUMOR CELLS MEDIATED BY TOTAL T CELLS AND TREG DEPLETED T 
CELLS. The values recorded by the xCELLigence system are displayed as dimensionless cell indices. 
Controls (grey and blue) were also measured and compared with the co-cultures of tumor cells and T cells 
(green and red) (top). Slope values were defined in distinct phases of the killing marked by the brackets 
A, B and C and visualized as bar graphs (bottom).  
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The spikes interrupting the curve during the tumor cell growing phase can be explained by the daily 
removal of the plate from the analyzing unit for change of the media. A massive decrease of cell index 
values directly after addition of the T cells to the culture could be observed at t=96 hours. This 
coincides with the time point when T cells were added and thereby half of the tumor cell medium was 
replaced by lymphocyte medium. This decrease in some samples is followed by a recovery phase 
accompanied be a re-increase of the cell index (between t=96 hours and t=105 hours).  
As depicted in Figure 5.25 the addition of non-adherent T cells to the wells did not have any effect on 
the impedance and the resulting cell index (blue control curve). Slight differences in the growing 
behavior of tumor cells during the first 96 hours is reflected by higher or lower cell index values of the 
tumor cell cultures that were then subjected to different treatments. At that time point the tumor cells 
subsequently co-incubated with the total T cell fraction had a higher cell index than tumor cells co-
incubated with Treg depleted T cells (cell indices for different time points are summarized in Table 
5.3).  
 
Time point 
(hours after start 
of experiment) 
description T cell total 
cell index 
Treg depleted 
cell index 
p-value 
96:00 after tumor cell growing phase 4.34 5.23 0.0569 
105:00 after media change and recovering 4.02 4.47 0.2544 
132:00 crossing point of both curves 4.21 4.21 0.9273 
192:00 end of experiment 3.38 2.38 0.0619 
TABLE 5.3  CELL INDICES FOR TUMOR CELLS CO-INCUBATED WITH TOTAL T CELLS AND TREG 
DEPLETED T CELLS. The values recorded by the xCELLigence system are displayed for different time 
points beginning after tumor cell adherence and proliferation.  
The starting point for measuring the real effect of T cells on tumor cells was set to 105 hours after start 
of the experiment which represent the end of the recovery phase. Here, the indices for the Treg 
depletion experiment were still higher than for the total T cell experiment. These differences in the cell 
indices underscore even more the effects that the different T cell fractions had on the tumor cells 
which will be explained below. 
During the following 96 hours of co-incubation of total T cells with tumor cells the curve showed a 
slight overall decrease its course is comparable with the grey control curve (tumor cells without T 
cells). The tumor cell culture that later on was treated with the Treg depleted T cells had reached a 
higher cell index after 96 hours growing. After change of the media the cells did not show a recovering 
phase but from that time point on a constantly decreasing curve which, although initially higher, 
crossed the curve of the tumor cells treated with total T cells at approximately 132 hours. At the end of 
the measurement the cell index of this curve was far lower (2.38) than that of tumor cells treated with 
total T cells (3.38) (p=0.0619).  
 
The trends of the curves can be better characterized by determining the slope (in 1/h) over the 
complete co-incubation period (starting from the recovering phase, phase A) and also in single 
sections (B, C) (Figure 5.25). The analysis of the overall slope demonstrated that the values for total T 
cells and Treg depleted T cells are negative, but the values for the “Treg depleted” curve show a 
greater descending slope. The analysis of the slope in the first killing phase (B) demonstrated, that the 
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slope was positive for the total T cell curve (+0.0068) while the Treg curve was decreasing (-0.0074). 
In the last section (C) from the crossing point until the end of the experiment (132 hours - 192 hours) 
both curves displayed negative slopes, the slope for the Treg curve (-0.0297) however is twice the 
value of the total T cell curve (-0.0136). The graphical visualization of the slope values calculated for 
the different cultures and the control also demonstrated that the curve for total T cells (red) is similar 
to the control curve (grey) and that the curve for Treg depletion (green) behaves completely different. 
The slope values explain the differences observed for the cell indices for the both co-cultures, with the 
Treg curve starting at a higher cell index and finally falling below the total T cell curve.  
 
In summary, the real-time measurement of the T cell mediated cytotoxicity against autologous tumor 
cells demonstrated that Treg depletion enhances the killing of tumor cells and thus confirms the results 
obtained in the first experiment by CD107a degranulation assay.  
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6. 
 
DISCUSSION AND 
CONCLUSION 
 
6.1  Overview of the results obtained during the thesis  
The central goals of this thesis were to generate a deeper understanding of the immune status of 
patients with HPV-associated precancerous lesions and cancers and evaluate possible intervention 
strategies to enhance anti-tumoral immune responses.  
In the first part (chapter 4) immune markers that might contribute to tumor immune evasion were 
investigated on the immune cell side and on the tumor cell side. It could be shown that immune 
infiltrates in cervical lesions are denser in high-grade lesions compared to low-grade lesions. This was 
observed for different immune cell markers (CD3, CD8, GranB, Foxp3 and CD3ζ) and does not point 
to a clear immune activation or suppression (chapter 4.2). Invasive cervical cancer, however, was 
characterized by a further significant increase in Foxp3+ regulatory T cells accompanied by 
significantly decreased CD8/CD3 and CD3/CD3ζ ratios which might be a hint for the 
immunosuppressive state of patients with invasive disease. Although the changes between different 
infection and histomorphological stages in precancers were not significant large variances in T cells 
densities in all histomorphological CIN grades could be observed, for example for Tregs and also 
CD8+ T cells. This might indicate that more or less infiltration with distinct T cell subtypes - effector 
T cells or immune suppressive T cells - is associated with progression or regression of the lesions. To 
also gain a deeper insight in the immunological modification on the tumor side contributing to 
immune evasion mechanisms the expression of HLA antigens was investigated within this thesis 
(chapter 4.3). Alterations in terms of HLA class I antigen losses and down-regulation, especially of 
HLA class I heavy chain A, and HLA class II de novo expression in precancerous lesions and cancers 
were common. The selective down-regulation of HLA class I antigens could represent another 
effective immune evasion mechanism. Interestingly, it could be demonstrated in a longitudinal setting 
(chapter 4.4) that immune infiltrates in CIN can be influenced by local immune modulatory drug 
treatment based on imiquimod and that a response to the immune stimulatory treatment with 
imiquimod is associated with increasing immune cell densities of CD3+ and CD8+ T cells. The major 
methodological approach of this first part (chapter 4.1) was the establishment of automated cell 
detection and quantification platform for immune cell infiltrates in cervical precancerous lesions. This 
tool allows high-throughput screening of larger cohorts on the search for immunological prognostic 
markers and also for monitoring of treatment strategies.  
Based on the findings obtained from the immunological characterization of CIN lesions and cervical 
carcinoma samples in the first part therapeutic strategies could be deduced for the second part of this 
work (chapter 5). The approach based on immuno-modulatory drug treatment was pursued in this 
chapter and also depletion of regulatory T lymphocytes was evaluated in different experimental 
settings. Immune modulation by TLR-agonist treatment was further investigated by comparing two 
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different compounds: the approved substance imiquimod and a new purine base derivative called 
TMX-202 were tested for efficiency regarding immune stimulation (chapter 5.1). It was demonstrated 
that TMX-202 in comparison to imiquimod induces massive IL-6 secretion. In an in vitro priming 
experiment of naïve T cells it was also shown that this substance can stimulate the adaptive immune 
response and enhance the killing of CaSki cells. One aim of the second part was also to establish a 
HPV-positive HNSCC tumor cell line as an autologous model for HPV-associated cancers (chapter 
5.2). Autologous systems are of special interest for immunological studies involving tumor cell killing 
as alloreactivity of immune cells against an incompletely HLA-matched tumor cell lines can be a 
problem. This model was used to test another strategy aiming at the circumvention of possible immune 
suppressive effects mediated by regulatory T cells (chapter 5.3). The killing effects of T cells after 
Treg depletion and without Treg depletion against the autologous tumor cell line were compared and 
found to be enhanced with Treg depleted T cells in two independent experimental approaches.  
 
 
 
FIGURE 6.1  THE HPV-RELATED CANCER PROGRESSION MODEL INTERPRETED IN THE CONTEXT OF 
THE RESULTS OBTAINED IN THE COURSE OF THIS THESIS. 
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6.2  An automated cell quantification tool allows the analysis of 
the immune cell contexture of cervical precancerous 
lesions in high-throughput approaches 
The tumor micromilieu is thought to be highly important for a better understanding of the factors that 
influence tumor development and progression. Parameters of interest are the immune cell composition 
in term of densities and different phenotypes of immune cells entering the tumor area but also features 
inherent to these cells such as production of enzymes or cytokines that might be released in the tumor 
environment. The importance of the “immune cell contexture” in primary tumors of different sites and 
their metastases has frequently been reported and it has been demonstrated that the quality of this 
tumor micromilieu impacts the clinical outcome of the patients (reviewed in FRIDMAN et al., 2011; 
FRIDMAN et al., 2012; FRIDMAN et al., 2014).  
The idea to search for biomarkers that might be relevant for prognosis and for the prediction of the 
patient’s clinical outcome is widespread in the field of oncology and tumor biology and not restricted 
to any tumor entity (LLOYD et al., 2010) (GALON et al., 2006). On the hunt for suitable prognostic 
cancer biomarkers whole slide imaging and automated quantification tools are the approaches that 
scientists currently strive for. The impact of this methodological approach is reflected by the number 
of up-to-date publications related to this topic (IRSHAD et al., 2014) and the multitude of reviews that 
address not only general aspects of digitalized pathology and the state-of-the-art of this relatively new 
field but also the challenges for imaging informatics and the needs of pathologists (KOTHARI et al., 
2013; TAYLOR, 2014; WEBSTER and DUNSTAN, 2014). 
The characterization and definition of prognostic biomarkers is also highly important in the screening 
of cervical intraepithelial neoplasia (CIN). They are frequently detected especially in young women, 
but they often remain without any clinical consequence due to a high regression rate. Virtually all 
women diagnosed with a high-grade CIN are surgically treated resulting in over-treatment. To solve 
this problem reliable biomarkers are necessary for prognosis and risk-adapted treatment strategies.  
The first step in the direction of virtual microscopy of cervical precancers was done with the 
establishment of a platform used for the scanning and evaluation of cervical cytology slides (GRABE 
et al., 2010). At that time an algorithm was developed that allows the automated detection of p16
INK4a
 
stained cells and reliable discrimination from unstained cells.  
In the context of immune cell characterization aiming at identification of potentially immune 
suppressive or cell-mediated cytotoxic mechanisms that could represent progression and regression 
markers the developed tool for automated cell detection and quantification is highly important. It is a 
prerequisite for defining immunological markers indicative for the clinical course of cervical 
intraepithelial neoplasia. One major aim of the presented thesis was the development of such a 
platform for the quantification of immune cell infiltrates in cervical precancerous lesions.  
As outlined in chapter 4.1 this aim could be achieved in a cooperation project with the TIGA Center, 
Heidelberg. Continuous feedback given between computer scientists, pathologists and immunologist 
allowed the method to be brought to perfection. The use of available server structures for data storage 
allowed all cooperation partners involved in the project to have access to the whole slide scans. The 
establishment of the method was based on CIN samples stained for CD3 and CD8 and involved 
continued control of the cell detection rate and manual comparison of computed cell signals with the 
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brown DAB staining signals of digitalized slides. Several rounds of improvement including adaption 
of annotation tools and defining the threshold for signal recognition also for weaker stains were 
undergone until the algorithm finally was applied to the patient samples. 
 
The established system has several advantages in comparison with existing manual approaches in the 
investigation of immunological approaches. (1) It offers high reproducibility as the procedure is based 
on standardized immunohistochemical staining protocols and application of a defined cell detection 
and quantification algorithm. (2) It represents an objective way for cell quantification and assures 
reliable discrimination of positively stained cells from negative cells. Especially the precise 
demarcation of the basal membrane allows immune cells in this region exactly to be determined: this 
is very challenging during manual quantification and requires the utmost concentration of the 
investigator as high immune cell densities can be found in this region. (3) Manual quantification 
methods mostly are restricted to smaller areas. This novel method which is based on whole-slide-
images of the affected tissue allows the comprehensive assessment of not only the tumor or lesion 
itself but also of the surrounding tissue, the whole microenvironment which seems to largely impact 
the course of the disease. (4) It offers time-effectiveness and allows high-throughput screening of large 
cohorts which could be analyzed for a variety of different (immunological) markers.  
The advantages of the automated system over manual counting of positively stained cells under the 
microscope in terms of objectivity reproducibility of the results are widely recognized (FUCHS et al., 
2008). Nonetheless, the established platform shall be applied to larger sample sets in the near future to 
validate the method. Thereby, the intra-observer variability by comparison of repeated manual 
counting and automated quantification shall be evaluated as well as the inter-observer variability by 
comparison of manually and automatically quantified immune cell counts of different investigators.  
 
In the long run the technological basis of this study shall be further developed, the parameters to be 
analyzed shall be expanded and the underlying algorithms have then to be adapted to these needs. 
Many other markers could be interesting and as their diversity is high and the sample material limited 
immune-fluorescence allowing double staining appears as an interesting option. Additionally, further 
immune-cell related information, such as definition of T cell clusters, that frequently are observed in 
the tumor microenvironment (EDWARDS et al., 1995; HALAMA et al., 2009), might be of interest. 
Therefore the coordinates of each cell have to be offset against the positions of the surrounding cells to 
evaluate how many cells are in direct contact with each other and how far they are located from the 
epithelium.  
The actually available operations shall also be extended and one major aim is rendering the annotation 
of the lesions easier and faster. Currently the exact annotation of the lesion has to be performed 
manually by drawing the exact borders at the basal and superficial cell layers. The improvement could 
be achieved by including a previously described algorithm that allows the automated separation of 
stromal and tumor tissue based on a DAPI staining of the nuclei (LAHRMANN et al., 2011). This 
algorithm could be adapted to CIN lesions allowing the automated annotation of the basal membrane. 
This procedure would then require only an approximate demarcation of the abnormal epithelium to 
initiate the annotation, the basal membrane, however, would then be automatically detected in this 
region and the ROIs would be calculated as described in chapter 4.1.2. This method would be even 
more time efficient and exact.  
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Another challenge of the project and a step towards even more automation regarding the annotating 
step of the process is the usage of registration methods (MOLES LOPEZ et al., 2014). By elaborating 
this method, the lesion regions would have to be defined only once on the p16
INK4a
 reference slide, 
either manually or automatically, which would then be used as template to automatically transfer the 
annotated region to all other stained and digitalized slides by pattern recognition. The p16
INK4a
 staining 
could be reliably used for the detection of transformed high-grade lesions, as it is a surrogate for 
oncogene overexpression and in these cases displays as strong and diffuse staining pattern. A few 
slides, however, do not express p16
INK4a
 and still would have to be annotated manually. Nevertheless, 
image registration could reduce the workload as an annotated p16
INK4a
 stained slide could be used as a 
reference template for several other consecutive stained slides.  
Also the morphological appearance could be used and integrated in the computational detection of the 
lesion as CIN lesions are graded according to the degree of morphologically atypical epithelial cells. 
While in CIN1 the basal third of the epithelium is affected, CIN2 is defined as showing abnormalities 
until the middle third and in CIN3 atypical cells can also be found in superficial third of the 
epithelium. For p16
INK4a
-negative low-grade lesion that have not yet entered the transforming infection 
stage a combination of information gained from the morphological appearance and an epithelial 
marker would be conceivable to identify the p16
INK4a
-negative lesions (KEENAN et al., 2000; WANG 
et al., 2007). An algorithm could be developed that recognizes the lesion by computational analysis of 
the cellular morphology and p16
INK4a
 positivity in parallel and by specifically distinguishing the lesion 
from the background and also the stromal tissue. This would allow an objective and standardized 
definition of the intraepithelial neoplasia and thus the corresponding p16
INK4a
 reference slide could be 
used as template for the automated annotation of the following serial slides stained with different 
immune markers.  
 
In conclusion, this methodological approach is in accordance with the actual needs of the classical 
pathology and the contemporary trend towards whole slide imaging that replaces visual inspection and 
evaluation of glass slides under the microscope and allows for high-throughput analyses. Automated 
quantification platforms allow the classical pathological discipline to be transferred in to the world of 
digitalization. The establishment of such a system for CIN lesions was a necessary step to make up 
leeway and close the gap to the achievements already made for other tumor entities (GALON et al., 
2006; KUNZ et al., 2014; LLOYD et al., 2010). This new approach facilitates sharing of sample 
material between pathologists and scientists as it did also in the here described cooperation project and 
might improve the reproducibility not only in terms of pathological diagnosis (BUENO et al., 2014) 
but especially in the scientific investigation of biomarkers predicting the clinical course of CIN 
lesions. The established method allows the immune cell contexture in the whole affected area to be 
taken into account and immune cells to be quantified in a standardized and objective way and 
therefore is highly relevant for the prediction of biomarkers and as guidance for immunotherapy.  
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6.3  Immune cell densities and composition are different in 
high-grade lesions and cancers compared with low-grade 
lesions  
A non-negligible proportion of morphologically defined low-grade CIN1 overexpresses p16
INK4a
 
(TSOUMPOU et al., 2009) indicating that within these lesions there is to a certain extent already viral 
oncogene overexpression constituting the initial transforming event. Only a small fraction of these 
early transforming infections stages, however, progresses towards higher stages (CIN2/CIN3) (WANG 
et al., 2004). The study presented herein addressed the question whether density and phenotype of 
infiltrating immune cells are different in low-grade CIN that have already entered the transforming 
stage (p16
INK4a
-positive) and those that are still in the permissive stage (p16
INK4a
-negative) and thus 
correlates with the early induction of transformation in low-grade lesions or whether this shift rather is 
associated with established and morphologically advanced high-grade dysplasia that may have 
accumulated chromosomal instability. To answer these questions, different T cell phenotypes in CIN 
were quantified in a cross-sectional study cohort and analyzed in relation to the p16
INK4a
-expression of 
the lesions. In addition to well characterized immune cell markers (CD3, CD8, Granzyme B and 
Foxp3) also CD3 ζ-chain was included as here data for CIN are scarcer. 
T cell infiltrates were compared between non-transforming and transforming infection stages in low-
grade CIN (chapter 4.2.2). The analysis revealed that p16
ÌNK4a
-positivity in a substantial proportion of 
low-grade CIN (CIN1) representing the early transforming infection stages, was not associated with 
significant changes in densities of different T cell phenotypes infiltrating the lesion-adjacent stroma 
and the lesion. T cell densities in these p16
INK4a
-positive low-grade CIN were similar to those in 
p16
INK4a
-negative low-grade CIN demonstrating that the onset of p16
INK4a
 expression which represents 
the beginning of the transforming infection state was demonstrated is not associated with changes in T 
cells densities or in the composition of the infiltrate.  
Changes obviously occur at a later time point after transforming processes have been initiated: in later 
CIN stages (CIN2/3) compared to low-grade CIN the T cell infiltrate densities fundamentally changed 
irrespective of the T cell phenotype (chapter 4.2.3). The finding of increased T cell density in high-
grade lesions – observed for all investigated T cell subtypes in both compartments (except epithelial 
Treg cells) - is in accordance with other studies describing also denser infiltration and altered immune 
cell composition in increasing clinicopathologic CIN stages (BONTKES et al., 1997; JAAFAR et al., 
2009; MONNIER-BENOIT et al., 2006).  
Additionally, the higher absolute T cell infiltration in high-grade CIN compared to low-grade lesion 
was accompanied by lesion/stroma ratios tending to be decreased for all T cell subtypes except for 
GranB which was slightly increased. This demonstrates that despite dense infiltration with immune 
cells attracted to the adjacent stromal compartment the recruitment of T cells into the lesion, where T 
cell effectors should do their job and eliminate transformed cells, is hampered in high-grade lesions. 
This effect may - in combination with immunological tolerance – favor progression and the outgrowth 
of the lesion although dense immune cell infiltrates are present at the lesion site.  
Invasive cervical carcinomas were compared with high-grade CIN (chapter 4.2.3) and showed a 
further increase in total T cell numbers. Significantly higher densities were observed for CD3+, 
GranB+ and Foxp3+ T cells. This is also in agreement with several other studies reporting on higher 
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densities of CD4+ T lymphocytes (ADURTHI et al., 2008; LODDENKEMPER et al., 2009), CD8+ T 
cells (ADURTHI et al., 2008; EDWARDS et al., 1995; LODDENKEMPER et al., 2009) and also 
Foxp3+ regulatory T lymphocytes (ADURTHI et al., 2008; HOU et al., 2012; WU et al., 2011). 
One explanation for the denser T cell infiltration in high-grade CIN and cancer could be the increased 
antigenicity due to the permanent viral oncogene expression as proposed by Loddenkemper et al. 
(LODDENKEMPER et al., 2009) or the potential expression of tumor-associated cellular antigens. 
It has been described in literature that genomic alterations are induced following viral oncogene 
overexpression initiating transformation of the host cells and that the accumulation of distinct 
secondary alterations is driving the progression of a lesion (DUENSING and MUNGER, 2004). 
However, studies based on comparative genomic hybridization revealed that these genomic alterations 
are rare in low-grade lesions irrespective of their p16
INK4a
-status (THOMAS et al., 2013). The results 
obtained from the presented study show that despite p16
INK4a
-positivity indicating viral E6 and E7 
overexpression, transforming low-grade CIN are not yet characterized by marked immune cell 
infiltrate changes, which only occur – as well as the accumulation of genomic alterations 
(chromosomal alterations) - in later high-grade stages of CIN.  
Interestingly, the lesion/stroma ratio for GranB+ activated CTLs and also the epithelial CD8+/CD3+ 
ratio were significantly decreased in invasive cancer samples, a finding confirmed by other studies 
speculating on the ineffectiveness of effector T lymphocyte responses despite a strong infiltration due 
to immunoregulation mechanisms provoking further T cell recruitment to the lesion/tumor while 
disease progression is unhampered at the same time (ADURTHI et al., 2008; EDWARDS et al., 1995; 
LODDENKEMPER et al., 2009; MONNIER-BENOIT et al., 2006). Immune suppression mechanisms 
seem to be more important in high-grade lesions where all sorts of immune cells are attracted to a 
greater extent. In cervical cancer the highest Treg density could be found, which was constantly 
increasing with disease severity. The presence of regulatory T cells, however, could also be observed 
in low-grade lesions. This finding together with the fact that they show large variances in each of the 
diagnostic categories point to the role they could play in disease progression and clinical outcome of 
the patients. Also one might speculate that the observed increase of total CD3+ T cell infiltration 
correlates with an increased proportion of other types of immune regulating, inhibiting cells. This 
would have to be tested with other markers. With only one immune regulation T cell type, represented 
by Treg cells, investigated in this study, the exact mode of action of immune control mechanisms 
enabling HPV-transformed cells to evade the immune system and allow disease progression, remains 
still to be identified in prospective studies. A comprehensive overview will be given in chapter 6.4 
where different immune regulation mechanisms as possible markers for future studies will be 
discussed. Also strategies adapted by the tumor cells themselves might be involved in the 
circumvention of host immune responses and enable the cells to further grow out to high-grade lesions 
and invasive cancers. One of these mechanisms is the alteration of the antigen-presentation capacity 
(chapter 4.3) which prevents potential HPV-associated antigens to be presented to immune cells. This 
could hamper the activation of cytotoxic T lymphocytes – that as demonstrated in the course of this 
analysis are frequently are present in the tumor environment – and thus favor disease progression.  
T cell infiltration of CIN lesions and the adjacent stromal compartment is highly heterogeneous with 
regard to the T cell densities and also phenotypes and was shown to increase with histomorphological 
lesion grades. The correlation of T cell infiltrates with the p16
INK4a
 status and thereby with biologically 
defined progression steps of precancerous lesions, which was done for the first time in this study, 
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demonstrated that there are no differences in the T cell numbers between p16
INK4a
-negative and 
p16
INK4a
-positive low-grade CIN. Only in later, morphologically more advanced high-grade CIN 
(p16
INK4a
-positive CIN2/3) remarkable alterations of T cell densities could be found. This is in 
agreement with the idea of the local selection and outgrowth of more advanced abnormal subclones 
that have acquired genomic alterations and the influence that these aberrations have on the local 
immune milieu during progression of established lesions.  
 
The above described heterogeneous T cell densities within the same histomorphological category were 
reported previously for example for Treg cells by Adhurti et al. who argue that this T cell phenotype 
varies over time and is dependent of persisting HPV infections (ADURTHI et al., 2008). It has been 
demonstrated that also a proportion of established high-grade CIN (CIN2/3) regress spontaneously 
(MUNK et al., 2007) and one could speculate that the dynamics of progression and regression 
correlates with the variation in T cell densities and that this could be a valuable progression marker 
especially for high-grade lesions that all are p16
INK4a
-positive for which reason p16
INK4a
 alone cannot 
predict progression. The density and phenotype of infiltrating immune cells could be a source of 
predictors for the natural course of CIN and the clinical outcome as it has been described for various 
other cancer types (CUNHA et al., 2012; DAVIDSSON et al., 2013; GALON et al., 2006; KIM et al., 
2013). Single longitudinal studies reported on higher GranB-expressing cytotoxic T cells in regressing 
CIN (TRIMBLE et al., 2010; WOO et al., 2008) and this might also be true for other T cell types in 
both outcome groups.  
With the samples deriving from the Austrian imiquimod trial described in section 4.4 and based on 
automated high-throughput screening methods as described previously (chapters 4.1 and 6.2) these 
analyses can be transferred to a prospective study of high clinical relevance. T cell densities and 
phenotypes there can be investigated in relation to the clinical outcome and the correlation with 
regression or progression of the lesions is likely to contribute to a better understanding of the here 
discussed heterogeneity in T cell densities. This might allow the definition of the “immune evasion 
phenotype” – an immunological phenotype associated with immune evasion. Once this combination of 
immune characteristics is defined it could also be used as a clinically relevant immune cell marker 
panel to estimate the progression risk of patients.  
 
6.4 HLA class I and class II antigen expression is altered in 
cervical intraepithelial neoplasia and cancers  
 
Alterations of HLA class I antigens on tumor cells have been reported in different tumor entities and 
are believed to play – in addition to the variation in T cell infiltrate densities – an important role in the 
battle of the host’s immune system against cancer cells. Modulation of the antigen presentation 
capacities of the tumor cells is an elaborated mechanism by which tumor cells adopt to the host’s 
immune system to possibly evade an immune attack (CHANG and FERRONE, 2007). HLA class I 
antigen expression is reported to be associated with the clinical outcome of the patients in different 
cancers such as HNSCC (MEISSNER et al., 2005), rectal cancer (REIMERS et al., 2014) and 
melanoma (HICKLIN et al., 1998). For cervical cancer patients a negative correlation between absent 
HLA class I heavy chain expression and a poor clinical outcome (MEHTA et al., 2008) has been 
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shown which is explained by presence or absence of recruitment of distinct T cell phenotypes to the 
tumor (JORDANOVA et al., 2008). The vast majority of these analyses have been performed in 
cancer patients while the role of HLA class I and class II antigen modulation in earlier stages of 
cervical carcinogenesis is less well characterized. Also studies involving both components of HLA 
class I complexes, the heavy chain and the light chain, together with HLA class II antigen expression 
have been lacking. To close these gap CIN and cervical cancer samples (n=40) were analyzed for 
HLA class I and HLA class II antigen expression (chapter 4.3).  
 
With regard to HLA class I antigen expression, the analyses performed during this thesis demonstrated 
that normal, non-dysplastic epithelium adjacent to the lesions showed strong, homogenous and 
membranous expression for HLA class I heavy chains and β2m in all observed regions. In contrast, 
CIN and invasive cancers are characterized by a high frequency of alterations in HLA class I antigen 
expression.  
Importantly, the observed losses of HLA class I expression in the majority of the analyzed samples do 
not represent total HLA class I loss, but often affect only parts of the lesion/tumor defined as 
heterogeneous expression pattern. About 40 % of lesions (45.0% of CIN and 35.3% of cancers) still 
retain the expression of HLA class I heavy chain A of the cell surface. With regard to cytoplasmic 
expression the percentage of lesions that express HLA class I heavy chain A is about 75% (80.0% of 
CIN and 70.6% of cancers).  
Alterations of HLA class I heavy chain expression is more frequently were observed of for the staining 
with HCA-2 representing HLA class I heavy chain A epitopes while staining results for HC-10 (heavy 
chains B and C) and β2m less frequently showed alterations.  
 
Possible mechanisms explaining the higher frequencies of losses observed with the HCA-2 antibody 
mainly recognizing HLA-A heavy chains could be discussed as following: One potential explanation 
might be that in these cervical lesions a selective loss of the HLA-A locus occurs more frequently as 
compared with the HLA-B and HLA-C loci which visualized by the HC-10 antibody (reviewed in 
SELIGER et al., 2002). Selective loss of HLA class I allospecificities in malignant cells has also been 
reported in melanoma (PASCHEN et al., 2003), renal cell carcinoma (LUBOLDT et al., 1996) and 
colorectal cancer (KLOOR et al., 2005). This alteration potentially reflects immune selection caused 
by the massive immune infiltrates entering the tumor microenvironment (chapter 4.2) and might be 
involved in down-regulated presentation of tumor-associated antigens. Additionally, tumor antigens 
with a higher antigenic potential might be bound by HLA heavy chain A compared with the other 
classical heavy chains of the HLA class I complex. Selective loss or down-regulation of HLA-A could 
then be considered as an adaption of the tumor cells under the immune selective pressure of the host’s 
immune system (CHANG et al., 2003). It is known from other tumor types that the presence or 
absence of distinct HLA haplotypes, not only HLA class I but also class II antigens, contribute to a 
higher susceptibility for cancer (RAZMKHAH and GHADERI, 2013), and it is conceivable that this is 
also true for the development of cervical and other HPV-associated cancers.  
 
Concerning the observed HC-10 staining pattern (less frequent alterations), a definitive conclusion 
concerning HLA-B and HLA-C heavy chains in this context cannot be drawn for different reasons. 
First of all, the antibody has overlapping specificity for HLA-B and HLA-C heavy chains and also for 
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some HLA-A epitopes. If one of the antigens is down-regulated, the presence of the other heavy chain 
subtype would still result in a positive staining signal (STAM et al., 1986). 
 
Furthermore, other underlying mechanisms such as defects in the antigen-processing in the cytosol and 
endoplasmatic reticulum might also be involved resulting in disturbed antigen loading and transport to 
the cell membrane. This could be caused by loss of transporter-associated with antigen processing 
(TAP) (BANDOH et al., 2010) or tapasin (HAN et al., 2008) which are involved in the transport of 
antigenic peptides into the endoplasmatic reticulum and loading on HLA class I molecules.  
Total loss of HLA class I antigens is causally linked to complete loss of β2m expression due to 
structural defects of one of the β2m locus on chromosome 15. In this case, HLA class I heavy chains 
cannot any longer be trafficked by the endoplasmatic reticulum and golgi apparatus to be finally 
expressed on the cell membrane (reviewed in SELIGER et al., 2002). Cytoplasmic β2m expression is 
retained in 100% of CIN2 samples and heterogeneous expression of β2m expression could only be 
observed in the minority of CIN3 and cancer samples. None of the samples were negative for 
cytoplasmic β2m expression. This implies that loss of β2m is not the major mechanism of immune 
evasion contributing to the cervical carcinogenesis. This is in contrast to other tumor types such as 
melanoma or microsatellite unstable colorectal cancers where the β2m wild-type allele is lost 
(PASCHEN et al., 2003; TIKIDZHIEVA et al., 2012).  
 
The fact that expression in most of the regions is retained argues against a total functional disruption. 
Selective loss or down-regulation could be mediated by the interaction of HPV with the expression of 
HLA class I molecules. It has been shown that HPV16 E7 induces HLA class I down-regulation 
(BOTTLEY et al., 2008) as well as HPV16 E5 (CAMPO et al., 2010). This might represent a 
mechanism developed by the virus to circumvent immune attack of virally infected cells by preventing 
antigen-presentation of viral antigen and thus to establish the infection and promote the completion of 
the viral life cycle (ASHRAFI et al., 2005).  
Once the underlying mechanisms are clear, the re-induction of full HLA class I antigen expression by 
therapeutic intervention (LANZA et al., 1995) may be a goal and naturally occurring immune 
responses might then be successfully eradicate the lesion. In addition, treatment strategies based on 
vaccines or other immune enhancing therapeutics can probably restore or further enhance the immune 
attack against tumor cells.  
 
The method based of immunohistochemical analyses of HLA class I complexes certainly has 
limitations. The formalin fixation process of the tumor samples leads to dissociation of assembled 
complexes into free heavy chains and β2m. In contrast to fresh, unfixed tissue material or cells, where 
functional HLA class I complexes can be detected for example with the W6/32 antibody recognizing 
assembled HLA-A/B/C complexes, on paraffin-embedded tissue the heavy and light chains have to be 
stained separately by distinct antibodies as described previously (KLOOR et al., 2005). This is the 
reason why this approach does not allow functional conclusions to be drawn from the analysis. 
Although membranous expression of the components are considered to be a surrogate for the potential 
antigen-presentation capacity by HLA I antigen complexes, this method is remains of limited 
accuracy. However, the observed higher frequency of HLA-A losses are not thought to be caused by 
deficient antibody specificity as the antibodies used in this study are well characterized and widely 
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accepted for use in immunohistochemical analyses of HLA class I expression patterns (SERNEE et al., 
1998 and STAM et al., 1986).  
 
HLA class II antigen expression can be detected in different solid tumors of non-lymphoid origin 
(ALTOMONTE et al., 2003) and also cervical precancerous stages and cancers were found to be 
positive for HLA class II molecules (CHIL et al., 2003; GLEW et al., 1992). The biological function 
in the context of antigen-presentation and activation of effector T cells still remains unclear. The 
investigation of HLA class II antigen expression was therefore included in the characterization of 
antigen-presentation mechanisms with the aim to unravel a possible correlation with the classical 
antigen-presentation pathway mediated by HLA class I antigens.  
 
The staining with the monoclonal antibody LG-612.14 for HLA class II chains DP, DQ and DR 
demonstrated that the majority of CIN2 and CIN3 lesions are positive for HLA class II antigens. 
Around 80% of them displayed membranous HLA class II antigen staining. Similarly, cervical 
carcinoma samples also are positive for membranous HLA class II molecules in around 85% of all 
cases.  
This is a strikingly high percentage of precancerous lesions and invasive cancers compared with other 
solid tumors of different origins that are reported to express HLA class in tumor cells. Among these 
are melanoma, gastric, colorectal and breast cancer which to a lesser extent show HLA class II antigen 
expression, 50-60% of melanoma for example (reviewed in ALTOMONTE et al., 2003).  
 
These observations raise the question of the biological significance and the functional relevance in 
terms of antigen-presentation. In consideration of the fact that around 85% of CIN2, CIN3 and 
invasive cancers express HLA class II with 38.4% to 52.6% being scored “positive” and showing 
membranous expression on virtually all tumor cells, this might probably not contribute to efficacious 
antigen-presentation directly mediated by tumor cells and a stimulation of anti-tumoral immune 
responses.  
Although it has been shown in the past that tumors – under inflammatory processes - might present 
peptides via the HLA class II antigen complex to CD4+ T cells and that these can mediate cytotoxicity 
leading to tumor rejection (DENGJEL et al., 2006; EKKIRALA et al., 2014) the sole binding and 
presentation of peptides does not necessarily lead to the induction of a cell-mediated immune 
response. This also requires the presence of co-stimulatory molecules, such as CD28, and their 
absence rather induces antigen-specific immune tolerance mechanisms favoring disease progression 
(BAL et al., 1990; GASPARI et al., 1988; HARDING et al., 1992).  
With the results seen in this light one might speculate whether HLA class II antigen-negative low-
grade lesions therefore represent those that are more likely to regress as they would not – as described 
in this scenario – induce immune suppression. This question however can only be addressed in a study 
providing information about the functional role of HLA class II antigen expression for example by 
correlating it with different immune cell phenotypes present in these lesions and with the clinical 
outcome of the patients which requires a longitudinal setting such as the Austrian Imiquimod trial.  
 
By interpreting the alterations in HLA class I and class II alterations as adaptions of the tumor cells 
under the immunoselective pressure of the host’s anti-tumoral immune responses, the roles of HLA 
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class I and II in enabling CD8+ T lymphocytes and NK cells to recognize, bind and kill tumor cells 
have also to be taken into consideration. The frequently observed HLA class I down-regulation or 
complete loss in tumors was early associated with impaired CD8+ CTL-mediated anti-tumoral 
responses (reviewed in GARRIDO et al., 1997). The absence of HLA class I molecules on the tumor 
cell however is associated with the induction of NK-cell mediated killing (BOTTINO et al., 2004). 
From the developing tumor’s point of view this would be a weak immune evasion mechanism. It was 
demonstrated that HLA class II molecules expressed on tumor cells protect them from being attacked 
and lysed by NK cells (JIANG et al., 1996). Expression of HLA class II antigens might therefore also 
be considered as – secondary – evolutionary development allowing tumor progression. The combined 
alterations, HLA class I down-regulation and HLA class II expression on tumor cells could therefore 
represent mechanisms that play together to circumvent cell-mediated cytotoxicity.  
 
HLA class II expression could be caused by HPV infections and interference of the virus the host 
cell’s antigen-presentation machinery. Such a correlation, however, could not be demonstrated 
(GLEW et al., 1992). One could speculate that a so far unknown event that is related to the 
transformation processes in high-grade lesions be associated with HLA class II antigen expression. 
The observed staining pattern in precancerous lesions could also represent the phenotypical heritage of 
the initially infected keratinocytes that did not resolve the HPV infection and further grew out to 
precancerous lesions. This hypothesis is supported by the observed peculiar staining pattern of 
columnar epithelium in the squamocolumnar junction in combination with the absence of HLA class II 
expression in normal squamous epithelium. It has recently been shown that a distinct cell population 
present in the squamocolumnar junction zone is susceptible to HPV infections and furthermore is 
characterized by a distinct protein expression profile (HERFS et al., 2012). It is conceivable that HLA 
class II expression is another characteristic of these highly metaplastic cells. If the assumption holds 
true that the vast majority of cervical lesions originate in this region and develop by clonal expansion 
of distinct cells, the strong HLA class II expression could be explained by the maintenance of this 
phenotype in outgrowing lesions. This was hypothesized earlier in a study also observing high 
expression in the metaplastic epithelium and strong expression in cervical precancerous lesions and 
cancers (CHIL et al., 2003). This phenomenon then would rather be explainable by cell-intrinsic 
characteristics than an adaption caused by interaction of the viral infection with the host cell’s antigen-
presentation machinery. Interestingly, only half of the CIN1 were positive for HLA class II antigen 
staining and this did not correlate with p16
INK4a
 expression representing the transforming infection 
stage. Considering the high frequencies of HLA class II expression in later stages, one could speculate 
that low-grade lesions positive for HLA class II antigen expression are more likely to progress which 
could not addressed in this study but requires a longitudinal approach.  
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6.5 The density and composition of immune cell infiltrates can 
be influenced by immuno-modulatory drugs  
 
Several studies have demonstrated that the composition of immune infiltrates and the behavior of 
immune cells such as migration can be influenced by immune modifying agents such as imiquimod 
(HACKSTEIN et al., 2012; HUANG et al., 2009b; SUZUKI et al., 2000). Imiquimod is TLR7/8 
agonist and its potential to enhance the patient’s immune response prompted physicians to initiate a 
multitude of trials in order to investigate is efficacy in off-label indications such HPV-associated 
vulvar intraepithelial neoplasia (WESTERMANN et al., 2013) (VAN SETERS et al., 2002) (VAN 
SETERS et al., 2008). Although imiquimod is known to cause local and systemic side effects, it 
appears to be a promising alternative to surgical standard treatment. In particular, in women affected 
by multifocal VIN imiquimod treatment can replace cold knife excision as a first intervention option 
(FREGA et al., 2013). Also in CIN patients there is a non-negligible need for conservative treatment 
strategies as the surgical standard treatment, LEEP conization, is supposed to affect the outcome of 
subsequent pregnancies and provoke pre-term birth (ARBYN et al., 2008; SIMOENS et al., 2012).  
 
The Austrian imiquimod trial was the first randomized, placebo-controlled trial performed to test the 
efficacy of topical imiquimod treatment in patients with high-grade CIN (GRIMM et al., 2012). Three 
biopsies per patient were taken over 20 weeks during the treatment and after the completion of the 
treatment protocol and the clinical outcome of each patient was defined based on the last biopsy taken. 
These tissue specimens allow the investigation of changes in immune cells densities under treatment 
with a TLR7/8 agonist and might give insights in how the immune modifier acts and which immune 
cell composition is associated with a clinical response to the treatment. Of this unique patient cohort 
cervical biopsies of 10 patients could be obtained who received imiquimod therapy over 16 weeks. 
Albeit numerically restricted, these samples represent very valuable patient material allowing address 
questions that have never been investigated before.  
The tissue specimens that could be obtained of this trial were characterized by p16
INK4a
 staining and 
then analyzed based on the method described in chapter 4.1 for total T cell infiltration represented by 
CD3+ cells and cytotoxic lymphocytes represented by CD8+ T cells. The obtained data were 
comparatively evaluated as immune infiltrates in non-responders and responders to the imiquimod 
treatment (described in chapter 4.4). In a first approach the question was addressed whether CD3 and 
CD8 T cells in initial CIN2/3 biopsies are different between lesions that subsequently regressed 
(responders to imiquimod) and those that persisted or even progressed (non-responders). Interestingly, 
in non-responders a higher initial infiltration with CD3+ T cells was observed compared with 
responders. The fact that these patients do not respond to the imiquimod treatment might be an 
evidence for the presence of cell types others than effector cells present in the lesion 
microenvironment. Although only one single T cell subtype was investigated (represented by CD8+ T 
cells) and a definitive conclusion cannot be drawn from these results, the preliminary results allow the 
speculation that the difference between non-responders and responders lies in a higher densities of T 
cells phenotypes eventually responsible for immune regulation such as Treg cells. The higher absolute 
T cell densities represented by CD3+ T cells could possibly be explained by a higher fraction of these 
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“unfavorable” cell types which are absent in responders and thus having a lower CD3+ T cell 
infiltration. Responders were characterized by lower total CD3 T cell infiltration. They had, however, 
higher total CD8+ T cell densities and CD8/CD3 T cell ration compared with non-responders. The 
higher proportion of cytotoxic T cells in responders before treatment might constitute a better initial 
situation probably leading to an enhanced response to imiquimod.  
Additionally, the cohort is predestined to answer the question whether the immune cell densities and 
composition are different between non-responders and responders at the end of the imiquimod 
treatment. It allows also the analysis of possible changes of the local immune cell composition that 
occur during the treatment and their effect on the clinical response of the patients. The total T cell 
infiltration with CD3+ T cells in responders after treatment compared with the initial biopsy indicated 
that imiquimod locally applied to the cervix attracted immune cells to the lesion site. Responders also 
showed a further increased infiltration with CD8+ T cells that could not be observed in non-
responders. The densities after treatment exceeded the CD8+ cell counts of the initial biopsies taken 
before the treatment was started. However, the CD8/CD3 ratios were not higher after treatment 
compared with the initial CD8/CD3 ratio in the biopsies taken before treatment, which might indicate 
that together with CD8+ cytotoxic T cells also other T cell subtypes must have been attracted to the 
lesion site in a proportional way representing a non-negligible proportion of T cells. This might be an 
explanation why the CD8/CD3 ratio is not influenced to the extent one would expect from the absolute 
CD8+ cell counts. In non-responders the total T cell infiltration represented by CD3+ T cells was not 
different at the end of the treatment compared with the initial biopsies. Interestingly, non-responders 
after treatment compared with week 0 showed a further decreased CTL infiltration regarding the 
absolute cell counts leading also to even lower CD8/CD3 ratios than before the treatment. The exact 
composition of the initially dense CD3+ T cell infiltrate in non-responders, aside from the 
characterization of CD8+ T cell densities, remains largely unclear and warrants further investigation of 
immune cell phenotypes possibly responsible for the unfavorable immune cell composition that might 
be associated with treatment resistance. On the other hand, it is also worthwhile to characterize in 
more detail T cell subtypes others than CTLs in responders and the underlying mechanisms 
contributing to a clinical response to imiquimod. 
It has been demonstrated before that generally low immune cell densities in the tumor environment are 
associated with a poorer prognosis in cervical cancer (NEDERGAARD et al., 2007), especially low 
CD8+ T cell counts in combination with high regulatory T cells infiltration correlates with poor 
prognosis (SHAH et al., 2011). A major aim of cancer immunotherapy therefore is to enhance the anti-
tumoral immune responses and to attract immune cells to the lesion site. It has been shown in the past 
that imiquimod treatment in patients with vulvar intraepithelial neoplasia contributes to the 
normalization of immune cell counts, for example by maturation of immature Langerhans cells, and 
thus induces histological regression of the lesions (TERLOU et al., 2010). Changes in immune cell 
counts are conceivable to be also the underlying reason for regression of the proportion of CIN 
patients that had responded to imiquimod therapy. It appears to be obvious that the enhanced CD8+ T 
cell infiltration into the lesion might contribute to the better outcome of these patients as it has been 
reported before (DE VOS VAN STEENWIJK et al., 2013; PIERSMA et al., 2007) and that imiquimod 
also in cervical intraepithelial neoplasia might be able to expand pre-existing CD8+ T cell response 
(TODD et al., 2004).  
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As discussed above (chapter 1.3.3), p16
INK4a
 is a reliable marker routinely used in clinical practice and 
specifically highlighting the stage of infection as it is a surrogate that indicates the presence of HPV 
oncogene activity and induction of transformation of the cell (VON KNEBEL DOEBERITZ et al., 
2012). Its overexpression, however, only proofs the presence of HPV transformed cells and does not 
indicate if the lesion will progress into high-grade CIN and cancer or regress, which happens in a non-
negligible proportion of all cases (SCHIFFMAN and WENTZENSEN, 2010). Until now the 
prediction of possible regression and progression therefore has remained an unsolved diagnostic 
problem and consequently in the clinical practice all high-grade CINs are routinely treated by surgical 
intervention irrespective of the individual risk for progression. The characterization of distinct immune 
cell phenotypes and the combination of different immune markers to define a biomarker tool appears 
as an interesting option for the prediction of the progression risk. Although the here presented analysis 
was based on a small sample size of only 10 patients and differences were not yet significant the data 
argue for a consistently differential T cell distribution in non-responders compared with responders.  
The both markers analyzed so far representing the total T cell infiltration as measured by CD3+ T cells 
and possible cytotoxic responses as indicated by CD8+ T cells already provided interesting insights in 
their potential prognostic role (as measured by responsiveness to imiquimod treatment). However, 
other immunological markers might be of interest to gain more insight in the mode of action of 
imiquimod and to identify further prognostically relevant mechanisms. In the past, imiquimod has 
been reported in the context of Langerhans cell migration (SUZUKI et al., 2000) and recruitment of 
CD8+ T cells via the integrin CD49a (SOONG et al., 2014). It induces furthermore the expression of 
cytokines and chemokines, such as CXCR3, IFN-γ and reduces IL-10 and TGF-β expression 
(HUANG et al., 2009b; SOONG et al., 2014; WENZEL et al., 2005). Interestingly, imiquimod also 
seems to turn myeloid and plasmacytoid dendritic cells into effector cells by inducing them to express 
perforin, Granzyme B and TRAIL (STARY et al., 2007). These markers only represent a restricted 
selection of possible markers that could be analyzed to determine the effects of TLR7/8 agonist 
treatment and to characterize the typical immune cell phenotypes of regressing or progression lesions. 
Also markers that represent immune evasion mechanisms would have to be taken into consideration to 
characterize the “immune evasion phenotype”. Markers that might contribute to progression of lesions 
or mediate resistance to immuno-modulatory treatments are discussed in more detail in the following 
section 6.6.  
 
The samples obtained from the Austrian imiquimod trial demonstrate how important longitudinal 
information is for the understanding of immune cell densities and phenotypes influencing the course of 
the disease. As the trial included also a placebo-controlled patient group the natural course of CIN 
without therapeutic intervention (Figure 6.2), T cell infiltrates can be associated with progressions of 
treated and untreated patients also a T cell infiltration profile important for spontaneous regression 
(under placebo) might be identified. By its longitudinal setting and the placebo controlled patient 
group the Austrian trial is a precious study cohort to better understand immune cell composition in 
regressing and progressing CIN lesions in the placebo group or in the imiquimod group. This allows 
also the determination of immune cell compositions associated with spontaneous regression or 
susceptibility to imiquimod therapy. On the long run this cohort could be the clue for a better 
understanding of the factors that influence progression and regression and might be decisive for the 
definition of immune markers for a more risk adapted treatment of patients. Thus, not all patients with 
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high-grade lesions might have to undergo classical surgical treatment but could alternatively be tightly 
monitored and wait for spontaneous regression or non-surgically be treated with an immune 
modulator.  
 
 
FIGURE 6.2  OVERVIEW OF THE TREATMENT SCHEDULE OF THE AUSTRIAN IMIQUIMOD TRIAL AND 
OUTCOME OF THE PATIENTS. The setup of this trial does not only allow to compare effects of 
imiquimod treatment in responders and non-responders but also to define T cell phenotypes associated 
spontaneous regression (placebo group) or disease progression (under treatment or placebo).  
 
With preliminary results (chapter 4.4) obtained in the here described characterization of CD3+ and 
CD8+ T cell infiltrates clinical impact of this study begins to show even though only few samples and 
only two T cell markers were investigated so far. Despite the relatively small sample size differences 
in immune cell densities could be observed when the patients were stratified for clinical outcome. 
Furthermore, it could be demonstrated that the local therapy of cervical intraepithelial neoplasia with 
the immuno-modulatory drug imiquimod can influence the T cell infiltration in terms of density and 
composition. Significant differences remain to be shown in a larger setting where all patients of both 
treatment arms, in total 59 patients, shall be included.  
 
As discussed formerly (section 6.1) the densities and phenotypes of tissue infiltrating immune cells is 
investigated in various cancer types to define prognostic markers. Furthermore, the characterization of 
the immune cell contexture (FRIDMAN et al., 2014) is indispensable for the mechanistic 
understanding of cancer immunotherapy playing a more and more important role in clinical praxis. 
The whole-slide-imaging and quantification platform implemented in CIN histopathology (chapter 
4.1) will be used to characterize the patient cohort of the imiquimod trial. The developed method will 
allow quantifying in a standardized way the immune cell composition of the complete 
microenvironment and provides a highly information-rich profile which can be used for the definition 
of a prognostic biomarker tool.  
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6.6 The search for the prognostic markers characterizing the 
immune evasion phenotype has to be continued 
The characterization of immune infiltrates in cervical intraepithelial neoplasia (chapter 4.2) has 
demonstrated that despite a generally higher infiltration with different T cell phenotypes in high-grade 
CIN, these lesions have progressed to a certain extent and may further progress into invasive cancer 
(SCHIFFMAN and WENTZENSEN, 2010). In addition to the presence of Treg cells in the cancer 
environment, decreasing CD3ζ-expression possibly leading to a lack in T cell activation and changed 
ratios of effector cells (decreased CD8/CD3 ratio) that were observed in the CIN studies, other 
markers still may be of interest and contribute to progression (Table 6.1). This chapter discusses 
possible markers and reviews mechanisms described also in other than HPV-related diseases that 
could be considered in the further analyses of the Austrian imiquimod cohort (chapter 6.5) in order to 
define the immune profile that characterizes the immune evasion phenotype of progressing CIN.  
 
Of course, not all immune cell phenotypes, receptors and ligands or cytokines represent markers 
exclusively associated with immune suppression and evasion. The majority of the here listed 
mechanism are originally associated with cytotoxic immune response (Table 6.x). However, their 
altered expression, down-regulation or changes in their ratios to other markers or cell phenotypes 
harbor potential immune inhibiting effects.  
The following list does not claim to be complete but rather is a try to summarize the most important 
players in immune evasion that exert the effect on different levels. The different aspects were 
classified in different categories in dependence on whether immune cell phenotypes or rather signaling 
molecules or receptor and ligands are involved.  
 
 
Evasion mechanism Effect References 
A) immune cell phenotypes 
CD4+CD25+Foxp3+ Treg cells 
promote progression of primary tumors, possibly 
also involved in promoting metastasis 
(HALVORSEN et al., 
2014) 
CD4+CD69+CD25- Treg cells 
express CD122 and membrane-bound TGF-β1 by 
which they mediate immune escape and tumor 
progression 
(HAN et al., 2009) 
reversal of the CD4/CD8 
T cell ratio 
Together with presence of Treg cells has a negative 
impact on clinical outcome 
(SHAH et al., 2011) 
immature dendritic cells 
convert anergic T cells into immune suppressive 
Treg cells 
(PLETINCKX et al., 
2014) 
loss of co-stimulatory 
molecules CD27 and CD28 on 
T cells 
Senescent T cell phenotype induced by tumor cells; 
leads to suppression of responder T cells 
proliferation and promotes tumor progression 
(MONTES et al., 
2008) 
γδ-T17 cells accumulation of myeloid-derived suppressor cells (WU et al., 2014) 
myeloid derived suppressor 
cells (MDSCs) 
suppression of T-cell and NK cell function 
reviewed in (DIAZ-
MONTERO et al., 
2014) 
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lack of Langerhans cells impaired antigen-presentation in the epithelium 
(FAUSCH et al., 
2002) 
CCR8(+) inflammatory 
myeloid cells (monocytes and 
granulocytes) 
CCL1 secreted by tumors binds CCR8  tumor-
induced inflammation  immune evasion 
(ERUSLANOV et al., 
2013) 
B) cytokine and chemokine microenvironment  
TGF-β immunosuppressive cytokine that hampers the Th1 
response 
(PALOMARES et al., 
2014) 
IL-10 immunosuppressive cytokine that hampers the Th1 
response 
(SYRJANEN et al., 
2009) 
IL-13 immunosuppressive cytokine that hampers the Th1 
response 
(DEEPAK et al., 
2010) 
chemokine CXCL12 and 
chemokine receptor CXCR4 
promote tumor growth, invasion, metastasis and 
therapeutic resistance 
reviewed in 
(CHATTERJEE et al., 
2014) 
C) endothelial factors, T cell homing and migration   
decreased mucosal addressin 
cell adhesion molecule 
(MAdCAM) expression 
decreased CD8+ T cell access to cervical 
tissue  
(TRIMBLE et al., 
2010) 
vascular cell adhesion 
molecule-1 (VCAM-1) 
expression by tumor cells promotes T cell migration 
away from the tumor 
(WU, 2007) 
E-cadherin down-regulation associated with decreased numbers of Langerhans 
cells in the epithelial and viral immune evasion 
(LEONG et al., 2010) 
D) antigen processing and presentation in tumor cells 
HLA class I antigen down-
regulation 
promotes escape of tumor cells from recognition 
and destruction by HLA class I-restricted, antigen-
specific cytotoxic T lymphocytes 
reviewed in (CHANG 
et al., 2003) 
increased non-classical HLA 
class I antigen (HLA-G) 
expression  
impairs the cell-mediated anti-tumoral immune 
response  
(RODRIGUEZ et al., 
2012) 
dysregulation of transporter 
associated with antigen 
processing (TAP) 
Disturbed antigen loading on HLA class I heavy 
chains resulting in impaired antigen presentation 
(BANDOH et al., 
2010) 
E) altered immune cell ligand/receptor expression  
up-regulation of CD94/NKG2A inhibitory NK receptors  (SHEU et al., 2005) 
MHC class I chain-related 
molecule A (MICA) down-
regulation 
CTL and NK cell ligand, impaired effector cell 
activation 
(LU et al., 2011) 
abnormal CTLA-4 expression 
and dysregulation 
down-regulation of T cell proliferation and effector 
function 
(MAO et al., 2010) 
PD-L1 expression in tumors binding to PD-1 on TILs leads to impaired T cell 
functions through suppression of T cell receptor 
signaling  
(MAINE et al., 2014), 
reviewed in 
(MCDERMOTT and 
ATKINS, 2013) 
Fas and FasL expression on Changes in Fas expression promotes tumor growth (ABRAMS, 2005) 
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tumor cells by reduced apoptosis sensitivity, FasL expression 
on tumor cells mediates killing of T cells entering 
the tumor  
F) other mechanisms    
micro-RNAs (miRNA-155) reduced levels of miRNA-155 results in decreased 
numbers of CD8+ effector T cells  
(DUDDA et al., 2013) 
IDO, TDO expression in tumor 
cells  
catalyzes immunosuppressive kynurenine leading to 
cell cycle arrest and functional anergy of effector 
cells, Treg differentiation and activation  
reviewed in (MUNN 
and MELLOR, 2013; 
PLATTEN et al., 
2012) 
matrix-metalloproteinase 
(MMP-1, MMP-2 and MMP-9) 
expression  
NK cell dysfunction; down-regulation of IL-2 
receptor a (IL-2Ra) expression on activated tumor-
infiltrating lymphocytes 
(PENG et al., 2014) 
(SHEU et al., 2001) 
increased inducible nitric oxide 
synthase (iNOS) expression, 
high levels of nitric oxide (NO) 
 
nitric oxide acts as signaling molecule and promotes 
cancer formation, progressions and metastasis 
(CHENG et al., 2014) 
microparticles (subtype of 
extracellular vesicles 
containing nucleic acids and 
proteins) 
involved in immune evasion, angiogenesis, tumor 
invasion and metastasis 
(VOLOSHIN et al., 
2014) 
expression of sialic acids on 
tumor cells  
promote immune evasion via interaction with the 
inhibitory receptor Siglec 
(BULL et al., 2014) 
TLR4 expression on tumor 
cells 
TLR stimulation induces synthesis of IL-6, iNOS 
and other factors, mediates resistance of tumor cells 
to CTL attack and promotes immune evasion  
(HUANG et al., 2005) 
TABLE 6.1  POTENTIAL MARKERS FOR THE DEFINITION OF THE “IMMUNE EVASION PHENOTYPE”. A 
combination of markers that contribute to immune evasion in HPV-related precancerous stages and 
cancers could be used as a diagnostic biomarker tool.  
The immunohistochemical analyses of cervical precancerous and cancerous lesions performed in the 
first part of this work gave hints of immunosuppressive and immune evasion mechanisms that might 
play a role in the progression of HPV-associated diseases. The presence of Tregs in these lesions, 
varying from low densities to high infiltration within one diagnostic category and increased in cancers 
compared to precancerous stages as well as varying densities of effector T cell phenotypes in the 
lesions implies that these variations might contribute to either the progression or regression of the 
lesions. Furthermore, this indicates that the quality of the immune infiltrates might correlate with the 
clinical outcome and could be the basis for defining prognostic markers. To better understand which 
combination of markers is the most relevant for prediction of progression or regression. Here again the 
longitudinal nature of the Austrian imiquimod trial is extremely valuable as it allows to decipher 
distinct immunological constitutions associated with progression of high-grade lesions – in untreated 
patients and under the influence of imiquimod. In combination with the automated cell quantification 
method allowing high-throughput screening of larger patient cohorts and a broad variety of different 
immune markers the identification of a prognostically relevant biomarker tool usable for treatment 
decision appears as a realistic goal.  
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The positive effect of immuno-modulatory drugs on the density and composition of the T cell infiltrate 
could be demonstrated for imiquimod for CD3+ and CD8+ T lymphocytes (chapter 4.4).  
In the second part of this thesis different intervention strategies were investigated in more detail in 
immune and tumor cell based in vitro assays. Here, immuno-modulatory agents (chapter 5.1) and also 
manipulations directly on the cellular levels in terms of Treg depletion (chapter 5.3) were analyzed to 
explore the potential of different immunological treatment strategies.  
 
 
6.7  A new immune modulatory drug, TMX-202, shows 
promising effects the priming of naïve T cells to HPV-
associated antigens 
Immune modulation has been shown to be one mechanism that potentially leads to tumor eradication 
by enhancing the host’s immune responses against abnormal cells. Aldara, the 5% imiquimod cream 
formulation, is an immuno-modulatory TLR7/8 ligand-based substance approved for the treatment of 
warts, actinic keratosis and basal squamous carcinoma (chapter 1.x). Because of lacking conservative 
treatment options it is also given as an off-label drug to patients with anal and vulvar intraepithelial 
lesions and melanoma in situ (DAVID et al., 2011) and investigated in a multitude of trials to prove its 
efficacy in these off-label indications. Its efficacy could also be demonstrated in the first randomized, 
controlled trial enrolling high-grade CIN patients (GRIMM et al., 2012). Although imiquimod is 
considered to be safe, it causes local and systemic adverse effects which require the treatment protocol 
to be interrupted (chapter 1.5.3). Considering the potent immuno-modulatory capacity of imiquimod 
by induction of a strong cytokine release and a Th1-dominant anti-tumor immune response and the 
non-deniable need for such an immune stimulating treatment it is worthwhile to consider alternate 
drugs for TLR activation.  
In cooperation with a company specialized in immuno-modulatory drugs, Telormedix S.A., which 
provided a new substance for initial tests, the potency of TMX-202 a purine-like TLR7 agonist 
bioconjugated to a phospholipid (Figure 1.11) agonist could be tested in different experiments 
(CRAIN et al., 2013). Within the presented thesis, its immuno-stimulatory effects were tested in vitro 
in the HPV-setting as it could be an interesting substance for a combinatorial drug approach that 
increases the immune response to papillomaviruses. The results obtained in these experiments 
contributed to a patent application.  
It has been shown in the past that the TLR expression levels in B cells can be up-regulated by both 
activation of the antigen-receptor or stimulation of the TLR itself by treatment with a TLR-ligand 
(BOURKE et al., 2003). This finding implies that external stimuli simulating infection could regulate 
the expression levels of TLRs by a positive feedback loop. Therefore, possible regulatory mechanisms 
on the expression levels of TLRs were also tested under the influence of imiquimod and the new TLR-
ligand TMX-202 and measured on the transcript and protein level. The PBMCs of four healthy donors 
were treated, two of them with imiquimod and TMX-202 to compare the effects of the approved and 
the newly developed drug and two of them were treated with different TMX-202 concentrations.  
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Donor 1 showed high changes in TLR7 mRNA expression which have to be interpreted with caution, 
as RNA concentrations following isolation were low. These low mRNA levels might have resulted in 
low Ct values and high-fold changes when visualized in a log2 scale. Also the effects of imiquimod on 
the PBLs of the first two donors were contradictory as donor 2 displayed higher changes in TLR7 
mRNA expression following imiquimod treatment while donor 1 responded to TMX-202 treatment 
with mRNA up-regulation. Whether this is a specific effect of imiquimod or rather induced by 
potential side effects that could be caused by the imidazoquinoline cannot be deduced from only 
donors tested. Also the results obtained for donors 3 and 4 were inconsistent with donor 3 showing no 
effect or even decreasing mRNA expression levels and donor 4 increasing TLRL7 mRNA expression. 
On the protein level for donors 1 to 3 no effect of any of the treatments could be observed. The 
PBMCs of donor 4, however, displayed increased TLR7 protein expression following treatment with 
TMX. In summary, only donor 4 showed a convincing influence of TMX-202 on both mRNA and 
protein levels that were consistently up-regulated after treatment and under both applied 
concentrations of 1µM and 10µM. The fact that natural infections lead to up-regulation of the 
corresponding TLRs in vivo accompanied by an enhanced cytokine release in a time dependent 
manner (HUANG et al., 2009a; KAUR et al., 2014) might be a reason for the responsiveness of donor 
4. A previous infection might have induced immune cell activation and thus enhanced their 
responsiveness. Secondary stimulation with a TLR-ligand might faster and to a higher extent than in 
the PBMCs of the other donors have up-regulated TLR7 expression on mRNA and protein level. The 
immune cells might still have been in an activated state and thus shown a greater reaction to the 
external stimulation.  
However, most importantly the down-stream effect of TLR agonist treatment which is considered to 
be the release of pro-inflammatory cytokines stimulating both innate and adaptive immunity 
(STANLEY, 2002). The pro-inflammatory cytokine plays a pivotal role in linking both arms of the 
immune system and mediates the transitions from inflammatory processes to the acquired immune 
response (reviewed in JONES, 2005). The pro-inflammatory processes after imiquimod and TMX-202 
treatment were therefore measured by IL-6 ELISA using the supernatants deriving from PBMC 
stimulation and were compared between the different treatment groups. It could be shown that 
imiquimod induced significantly higher IL-6 levels compared with the controls. TMX treatment, 
however, further increased the IL-6 release (by approximately two powers of ten) which was 
extremely significant compared with controls. These results confirmed data published for dose-
dependent IL-6 release measured in whole blood following TMX-202 treatment (CRAIN et al., 2013). 
In addition, it could be shown that the substance has a strong potential for the induction of a pro-
inflammatory cytokine milieu and this is not dependent on the TLR7 mRNA or protein expression 
levels but rather dose-dependent.  
 
With these insights gained in the mechanisms how TMX-202 could link the innate with the adaptive 
immune response its potential to probably enhance T cell responses against HPV-associated antigens 
were tested additionally in an in vitro approach. This experiment is based on the priming of naïve T 
cells with HPV-associated antigens loaded on dendritic cells in order generate antigen-specific T cells 
by bringing them repeatedly in contact with antigens presented by professional APCs. Therefore a 
well-established protocol used in our department was used (KAUFMANN et al., 2001).  
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One of the peptides used in this experimental approach were p16
INK4a
, a host cell protein which by its 
specific overexpression in HPV-transformed lesions and all HPV-induced cancers is a potential target 
protein for secondary vaccination approaches. In contrast to the viral proteins it is not HPV-type 
specific. The second antigen is the major capsid protein L1 of HPV16 which is known to be a strongly 
antigenic protein on which the prophylactic vaccines are based. The antigenicity of p16
INK4a
 as well as 
of HPV16 L1 were demonstrated in our phase I/IIa p16
INK4a
 vaccination clinical trial and by a 
therapeutic vaccine based on chimeric virus-like particles consisting of a L1p16
INK4a
 fusion protein 
(FAULSTICH, 2014). Both studies demonstrated that p16
INK4a
-specific and L1-specific cellular 
immune responses can be developed following vaccination.  
For p16
INK4a
 the peptide sequence used in the clinical trial was used. For L1 a series of 9-mer and 10-
mer HLA-A2 restricted peptides were predicted and chosen as described in section 3.x and were tested 
in a peptide-binding assay. One L1 sequence that was reported to induce L1-specific T cells following 
in vitro priming was included as positive control (KAUFMANN et al., 2001), together with an 
influenza matrix protein sequence, to evaluate the binding capacities to HLA antigens in the peptide 
binding assay. The p16
INK4a
 peptide used in the clinical trial also was considered to have a high 
binding affinity and therefore was considered to be a control peptide for the newly synthesized L1 9-
mer peptides.  
Of the tested L1 peptides three (L1_2, L_12 and L1_97; sequences in chapter 3.x) were demonstrated 
to meet criteria defined to identify the best binding antigens: they had a significantly higher MFI 
reflecting the binding capacity as compared with the background control and furthermore had a higher 
MFI compared with the lowest “positive” control.  
The effects of TMX-202 stimulation during T cell priming were compared with DMSO as vector 
control and investigate on different levels: on the one hand dendritic cells were characterized in more 
detail and on the other hand T lymphocytes were evaluated by their potency to kill tumor cells as 
measured by CD107a degranulation rates.  
The experiment was based on an autologous but HLA-A2 matched cell system involving CaSki cells 
as targets and T lymphocytes obtained from a HLA-A2 positive healthy donor as described formerly 
(RESSING et al., 1996).  
The effect of TMX-202 treatment during maturation of dendritic cell from monocytes was generally 
monitored by changes in the morphology and also cell numbers. In comparison to DMSO treated 
control cells monocytes under the influence of the immuno-modulatory drug earlier and to a larger 
extent showed a changing morphology from regularly shaped and round adherent monocytes, the 
plasmacytoid morphology, to the dendrite-like morphology with branched cell appendices 
(SOUMELIS and LIU, 2006). The better effect of TMX-202 treatment in comparison to the DMSO 
control could also be demonstrated by higher cell numbers obtained from the original fraction of 
PBMCs used for adherence of monocytes. Under TMX-202 influence consistently higher cell numbers 
could be harvested demonstrating the higher rate of surviving and maturing cells under immuno-
modulatory drug treatment. Furthermore, it could be demonstrated that TMX-202 treated dendritic 
cells extent expressed the co-stimulatory molecules CD80 and CD86 to higher extent compared with 
the DMSO treated cells. CD80 and CD86 become expressed during maturation of dendritic cells and 
are functionally relevant for T cell activation (DILIOGLOU et al., 2003). These results imply that 
dendritic cells generated from monocytes and treated with a basic mixture of GM-CSF and IL-4 
become functionally mature under the treatment with TMX-202. This is in accordance with recently 
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published data also demonstrating that TLR-ligands can induce dendritic cell maturation (DEIFL et 
al., 2014) (MASSA and SELIGER, 2013). This further indicates that the standard protocol based on 
GM-CSF and IL-4 supplemented with a cytokine cocktail consisting of IL-1β, TNF-α, PGE-2 and IL-6 
for the final maturation of dendritic cells (COLIC et al., 2004) might be substituted by one single 
agent, the immune modifier TMX-202, which by inducing high levels of IL-6 can also lead to 
functional maturation of dendritic cells.  
 
With regard to the TMX-202 mediated effects on T cells during the repeated stimulations with 
peptide-loaded dendritic cells the only parameters that could be investigated were the T cell 
morphology and viability as estimated by microscopic inspection and T cell numbers representing T 
cell proliferation as counted before each re-stimulation. As described in section 5.x at day x of the in 
vitro priming the T cells numbers in the DMSO experiment decreased, which was also reflected by 
less dense T cell culture upon visual inspection, while the TMX-treated T lymphocytes showed a 
continuously increasing growth curve. However, DMSO-treated T cells recovered over time until the 
end of the experiment and reached almost the number of the T cells under TMX treatment. This could 
be interpreted as a first hint for the efficacy of the immuno-modulatory drug to promote adaptive T 
cell responses either indirectly by stimulation with dendritic cells matured under TMX-treatment or by 
direct effects of the immuno-modulatory treatment on T cell differentiation and proliferation.  
 
The final readout of the 22 days lasting stimulation experiment was the measurement of T cell 
mediated killing of CaSki cells as indicated by CD107a released upon co-incubation of the effector 
cells with the target cells. Recognition of tumor cells induces cytolytic vesicles in effector T cells to 
localize to the membrane and to release lytic enzymes by fusion with the outer cell membrane and 
thereby CD107a contained in the inner membrane of the vesicles is transferred to the cell surface. The 
killing rates of T cells stimulated under DMSO treatment were compared with the killing potential of 
the T cell culture that were treated with the new immune modulator TMX-202. It could be 
demonstrated that T cells cultured in presence of TMX-202 led to better killing rates as represented by 
a higher fraction of CD107a-expressing CD8+ T cells. The treatment seems to promote a better 
stimulation of T lymphocytes and induction of antigen-specificity. It is conceivable that this is either 
related to more potent antigen-presentation mechanisms mediated by dendritic cells matured with 
TMX-202 substituting the classical pro-inflammatory cytokine mix (DEIFL et al., 2014), or caused 
directly by TMX-202 affecting T cell proliferation and differentiation into effector T cells (JIN et al., 
2012).  
Although the killing rates are not significantly different between the DMSO and the TMX-202 T cell 
experiment and the fractions of CD107a-expressing T cells killings were relative small, one should 
consider that the frequencies of naïve CD8+ T cells in the peripheral blood in general is very low. 
They represent only approximately 2.5% of all leukocytes contained in the peripheral blood 
(CHEVALLIER et al., 2013). 
It cannot completely ruled out that alloreactivity of the T lymphocytes against the heterologous tumor 
cell line also contributed to the killing effect, but the differences in the killing effects of the two T cell 
cultures (DMSO and TMX-202) still remain obvious. Spontaneous, non-antigen-specific reactivity of 
T cells in the presence of CaSki cells was not included in the experimental setup as all T cells were 
   6. Discussion and Conclusion  143 
stimulated with the mixture of possible antigens and this approach was solely focused on the effects 
that an immune modulator could contribute to such an in vitro “vaccination” of naïve T cells.  
To minimize the risk for alloreactivity of T cells against tumor cells, albeit matched for the HLA-A 
allele (HLA-A2), killing assays preferably should be carried out in an autologous cell system as it was 
established in the course of this thesis (chapter 5.2). Unfortunately, at the time point when the here 
discussed experiment was carried out the tumor cell line was not yet established.  
 
 
6.8  The generation of a HPV-associated head and neck 
squamous cell carcinoma cell line for immunological 
studies based on an autologous system  
Although a restricted number of HPV-positive head and neck squamous cell carcinoma cell lines are 
available and sporadically new HPV16-positive cell lines deriving form head and neck cancers are 
published (TANG et al., 2012) they might not be optimal for certain immunological studies. The 
establishment of an autologous system that provides a HPV-positive cancer cell line and at the same 
time - preferentially freshly isolated - immune cells of the same patients is invaluable. In our 
department this goal could be achieved for a colorectal cancer cell line in the past but a model until 
now was still lacking for HPV-associated cancers. Therefore the establishment of a HPV-positive cell 
line deriving from a HNSCC patient can be considered the major methodological approach of the 
second part of this thesis. Once a tumor cell culture was continuously growing and had undergone 
several passages without losing its adherence and proliferation capacities, which could be observed in 
1 out of 31 tumor explant cultures, it was subjected to further analyses to proof its association with 
HPV infection. The metastatic tumor cell line HN038M was stable for 11 months, showed continued 
proliferation and contained nearly 100% tumor cells after 13 months and 2 passages. The portion of 
epithelial cells contained in the culture was determined using BerEP4 antibody directed against the 
epithelial cell adhesion molecule (EpCAM) by which cells of epithelial origin can be stained 
specifically (BREZICKA, 2005) as the antibody does not bind to fibroblasts which are of mesodermal 
origin. This demonstrates that the underlying tumor preparation protocol established during this work 
(section 3.4.2) successfully eradicates contaminating fibroblast over time by sequential trypsinization 
and the maintenance of tumor cells keeping their proliferating potential.  
Importantly, only a fraction of about 20% of all HNSCC tumors is contributable to HPV (GILLISON 
et al., 2000). The primary tumor from which the metastasis derived that could be established as cell 
line was an oropharyngeal cancer located in the area of the palatine/lingual tonsil where most of the 
typical HPV-associated oropharyngeal cancers occur. Nonetheless, the cell line had to be characterized 
for clear signs of HPV presence and contribution of the virus to the tumorigenesis. These results were 
also compared with the analysis performed in the cooperating clinic. Such investigations allowed the 
non-HPV induced cancers clearly to be distinguished from those who are caused by underlying HPV 
infection and transformation caused by viral oncoproteins E6 and E7 that interfere with the host cell 
pathways.  
The staining of cultured tumor cells for p16
INK4a
 revealed a strongly positive staining pattern for the 
cells harvested from the culture of HN038M. As p16
INK4a
 is a surrogate for viral oncogene 
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overexpression in transforming infection (chapter 1.3.3), this result indicates the underlying HPV-
infection and transforming processes induced by the virus – more specifically by the activity of the 
viral oncogene E7 – in the cell line HN038M (VON KNEBEL DOEBERITZ et al., 2012). However, 
as p16
INK4a
 in the head and neck occasionally is expressed without any relation to HPV (PRIGGE et 
al., 2014) the sample was further subjected to HPV genotyping and viral oncogene expression was 
analyzed by western blot analysis.  
The GP5+/6+ primer-based PCR for amplification of HPV DNA clearly revealed amplified DNA 
located between the 100bp and 200bp marker bands for the tumor cell samples and the positive 
controls. It could be shown by Luminex-based HPV genotyping (SCHMITT et al., 2006) that the 
tumor cells of the HN038M cell line harbor HPV16 DNA (SCHMITT et al., 2006). These results were 
compared with the characteristics of the tissue material that was directly formalin-fixed and paraffin-
embedded following surgery. The paraffin-embedded tissue was stained for p16
INK4a
 by 
immunohistochemistry and it could be demonstrated that the conserved material of the metastasis 
equally shows a strong and diffuse staining pattern of p16
INK4a
-positive cells.  
Furthermore, HPV genotyping was also performed with DNA obtained from the original formalin-
fixed tissue samples it was demonstrated that both primary tumor and metastasis of this patient also 
are positive for HPV16.  
To rule out the possibility of an underlying permissive HPV infection that would not contribute to the 
transformation of the tumor cells but rather represent a secondary effect, the cell lines was tested for 
HPV16 E7 oncogene expression. Western blot analysis of samples collected at different time points 
representing an earlier and a later passage, revealed that the cell line strongly expresses the E7 
oncoprotein; with the same total amount of protein loaded on the gel, the cell line expresses even 
higher E7 levels as the SiHa control. It can therefore be concluded that in this cell line HPV16 
infection and oncoprotein activity was the driving mechanisms for carcinogenesis (MCLAUGHLIN-
DRUBIN and MUNGER, 2009).  
In the context of the planned immunological experiments involving killing of tumor cell by autologous 
immune cells, HLA class I antigen expression was an important characteristic of this cells line to be 
determined. HLA class I antigen expression and other antigen-processing components are frequently 
reported to be altered in HNSCC and might represent a major mechanism that contributes to immune 
evasion and thus tumor progression and metastasis (BANDOH et al., 2010; TANG et al., 2009) 
(MANDIC et al., 2004; NÄSMAN et al., 2013; PRIME et al., 1987). Flow cytometry analysis of the 
tumor cell line HN038M for HLA class I expression was performed with a monoclonal antibody 
(clone W6/32) detects functional HLA class I antigens expressed on the cell surface by recognizing 
heavy chains A, B and C. The analysis demonstrated that virtually all tumor cells expressed HLA class 
I molecules on their cell surface (97.02 %). In conclusion, there were no concerns to use this cell in 
subsequent immunological studies investigating the potential effect of regulatory T cells on the killing 
efficiency of effector T cells. The high HLA class I expression was considered to be the prerequisite 
for tumor cells to be theoretically recognized, bound and killed by cytotoxic T lymphocytes.  
 
Finally, the cell line was characterized by short tandem repeat (STR) profiling to exclude cross-
contamination by established and frequently used cell lines. The awareness of the rising frequency of 
falsely identified cell lines and cross-contamination of cultures by standard cell lines, led the American 
Type Culture Collection (ATCC) Standards Development organization workgroup to initiate a 
   6. Discussion and Conclusion  145 
consensus standard on the authentication of cell lines based on STR profiling which should be applied 
to standardize the procedure of cell line characterization and to assure the reliability of published 
results (BARALLON et al., 2010; CONNEXIN et al., 2010). The STR profiling allows cell lines to be 
identified on the individual level, to compare them with and distinguish them from cell lines contained 
in the database (NIMS et al., 2010). The STR profiling, carried out by Multiplexion GmBH, 
Heidelberg, showed that the new cell line HN038M is not identic with any of the cell lines contained 
in the database which is defined as less than 96% identity with the best fitting comparison sequence. 
Therefore, cross-contamination with other cell lines frequently used in the same laboratory room, such 
as the HPV-associated cell lines CaSki, HeLa, SiHa and the colorectal cancer cell line HCT116, can be 
excluded and the originality of the new HNSCC is demonstrated.  
  
With the tumor preparation and treatment protocol adapted to head and neck squamous cell carcinoma, 
the sampling of HPV+ tumors preparation and establishment of cultures will be continued in order to 
establish further autologous HPV-associated cell lines in the future. Enlarging the numbers of HPV-
associated tumor cell lines of patients that are alive is a valuable enrichment for the scientific 
community and would allow performing - as long as patient does well - further immunological studies 
based on autologous tumor and immune cells.  
With the cell line in hands a cell-based immuno-modulatory intervention strategy was tested by 
applying depletion of regulatory T lymphocytes from the T cell fraction and evaluating their killing 
potential against autologous tumor cells in comparison to undepleted T cells.  
 
 
6.9  Regulatory T cells seem to have an inhibitory effect on 
anti-tumoral immune responses against autologous tumor 
cells of a HPV-positive HNSCC patient 
The contribution of regulatory T lymphocytes to cancer progression is one non-negligible mechanism 
frequently discussed and considered as a major concern. The presence of dense Treg infiltrates are 
reported in different tumor entities and their frequent occurrence in cancers is causally linked to tumor 
development at different sites of the body (KIM et al., 2013; MICHEL et al., 2008; SHAH et al., 2011; 
WOLF et al., 2003). Regulatory T cells are thought to hamper different kinds of therapeutic 
vaccination approaches or other strategies elaborated to induce T cell mediated anti-tumoral responses 
– not only in the HPV-setting. In the context of cancer immunotherapy Treg depletion therefore plays 
a crucial role (reviewed in CURIEL, 2007 and NISHIKAWA and SAKAGUCHI, 2014). Results from 
the here described study (chapter 4.2) and also published data demonstrate that regulatory T 
lymphocytes play a non-negligible role in HPV-associated cervical cancers and the precursor lesions 
(LODDENKEMPER et al., 2009; MOLLING et al., 2007; VISSER et al., 2007; WU et al., 2011). 
The regulatory T cell phenotype characterized as CD4+CD25+Foxp3+ T cells has been shown to 
contribute to suppression of cytotoxic responses and in vitro Treg depletion is reported to T cell 
mediated immune responses (CHEN et al., 2012). The effect of Treg depletion, however, is rarely 
investigated in the setting of HPV-related diseases (CHUANG et al., 2009; TUVE et al., 2007) and 
mainly demonstrated in mouse models. Only one study could be found investigating Treg depletion in 
146     6. Discussion and Conclusion  
the context of nasopharyngeal carcinoma – without, however, considering possible underlying HPV 
infections (FOGG et al., 2013). Data concerning the role of Tregs in HPV-associated OSCC and the 
impact of Treg depletion is scarce.  
The established HPV16-positive tumor cell line deriving from an OSCC patient was used for an initial 
experiment which aimed at the investigation of the potential immunosuppressive effect mediated by 
regulatory T lymphocytes. The killing potential of PBMCs isolated from the blood of the OSCC 
patients against the autologous tumor cell line HN038M was measured in two different experimental 
approaches and was based on the comparison between Treg depleted T cells and the total (undepleted) 
T cell fraction. This last chapter thus completes the circle with regard to the immunohistochemical 
analyses performed in the first part of this work. Although it could not be demonstrated that regulatory 
T cells contribute to progression of precancerous lesions - because of the cross-sectional nature of the 
study -, the enormous variances in different diagnostic CIN grades might imply a functional role in 
tumor development. 
In a broad general approach - without considering possible underlying mechanisms - the effect of Treg 
depletion was measured by the impedance-based Roche Xcelligence System. The assay principle is 
explained in detail in section 3.2.4 and is based on impedance measurement reflecting changes in cell 
density, adherence and morphology. These changes for example can be caused by manipulations such 
as drug treatment inducing apoptosis. The convincing argument in favor of this system is the 
possibility to monitor the effects of treatments on tumor cells in real-time and in a label-free manner. It 
has been demonstrated to be applicable for monitoring vaccine-based cytotoxicity on tumor cells 
(PHAM et al., 2014), T cell mediated killing (PEPER et al., 2014) and also was compared with 
51
Cr- 
release assay (measuring the release of 
51
Cr from labelled target cells upon cytolysis) to demonstrate 
that the impedance-based assay can detect changes in the levels of antigen-specific cytotoxic T cells 
with increased sensitivity compared with the standard chromium release assay (ERSKINE et al., 
2012). It therefore represents an attractive alternative assay to established experiments as exposure to 
gamma radiation or other labelling reagents can be avoided, high reproducibility can be obtained and 
fewer cells are required for the experimental setup.  
For the above describe experiment the cell index values were measured during the growing phase and 
the killing phase of tumor cells and for Treg depleted T cells and the total T cell fraction. The cell 
index calculated for the T cell control wells demonstrated that the addition of effector cells to the 
adherent tumor cells did not affect the impedance. Therefore the impedance curves for the co-
incubated T cells and tumor cells can be considered to represent the true killing effect on tumor cells 
without requiring further normalization for T cell impedance. It could be shown that the T cells after 
Treg depletion induces a stronger decrease in cell index values and also in the slopes calculated for the 
cell index curves compared with the total T cell fraction (Figure 5.25). Decreasing cell indices can be 
interpreted as being caused by tumor cell lysis and T cell mediated cytotoxicity. The differences 
between Treg depleted T cells and the total T cell fraction are significant over the total killing period 
and also in the two defined sub-phases representing the first and second killing phase.  
 
To take into account the effects mediated by T cells with or without previous Treg depletion more 
specifically, CD107a degranulation assay was performed to gain information about the cytotoxic 
potential of the effector cells. This assay was first described in 2003 as a “novel technique to 
enumerate antigen-specific CD8+ T cells using a marker expressed on the cell surface following 
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activation induced degranulation, a necessary precursor of cytolysis” (BETTS et al., 2003). Although 
the here described experiment was performed in an antigen-independent manner it has been 
demonstrated that CD8+ T cells expressing CD107a are involved in antigen-specific cytotoxicity 
(BETTS et al., 2003) and that such assays allows the identification and analysis of tumor-reactive T 
cells in vitro (RUBIO et al., 2003). 
The performed CD107a degranulation assay showed that among T cells stained for CD4 and CD107a 
those subjected to Treg depletion showed a higher fraction expression CD107a compared with T cells 
that were not depleted from regulatory T cells. It has been reported that CD4+ T cells also can 
cytotoxic potential and contribute to elimination of tumor cells (reviewed in MARSHALL and 
SWAIN, 2011 and APPAY, 2004). This same trend could also been seen in the fraction of non-CD4+ 
T lymphocytes. This opens the question of the nature of the phenotype of the T cells contained in this 
population. Based on the assay principle for T cell isolation (chapter 3.2.4) which selects for CD3+ T 
cells the presence of natural killer cells (CD3-negative) in the isolated T cell fraction can be ruled out. 
Furthermore, the presence of HLA class I antigens on the tumor cells has been demonstrated and it is 
unlikely that NK cells, if present, would have any killing effect against HLA class I antigen expressing 
tumor cells (MORETTA et al., 1996). It can therefore be assumed that the non-CD4+T cell population 
is composed of a fraction of CD8+ CTLs and also natural killer T cells (NKT cells) which in contrast 
to NK cells express CD3.  
The percentage of CD107-expressing cells in both fractions, non-CD4+ and CD4+ T cells, are 
relatively low. It has been demonstrated in different settings that the frequencies of antigen-specific T 
cells are relatively low, and one can speculate that antigen-specific T cells circulating in the blood are 
even less frequent than tumor-infiltrating lymphocytes at the tumor site (reported frequencies range 
from 0.01% to 0.4% for CD8+ T cells) (HE et al., 1999; POLLACK et al., 2014). For HPV-associated 
antigens, due to effective immune evasion mechanisms the frequencies for antigens specific T cells 
might even be lower as reported for low levels of E7-specific precursor T cells (1 of 3947 T cells) in 
the blood (HOFFMANN et al., 2006). However, although changes remain low with regard to the 
absolute CD107+ T cell frequencies, the killing rate is 3 times higher after Treg depletion in the non-
CD4+ T cell fraction and such changes might have tremendous effects in vivo in respect to the low 
frequencies of potential antigen-specific T cells.  
 
In conclusion, both assays by addressing different parameters, the changes in impedance caused lysed 
tumor cells and the CD107a expression on the cell surface of T cells, demonstrated that Treg depletion 
enhances the killing efficiency of the remaining T cell fraction and that Treg mediated suppression 
might play a role in the investigated OSCC tumor probably having participated in disease progression. 
This finding might also be an explanation for disease recurrence after surgical treatment in this patient 
although HPV-associated HNSCC in general have a better prognosis and clinical outcome. Depletion 
of regulatory T cells might therefore be an important treatment option to be considered for HPV-
associated diseases in general and in OSCC in particular where data so far have been lacking and 
allows the circumvention of immunosuppressive effects.  
Intervention strategies in this context for example might be based on drugs that specifically target 
Tregs (FOGG et al., 2013). Recently also therapeutic approaches involving chemotherapeutic agents 
for control and reversal of the immunosuppressive effects mediated by regulatory T lymphocytes 
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might be applicable in anti-cancer therapy (reviewed in ALIZADEH and LARMONIER, 2014; 
D'ARENA et al., 2011; OHKURA et al., 2011).  
A combined therapy is conceivable involving immune stimulating agents such as TLR ligands and 
drugs combatting immune suppression, in the same way as today classical chemotherapeutic agents 
are combined such as cytostatic and cytotoxic drugs or combinations of antibody-based anti-cancer 
treatments. Probably here again, the combination of different strategies might be more effective than 
one single therapy alone by addressing the variability of mechanisms developed by HPV-associated 
diseases to circumvent the host’s immune attack  
Importantly, the single treatment strategies described in this thesis show a tendency to contribute to a 
reduced tumor growth. The combination of these strategies, however, is conceivable to improve and 
potentiate the effects obtained with each of these strategies alone.  
 
 
6.10 Future prospects  
The initial immunohistochemical analysis of immune cell infiltrated in cervical intraepithelial 
neoplasia and cancers demonstrated that changes of immune cell infiltrate are not associated with the 
onset of transforming infections in histomorphological low-grade lesions. The observed T cell 
densities are not yet different compared with non-transforming low-grade lesions. However, as lesions 
of the same histomorphological grade with different biological and clinical behavior are pooled within 
one diagnostic group - an approach which could not be avoided due to nature of most of the available 
patient cohorts - the T cells infiltrate data cannot be related to the clinical outcome of the patients. 
Interestingly, broad ranges of immune cell densities could be observed for distinct T cell subtypes, e.g. 
regulatory T cells and CD8+ cytotoxic T lymphocytes indicating that samples are characterized by a 
large heterogeneity. This might reflect samples of patients with either progressing or regressing 
disease. Only patients samples stratified for the clinical behavior of the lesions could unravel the 
impact of distinct immune cell phenotypes on disease outcome. The changes in immune cell densities 
and the phenotypic composition have to be in a prospective setting in order to gain a better 
understanding of how these changes are related with the clinical outcome of the patients.  
 
These aspects could perfectly be addressed in the patient cohort of the Austrian imiquimod trial. In the 
course of the 20 weeks treatment and observation protocol three biopsies per patient were sampled. 
The effect of a topical immuno-modulatory drug, imiquimod, was tested in a randomized, placebo-
controlled setting and the efficiency of the treatment was determined by comparing the imiquimod-
treated arm with the placebo-group. The small number of patient samples that could be obtained for 
the first analyses of T cell infiltrates in imiquimod treated patients represents extremely precious 
material and served as a basis for the first analyses of immune infiltrates in imiquimod-treated lesions. 
The first step was taken towards a deeper understanding of the immunophenotypic reversal mediated 
by immune modifiers such as TLR-ligands. However, if access will be gained to the placebo-treated 
patient samples, the natural course of untreated high-grade CIN lesions over time can be monitored 
and immune cell infiltrate data correlated with the course of the disease, e.g. progression or regression. 
The analysis of these samples is therefore considered to help answering the questions that could not be 
addressed in the cross-sectional study. T cell phenotypes that contribute to spontaneous regression 
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without previous therapeutic intervention can be investigated, as well as distinct immune phenotypes 
that rather are associated with disease persistence or progression. Also the analyses that have been 
initiated with the patients of the imiquimod treatment arm will be expanded to enlarge the sample size 
and validate the results obtained so far.  
 
In this context further immune markers might be relevant and should be included to enlarge the 
immune phenotypic characterization. Based on the list shown in section 6.6 the best marker 
combinations can be defined after having been evaluated in preliminary immunohistochemical 
analyses as it was done for some of the most important T cell markers in the first cross-sectional 
approach. It has to be demonstrated that the chosen markers are reliable predictors of the biological 
behavior of the disease and the clinical outcome of the patients. The final biomarker set might also be 
a combination of immune cell and tumor cell markers as long as they alone and even more in 
combination are predictive for the clinical course of the disease.  
 
On the long run this precious cohort will allow to define an “immune score”, a biomarker-based tool 
that could be applicable in the clinical routine to predict the risk for progression of CIN lesions and 
also the chance to respond to non-surgical interventions such as topical treatment with TLR agonists. 
This tool might help to make individualized and risk-adapted treatment decisions, minimize over-
treatment of a clinically heterogeneous disease and permit at least a distinct proportion of young 
women to obtain conservative treatment.  
 
HLA class I and class II antigens is a potential component of this novel “immune score”. However, 
with the results obtained so far, their biological relevance and their contribution to immune evasion or 
effective anti-tumoral immune responses is still not clear. Their impact on the quality of the immune 
response that might be initiated has to be elucidated by additional analyses. In a first approach T cell 
densities and also different T cell phenotypes infiltrating the tumor microenvironment should be 
correlated with the expression pattern of antigen-presenting molecules in the lesions. The best, 
clinically most relevant approach again would be a longitudinal one allowing the correlation with the 
patients’ outcome to reveal the role of these alterations in the context of immune evasion or either 
immune attack of the host. First analyses demonstrated that HLA class II expression indeed seems to 
impact immune densities in terms of CD3+ and CD8+ T cells. Thereby, a higher proportion of cells 
expressing HLA class II antigens as well as a higher fraction of cells showing membranous expression 
were associated with a trend towards denser T cell infiltrates (data not shown).  
All these investigations that finally should lead to the definition of an “immune score” for use in the 
diagnosis and prognosis will be based on the newly developed automated quantification method 
described in this thesis. It represents a highly standardized and objective method to quantify immune 
cells as the results of cell counting are not biased by subjective criteria defined by the investigator. 
Especially for the development of a clinically relevant immune cell based biomarker tool, the 
reliability of the results has to be demonstrated and they need to be validated in a larger sample cohort. 
Here, the established quantification platform is the method of choice as it allows high-throughput 
screening of large cohorts.  
 
.  
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FIGURE 6.3  GRAPHICAL OVERVIEW OF THE POSSIBILITIES TO COMBINE THE RESULTS AND 
ESTABLISHED METHODS IN THE FUTURE IN ORDER TO DEVELOP NEW DIAGNOSTIC 
TOOLS AND TREATMENT STRATEGIES. #  
 
The Austrian imiquimod trial together with the multitude of imiquimod trials performed in vulvar 
intraepithelial neoplasia (VIN) patients demonstrated the clinical efficacy of TLR-agonist based 
treatment that aims at immune modulation of the lesion microenvironment. The promising results 
obtained in this study make TLR-agonist treatment a strategy to be pursued. However, in consideration 
of the known side effects of imiquimod further immuno-modulatory treatment strategies were 
evaluated in the second part of the thesis. A second generation TLR-agonist, TMX-202, was tested in 
the in vitro priming of naïve T cells to p16
INK4a
 and HPV16 L1 peptides.  
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It could be shown that the substance has effects on dendritic cells maturation and T cell proliferation 
and also contributes to a slightly increased killing potential of T cells in the context of HPV-associated 
diseases. These first results warrant further studies to better characterize the potential of the new TLR-
agonist. The planning of a vaccination experiment based on p16
INK4a
L1 chimeric virus-like particles in 
a mouse model is under way. Here, TMX can be evaluated as a potential adjuvant. It is well 
conceivable that the cellular immune responses against L1 and p16
INK4a
 in mice vaccinated with the 
chimeric VLPs are potentiated by using TMX as an adjuvant, as effects were observed on both levels, 
the innate immunity and also adaptive immune responses  
With the oral squamous cell carcinoma cell line generated in the course of this thesis a valuable 
autologous model was established which can serve as basis for further immunological studies. For 
example the effect of TMX-202 treatment could now be validated in an autologous system to allay 
concerns regarding the alloreactivity between immune cells and an allogeneic tumor cell line. It 
represents a perfect model for the generation of antigen-specific T cells by in vitro priming with the 
auto-antigen p16
INK4a
 and viral antigens such as L1 and to test the killing potential of T cells against 
autologous tumor cells. The patient recruitment will be continued to obtain further tumor tissue 
samples for the generation of more cell lines. These are necessary to validate the results obtained from 
one single patient and to evaluate whether or not the findings are representative for HPV-associated 
diseases and the conclusions that were drawn can be generalized 
 
Although the results look promising, the effect of regulatory T cell depletion demonstrated in the 
autologous cell line HN038M will have to be tested in further cell lines to validate the results obtained 
in one patient. A combination strategy consisting of Treg depletion along with immuno-modulatory 
drug treatment would be highly interesting as the better killing effect observed after Treg depletion 
could further be enhanced if anti-tumoral response of the remaining cell fraction would be “enhanced” 
by TLR-ligand treatment. The experiment demonstrated how important strategies aiming at Treg 
depletion might be for the improvement of cancer immunotherapy approaches.  
This treatment strategy in general could be further refined by using drugs specifically targeting Tregs 
in order to deplete them from the total T cell fraction. A multitude of new and already established 
drugs are actually discussed to selectively eliminate the immunosuppressive effected mediated by 
regulatory T lymphocytes. Among these cyclophosphamide (Cytoxan) (CAMISASCHI et al., 2013), 
denileukin diftitox (TELANG et al., 2011) and ipilimumab (HODI et al., 2010) represent interesting 
therapeutic drugs. 
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9.1  Supplementary Figures 
 
FIGURE S9.1  Distribution of CD3+ and CD8+ T cell counts/mm² and the Ratio CD8/CD3 in the epithelium and stromal compartments in non-responders compared with responders in week 0 
(before treatment). The line in the center of each box represents the median value of the distribution; the borders of the box represent the upper and lower quartiles (25%-75%).  
  9. Supplementary Material 177 
 
 
 
FIGURE S9.2  Distribution of CD3+ and CD8+ T cell counts/mm² and the Ratio CD8/CD3 in the stromal compartments in non-responders compared with responders in week 0 (before 
treatment). The line in the center of each box represents the median value of the distribution; the borders of the box represent the upper and lower quartiles (25%-75%). 
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FIGURE S9.x  Distribution of CD3+ and CD8+ T cell counts/mm² and the Ratio CD8/CD3 in the stromal compartments in non-responders compared with responders in week 20 (after 
treatment). The line in the center of each box represents the median value of the distribution; the borders of the box represent the upper and lower quartiles (25%-75%). 
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FIGURE S9.x  Distribution of CD3+ and CD8+ T cell counts/mm² and the Ratio CD8/CD3 in the stromal compartments in non-responders compared with responders in week 20 (after 
treatment). The line in the center of each box represents the median value of the distribution; the borders of the box represent the upper and lower quartiles (25%-75%). 
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FIGURE S9.5  Distribution of ratios for epithelial to stromal cell counts non-responders compared with responders in 
week 20 (after treatment). The line in the center of each box represents the median value of the 
distribution; the borders of the box represent the upper and lower quartiles (25%-75%).
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FIGURE S9.6  Distribution of CD3+ and CD8+ T cell counts/mm² and the Ratio CD8/CD3 in the epithelial and stromal 
compartments in non-responders compared with responders. Data for week 0 (before treatment) and week 
20 (after treatment) are shown next to each other. The line in the center of each box represents the median 
value of the distribution; the borders of the box represent the upper and lower quartiles (25%-75%).
182      9. Supplementary Material   
 
 
 
FIGURE S9.7  Distribution of CD3+ and CD8+ T cell counts/mm² and the Ratio CD8/CD3 in the stromal compartments 
in non-responders compared with responders. Data for week 0 (before treatment) and week 20 (after 
treatment) are shown next to each other. The line in the center of each box represents the median value of 
the distribution; the borders of the box represent the upper and lower quartiles (25%-75%). 
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FIGURE S9.8  Peptide binding assay – repetition and validation of the results obtained in the first assay.  
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FIGURE S9.9  Human Cell Line Authentication Report for the HNSCC cell line HN038.  
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9.1  Supplementary Tables  
 
 
 
 
TABLE S9.1 Mean cell numbers, ranges and standard deviations (SD) for all T cell phenotypes in correlation with the 
lesion grades and p16INK4a expression status: intraepithelial and stromal cell numbers (per 0.0625mm²) 
and ratio lesion/lesion-adjacent stroma.  
 (1) p-values (comparison p16INK4a-negative and p16INK4a-positive low-grade CIN) 
 (2) p-values (comparison low-grade CIN vs. high-grade CIN) 
 (3) p-values (comparison high-grade CIN vs. invasive disease) 
 
 
mean range SD p-value mean range SD p-value mean range SD p-value
Low-grade CIN * p=0.1438 * p=0.2035 * p=0.6498
p16- CIN1 17.6 7.3-37.3 9.92 56.3 15.8-136.8 43.30 0.46 0.07-1.04 0.330
p16+ CIN1 13.3 1.3-45.3 12.14 32.6 11.5-84.8 19.39 0.41 0.07-0.89 0.249
High-grade CIN ** p=0.0273 ** p<0.0001 ** p=0.0799
CIN2 22.3 8.3-43.0 9.98 73.0 18.0-125.0 33.28 0.42 0.13-1.33 0.371
CIN3 25.2 4.3-99.3 25.52 110.1 33.5-260.5 63.10 0.26 0.06-0.64 0.212
Invasive disease *** p=0.2968 *** p=0.0414 *** p=0.9244
CxCa 43.8 2.0-161.1 42.72 140.5 34.3-336.0 77.58 0.41 0.02-1.52 0.403
Low-grade CIN * p=0.0864 * p=0.7856 * p=0.2012
p16- CIN1 8.5 0.0-23.0 6.72 17.6 1.8-39.5 13.89 0.72 0.00-1.90 0.655
p16+ CIN1 4.8 0.3-20.0 5.22 14.4 3.0-27.3 8.57 0.42 0.01-1.14 0.351
High-grade CIN ** p=0.0012 ** p<0.0001 ** p=0.4774
CIN2 14.8 3.7-32.3 9.68 37.0 7.8-56.8 16.90 0.59 0.14-1.85 0.642
CIN3 14.1 3.3-39.7 11.10 38.0 11.5-73.5 19.34 0.39 0.11-0.67 0.204
Invasive disease *** p=0.8802 *** p=0.2045 *** p=0.3929
CxCa 15.7 0.7-37.9 12.55 58.3 9.8-149.3 42.72 0.36 0.02-0.92 0.294
Low-grade CIN * p=0.9039 * p=0.5262 * p=0.9523
p16- CIN1 0.5 0.0-1.7 0.67 0.9 0.0-3.5 1.21 0.68 0.00-1.67 0.689
p16+ CIN1 0.5 0.0-4.7 1.29 0.5 0.0-2.3 0.70 0.46 0.00-1.33 0.582
High-grade CIN ** p=0.0028 ** p=0.0014 ** p=0.1838
CIN2 1.1 0.0-5.3 1.66 0.8 0.0-2.5 1.01 0.88 0.00-1.70 0.715
CIN3 2.2 0.0-8.3 2.29 2.7 0.8-12.3 2.75 0.73 0.00-1.93 0.542
Invasive disease *** p=0.9193 *** p=0.0095 *** p=0.0467
CxCa 1.5 0.0-5.3 1.63 5.7 0.0-20.0 5.98 0.40 0.00-1.67 0.427
Low-grade CIN * p=0.5375 * p=0.6444 * p=0.7237
p16- CIN1 3.4 0.3-9.7 3.72 17.4 0.0-46.0 17.13 0.25 0.04-0.67 0.200
p16+ CIN1 2.2 0.0-9.0 2.49 7.6 1.5-16.8 5.58 0.32 0.00-1.33 0.355
High-grade CIN ** p=0.2558 ** p=0.0076 ** p=0.2136
CIN2 5.8 2.0-17.0 4.05 21.7 6.0-37.8 12.29 0.39 0.07-1.06 0.343
CIN3 2.1 0.0-5.7 1.82 19.3 1.5-45.3 13.11 0.16 0.00-0.71 0.198
Invasive disease *** p=0.5933 *** p=0.0243 *** p=0.0464
CxCa 4.9 0.0-36.0 8.80 42.1 3.3-97.8 31.20 0.17 0.00-1.58 0.384
Low-grade CIN * p=0.1910 * p=0.2282 * p=0.3897
p16- CIN1 25.2 3.7-107.0 32.30 38.6 5.0-83.5 23.96 0.64 0.14-1.98 0.542
p16+ CIN1 10.4 3.7-31.0 7.42 26.5 8.5-49.0 13.97 0.42 0.14-0.73 0.203
High-grade CIN ** p=0.0286 ** p=0.0022 ** p=0.0672
CIN2 15.6 8.3-22.7 5.22 56.5 16.0-81.8 21.94 0.37 0.14-1.38 0.383
CIN3 16.3 5.3-38.9 9.00 58.6 13.5-141.5 37.57 0.38 0.12-1.21 0.281
Invasive disease *** p=0.7623 *** p=0.6801 *** p=0.6801
CxCa 17.0 2.0-45.3 13.09 60.8 14.0-115.0 34.58 0.39 0.04-1.31 0.363
 intraepithelial stromal intraepithelial/stromal
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TABLE S9.2 Means, ranges and standard deviations (SD) for the ratios calculated between different T cell phenotypes 
and CD3+ T cells in correlation with the lesion grades and p16INK4a expression status (means per 
0.0625mm²). 
 (1) p-values (comparison p16INK4a-negative and p16INK4a-positive low-grade CIN) 
 (2) p-values (comparison low-grade CIN vs. high-grade CIN) 
 (3) p-values (comparison high-grade CIN vs. invasive disease) 
mean range SD p-value mean range SD p-value
Low-grade CIN * p=0.1347 * p=0.1861
p16- CIN1 0.48 0.00-1.00 0.265 0.31 0.09-0.52 0.139
p16+ CIN1 0.39 0.01-0.87 0.215 0.43 0.26-0.70 0.159
High-grade CIN ** p=0.0258 ** p=0.1314
CIN2 0.70 0.216-1.906 0.464 0.53 0.275-1.018 0.226
CIN3 0.79 0.11-1.94 0.532 0.41 0.13-0.77 0.183
Invasive disease *** p=0.0090 *** p=0.2000
CxCa 0.52 0.04-1.69 0.479 0.40 0.18-0.82 0.186
Low-grade CIN * p=0.9039 * p=0.8950
p16- CIN1 0.04 0.00-0.11 0.049 0.02 0.00-0.05 0.020
p16+ CIN1 0.03 0.00-0.20 0.066 0.01 0.00-0.06 0.021
High-grade CIN ** p=0.0041 ** p=0.0508
CIN2 0.09 0.00-0.64 0.197 0.01 0.00-0.04 0.017
CIN3 0.19 0.00-0.77 0.230 0.03 0.00-0.14 0.038
Invasive disease *** p=0.3762 *** p=0.0418
CxCa 0.09 0.00-0.53 0.153 0.04 0.00-0.18 0.044
Low-grade CIN * p=0.8403 * p=0.6498
p16- CIN1 0.20 0.03-0.68 0.237 0.26 0.00-0.54 0.164
p16+ CIN1 0.20 0.00-0.67 0.197 0.23 0.07-0.46 0.117
High-grade CIN ** p=0.7690 ** p=0.8833
CIN2 0.26 0.06-0.40 0.100 0.32 0.20-0.55 0.102
CIN3 0.18 0.00-1.31 0.301 0.22 0.02-0.54 0.138
Invasive disease *** p=0.2318 *** p=0.5747
CxCa 0.18 0.00-0.87 0.266 0.28 0.08-0.60 0.1490.28
Low-grade CIN * p=0.8576 * p=0.8980
p16- CIN1 1.10 0.35-1.97 0.658 0.79 0.26-1.49 0.434
p16+ CIN1 0.99 0.32-1.75 0.459 0.88 0.49-1.60 0.340
High-grade CIN ** p=0.5522 ** p=0.0700
CIN2 0.80 0.53-1.00 0.174 0.82 0.60-1.27 0.206
CIN3 0.96 0.14-1.77 0.458 0.59 0.10-1.23 0.260
Invasive disease *** p=0.1171 *** p=0.0090
CxCa 0.67 0.23-1.88 0.525 0.47 0.16-0.80 0.176
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TABLE S9.3  Mean cell numbers, minima, maxima (per mm²) and standard deviations for CD3+ cell counts in 
progressing/persistent and regressing CIN2/3. The results are shown separately for the epithelium and all 
stromal compartments and all time points from week 0 over week 8 until week 20. 
 
 
 
 
 
mean min max STD mean min max STD p=
CD3 Epithel V1 537,0 36,2 1194,3 570,45 160,8 20,2 610,1 252,08 0.190
V4 751,3 114,5 1388,1 900,61 427,6 56,4 1846,7 698,63 1.000
V7 287,8 135,8 439,8 215,02 371,1 140,4 645,6 231,96 0.429
M100 V1 1606,1 669,7 3460,0 1270,71 1386,8 722,5 1890,1 541,14 0.905
V4 4593,7 1960,1 6790,1 2444,51 1978,2 483,2 6193,9 2176,92 0.167
V7 1843,5 1675,7 2011,2 237,26 2166,2 1172,4 4934,5 1375,77 1.000
M500 V1 1883,9 946,7 3699,8 1236,12 945,9 420,9 1936,5 663,05 0.190
V4 4565,1 2230,5 5750,2 2021,84 3079,7 237,7 7985,2 2800,21 0.381
V7 1532,7 1320,3 1745,2 300,47 2401,4 991,4 5600,2 1689,64 0.643
M1000 V1 883,0 396,2 1838,1 675,40 597,9 53,0 1831,8 719,44 0.286
V4 3308,3 1907,0 5408,2 1852,21 2159,1 173,9 6842,0 2478,56 0.381
V7 1056,9 639,0 1474,7 590,91 2008,0 432,1 5818,5 1948,59 0.643
M0-500 V1 3490,1 1860,3 7159,8 2491,96 2332,6 1155,8 3703,6 1092,75 0.730
V4 9158,8 4190,7 12540,3 4395,14 5057,9 734,3 14179,1 4926,73 0.381
V7 3376,2 3331,5 3420,9 63,21 4567,6 2598,7 10534,6 3021,80 1.000
M0-1000 V1 4373,0 2275,1 8042,6 2532,27 2930,6 1208,8 4346,4 1413,45 0.730
V4 12467,1 6097,6 16153,7 5538,95 7217,0 908,2 21021,0 7240,28 0.381
V7 4433,0 4059,9 4806,2 527,70 6575,6 3066,1 16353,1 4913,47 0.643
progressing/persistent CIN2/3 regressing CIN2/3
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TABLE S9.4 Mean cell numbers, minima, maxima (per mm²) and standard deviations for CD3+ cell counts in 
progressing/persistent and regressing CIN2/3. The results are shown separately for the epithelium and all 
stromal compartments and all time points from week 0 over week 8 until week 20. 
 
 
 
 
mean min max STD mean min max STD p=
CD8 Epithelium w 0 82,1 10,3 173,1 82,76 113,8 26,3 318,7 120,26 0,730
w 8 169,0 44,6 293,3 175,84 128,2 23,5 397,0 142,67 0,643
w 20 58,2 58,1 58,2 0,08 174,1 40,6 407,3 164,20 0,643
CD8 M100 w 0 394,2 99,2 784,0 319,65 973,3 236,1 1883,2 749,23 0,286
w 8 1082,1 446,1 1603,0 586,98 640,6 160,7 1421,2 572,09 0,262
w 20 246,9 127,4 366,4 169,03 852,2 191,5 1222,2 487,61 0,286
CD8 M500 w 0 598,8 308,8 1234,5 432,27 616,5 75,0 1882,3 723,28 0,730
w 8 947,4 377,7 1276,5 495,33 964,1 144,4 1815,8 635,94 1,000
w 20 201,3 80,8 321,8 170,38 985,8 176,9 2802,9 960,89 0,286
CD8 M1000 w 0 346,2 136,9 661,3 247,53 471,6 21,5 1136,3 501,54 1,000
w 8 694,9 422,1 861,4 238,14 691,8 173,2 1712,1 630,56 0,714
w 20 201,9 192,5 211,2 13,17 1220,1 171,4 4159,6 1508,64 0,429
CD8 M0-500 w 0 993,0 445,8 2018,5 734,29 1589,8 311,1 3765,5 1350,08 0,730
w 8 2029,4 823,8 2790,9 1056,11 1604,7 316,8 3125,7 1173,83 1,000
w 20 448,2 208,2 688,2 339,42 1838,0 368,4 4021,3 1330,51 0,286
CD8 M0-1000 w 0 1339,2 614,9 2444,4 779,36 2061,4 332,5 4901,8 1831,64 0,730
w 8 2724,4 1625,1 3335,0 953,97 2296,4 490,0 4837,8 1791,11 0,548
w 20 650,0 419,3 880,7 326,24 3058,1 563,5 8181,0 2781,83 0,286
progressing/persistent CIN2/3 regressing CIN2/3
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TABLE S9.5 Ratios for epithelial to stromal cells counts (means, minima, maxima and standard deviations) for CD3+ 
cell in progressing/persistent and regressing CIN2/3. The results for each stromal compartment are given 
and are shown separately for all time points from week 0 over week 8 until week 20. 
 
 
 
TABLE S9.6 Ratios for epithelial to stromal cells counts (means, minima, maxima and standard deviations) for CD8+ 
cell in progressing/persistent and regressing CIN2/3. The results are shown separately for the epithelium 
and all stromal compartments and all time points from week 0 over week 8 until week 20. 
mean min max STD mean min max STD p=
CD3 Epithelium/M100 w 0 0,34 0,05 0,91 0,403 0,09 0,03 0,32 0,128 0,063
w 8 0,13 0,06 0,20 0,103 0,20 0,06 0,44 0,148 0,857
w 20 0,15 0,08 0,22 0,098 0,19 0,09 0,40 0,140 0,643
CD3 Epithelium/M500 w 0 0,32 0,03 0,88 0,396 0,24 0,04 0,98 0,411 1,000
w 8 0,15 0,05 0,24 0,134 0,23 0,03 0,92 0,348 1,000
w 20 0,21 0,08 0,33 0,180 0,23 0,07 0,65 0,243 1,000
CD3 Epithelium/M1000 w 0 0,90 0,02 2,01 0,946 0,27 0,11 0,39 0,143 0,730
w 8 0,30 0,06 0,53 0,334 0,31 0,07 1,26 0,469 0,857
w 20 0,26 0,21 0,30 0,061 0,28 0,08 0,67 0,221 1,000
CD3 Epithelium/M0-500 w 0 0,17 0,02 0,45 0,200 0,07 0,02 0,24 0,099 0,413
w 8 0,07 0,03 0,11 0,059 0,09 0,02 0,30 0,107 1,000
w 20 0,09 0,04 0,13 0,065 0,10 0,04 0,25 0,091 0,643
CD3 Epithelium/M0-1000 w 0 0,14 0,01 0,37 0,165 0,04 0,02 0,14 0,054 0,413
w 8 0,06 0,02 0,09 0,052 0,07 0,02 0,24 0,088 1,000
w 20 0,06 0,03 0,09 0,042 0,07 0,03 0,18 0,063 1,000
progressing/persistent CIN2/3 regressing CIN2/3
mean min max STD mean min max STD p=
CD8 Epithelium/M100 w 0 0,16 0,08 0,25 0,084 0,11 0,07 0,17 0,040 0,413
w 8 0,11 0,04 0,18 0,103 0,24 0,05 0,62 0,207 0,429
w 20 0,31 0,16 0,46 0,211 0,22 0,05 0,37 0,145 0,429
CD8 Epithelium/M500 w 0 0,12 0,03 0,26 0,106 0,24 0,09 0,45 0,154 0,286
w 8 0,14 0,04 0,25 0,150 0,20 0,03 0,74 0,274 1,000
w 20 0,45 0,18 0,72 0,382 0,29 0,02 0,65 0,241 0,429
CD8 Epithelium/M1000 w 0 0,33 0,02 0,82 0,363 0,47 0,14 1,22 0,438 0,556
w 8 0,37 0,05 0,70 0,455 0,21 0,09 0,62 0,207 1,000
w 20 0,29 0,28 0,30 0,018 0,32 0,01 0,89 0,309 1,000
CD8 Epithelium/M0-500 w 0 0,07 0,02 0,13 0,050 0,07 0,04 0,09 0,019 1,000
w 8 0,06 0,02 0,11 0,062 0,12 0,03 0,34 0,116 0,429
w 20 0,18 0,08 0,28 0,139 0,12 0,01 0,22 0,089 0,429
CD8 Epithelium/M0-1000 w 0 0,05 0,01 0,11 0,046 0,05 0,04 0,08 0,017 0,905
w 8 0,05 0,01 0,09 0,055 0,09 0,02 0,22 0,081 0,643
w 20 0,10 0,07 0,14 0,052 0,09 0,01 0,18 0,065 0,643
progressing/persistent CIN2/3 regressing CIN2/3
190      9. Supplementary Material   
 
 
 
 
 
TABLE S9.7 Ratios for CD8 to CD3 cell counts (means, minima, maxima and standard deviations) in 
progressing/persistent and regressing CIN2/3. The results for the epithelium and all stromal 
compartments and all time points from week 0 over week 8 until week 20 are shown.  
 
 
 
 
 
 
 
 
mean min max STD mean min max STD p=
CD8/CD3 Epithelium w 0 0,19 0,11 0,29 0,074 2,50 0,20 5,84 2,576 0,063
w 8 0,30 0,21 0,39 0,127 0,46 0,20 0,79 0,256 0,643
w 20 0,28 0,13 0,43 0,209 0,47 0,12 0,78 0,260 0,429
CD8/CD3 M100 w 0 0,32 0,12 0,86 0,359 0,72 0,28 1,13 0,391 0,063
w 8 0,31 0,09 0,61 0,269 0,39 0,21 0,77 0,210 0,714
w 20 0,14 0,06 0,22 0,110 0,43 0,15 0,75 0,278 0,286
CD8/CD3 M500 w 0 0,47 0,14 1,30 0,555 0,68 0,17 1,43 0,586 0,730
w 8 0,28 0,07 0,57 0,261 0,44 0,12 0,62 0,219 0,262
w 20 0,12 0,06 0,18 0,087 0,42 0,10 0,63 0,241 0,286
CD8/CD3 M1000 w 0 0,48 0,18 1,03 0,374 0,82 0,41 1,89 0,632 0,190
w 8 0,25 0,15 0,45 0,172 0,46 0,25 1,00 0,283 0,262
w 20 0,22 0,14 0,30 0,112 0,51 0,16 0,72 0,198 0,143
CD8/CD3 M0-500 w 0 0,40 0,14 1,09 0,404 0,71 0,23 1,26 0,456 0,190
w 8 0,30 0,08 0,59 0,297 0,42 0,15 0,68 0,201 0,714
w 20 0,13 0,06 0,20 0,132 0,43 0,12 0,70 0,254 0,286
CD8/CD3 M0-1000 w 0 0,42 0,15 1,07 0,438 0,71 0,24 1,37 0,481 0,413
w 8 0,29 0,10 0,55 0,232 0,40 0,16 0,58 0,170 0,548
w 20 0,15 0,09 0,22 0,092 0,45 0,13 0,64 0,232 0,286
progressing/persistent CIN2/3 regressing CIN2/3
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 SYFPEITHI BIMAS 
x-mer Rank Start position aa-sequence score rank Start position aa-sequence score 
9-mer 1 60 ILVPKVSGL 30 1 67 GLQYRVFRI 139.17 
 2 97 RLVWACVGV 23 2 249 YLRREQMFV 133.74 
         
10-mer 1 12 YLPPVPVSKV 30 2 12 YLPPVPVSKV 735.86 
 2 2 SLWLPSEATV 27 1 2 SLWLPSEATV 577.28 
 
TABLE S9.8 Results of HLA-A2 epitope prediction for HPV16 L1. Two different databases, SYFPEITHI and BIMAS, were used for HLA epitope prediction in order to obtain L1 peptide 
sequences as potential antigens to be used for in vitro priming of T cells. The two peptides with the highest score of each database and for 9-mer and 10-mer peptides respectively 
were chosen for peptide synthesis. Because of total concordance between the two databased with regard to the results obtained for 10-mer peptides, in total 6 potentially antigenic 
L1 peptides were synthesized. In addition, the L1 peptide with the starting position 323 which is known from literature was synthesized as positive control.  
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TABLE S9.9 HPV Genotyping results for the tumor cell line HN038M and the corresponding archived (FFPE) tissue of the corresponding lymph node metastasis and primary tumor. Results 
are displayed as mean intensity values (MFIs) for the samples and controls and for all tested HPV-types. Samples or controls positive for the corresponding HPV types are 
marked in blue, also the hybridization control is highlighted in blue.  
 
 
 
Program Luminex 100 IS
Build 2.3
Date 5/13/201411:52:44 AM
SN LX10000266007
TemplateName Optiplex HPV Genotyping Kit
TemplateDescription Beadmix-Zusammensetzung entspr der Progen-Beschichtung
SampleVolume 50 uL
DDGate 7000 to 20000
SampleTimeout 70 sec
DataType: Mean Fluorescence Intensity
Sample
HPV06-
R02
HPV11-
R03
HPV16-
R10
HPV18-
R11
HPV26-
R12
HPV31-
R13
HPV33-
R14
HPV35-
R15
HPV39-
R23
HPV42-
R24
HPV43-
R25
HPV44-
R27
HPV45-
R28
HPV51-
R29
HPV52-
R40
HPV53-
R41
HPV56-
R42
HPV58-
R43
HPV59-
R45
HPV66-
R46
HPV68-
R48
HPV70-
R49
HPV73-
R66
HPV82-
R67
HPV            
β-globin-
R64
HPVHYB1-
R70
Total 
Events
HN038 M tumor cells 14.5 1 2627.5 0 1 0 3 2 3 1 2 1 1 1 2 1 2 1 1 2 2 1 4 3 17 4 2272
FFPE metastasis 8 0 2590 1 1 1 1 1 5 1 1 0 1 1 1.5 3 1 1 2 1 1 2 4 2 8.5 4 1095
FFPE primary tumor 10 2 1299 3 3 0 1 2 6 1.5 1 2 0 2 1 2.5 1 4 3.5 3 1 4 4 4 31 4 1570
HeLa positive control 16 0 87 415 0 1 1 1 3 1 1 1 4 1 1 2 1 1 2 2 1 2 4 4 62 4 2246
Caski positive control 17 0 3007 0 1 0 3 1 4 1 1 1 1 1 1 2 1.5 1 1 2 1 2 4 3 10 3 2621
H2O control 17 0 1 1 1 1 1 1 5 1 1 0 1 1 2 2 1 2 2 1 2 1 3 3.5 8 3.5 2442
no tissue/cells (empty tube) 19 0 0 0 1 0 0 1.5 4 1 1 1 1 1 2 2 2 2 1 2 2 2 4 2 9 3 2483
hybridization control 17 1 1 0.5 0 0 0 2 4 2 1 1 1 1 3 2 1 1 2 2 2 1.5 3 3.5 8 775.5 2449
